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Peritoneal Carcinomatosis: the Role of
Debulking Procedures
Peter R. Knight, MB, ChB, ChM, FRCSC, FACS, FRCS
Professor, Department o f Surgery, McMaster University, St. Joseph's Hospital, Hamilton, Ont.

the 3 days of his stay in
D uring
Southern Ontario, Dr. Paul Su-

garbaker, the 1988 Du Pont visit
ing professor, conducted grand
rounds at the Brantford General
Hospital, McMaster University Med
ical Centre and the Stratford Gener
al Hospital and also addressed the
annual meeting of the Southern
Ontario Surgical Society. His paper
on the surgical treatment of perito
neal carcinomatosis appears in this
issue of the Journal (pages 164 to
170).
The concept of debulking tu
mours to give chemotherapeutic
agents better exposure to residual
The Canadian Journal of Surgery
1867 Alta Vista Dr.
Ottawa, Ont. K1G 3Y6

tumour cells is, of course, not new.
For many years, gynecologists have
used omentectomy and other de
bulking procedures in combination
with various chemotherapeutic regi
mens in the treatment of carcinoma
of the ovary.
Pseudomyxoma peritonei is a le
sion of low-grade malignancy that
does not metastasize but recurs
locally. Repeated removal of these
locally recurring tumour masses in
the peritoneal cavity is usually asso
ciated with long-term survival. Re
moving such masses with laser or
ball-tipped cautery may well be a
reasonable approach.
Tel.: (613) 731-9331
Telex: 053-3152
Fax: (613) 523-0937
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ness expense 1

For general surgeons, accus
tomed to the ravages wrought by
recurrent and metastatic carcinoma
of the rectum and colon, this ap
proach may cause raised eyebrows.
Such patients usually present with
extensive seeding of the peritoneum
and bowel surfaces and neoplastic
adhesions so vicious that the ab
dominal contents are solidly stuck
together with multiple areas of ob
struction. The prospect of freeing
these peritoneal plaques of carcino
ma and disentangling and freeing
multiple loops of bowel by balltipped cautery on high voltage may
make even the most aggressive,
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optimistic surgeon pale. The addi
tion to this of excision of transverse
colon, spleen and terminal ileum,
the ligament of Treitz and the
greater and lesser omentum, makes
the procedure even more over
whelming.
The role of intraperitoneal che
motherapy1 has evolved from the
finding that patients who had ovari
an cancer and ascites had a high
rate of chemotherapy-induced myelosuppression when chemotherapy
was given intravenously. It was
found that the drugs accumulated
in the ascitic fluid and, eventually,
the ascitic fluid concentration of the
drug exceeded the plasma concen
tration. The ascitic fluid then pro
vided a slow release form of the
drug into the plasma, slurring the
terminal disappearance curve. It
was concluded that a diffusion bar
rier associated with the peritoneum
was the responsible factor.
The problem of poor distribution
of chemotherapeutic agents instilled
into the peritoneal cavity is obvious
in patients with bulky disease and
multiple adhesions. This distribu
tion can be shown radiologically by
adding Hypaque to the fluid intro
duced into the peritoneal cavity.
The distribution of dye-containing
fluid in ovarian cancer patients is
known to be excellent.1 For patients
who have metastatic colonic and
rectal carcinoma with dense adhe
sions and matting of the loops of
bowel, the distribution is likely to
be poor. The benefits of local che
motherapy may thus be lost. Dr.
Sugarbaker makes no comment on
the distribution pattern of his che
motherapeutic fluid.
The ability of intraperitoneally
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administered drugs to penetrate
solid intra-abdominal tumour mass
es directly has not been shown
experimentally for most anti-cancer
drugs. However, a mathematical
model defined by a set of non-linear
partial differential equations has
predicted 5-fluorouracil tumour
penetration to a depth of 600 ^m.
This represents a thickness of ap
proximately 50 to 60 cells.2 Thus,
intraperitoneal therapy would ap
pear to be limited in usefulness to
tumour nodules of only a few mil
limetres in diameter. 5-fluorouracil
is absorbed from the peritoneal cav
ity, thus the tumour would also be
exposed to chemotherapeutic cyto
toxicity via its capillary blood sup
ply. The vascularity of the deeper
parts of large, bulky tumours is
poor, limiting the availability of
chemotherapeutic levels of cytotox
ic drugs within large tumour mass
es. For these reasons, debulking is
a rational approach if it can be
achieved, even though after such a
procedure adhesions are very likely
to reform, preventing local access
of chemotherapeutic agents to the
debulked tumour masses.
The mortality and morbidity asso
ciated with debulking is obviously
high and many patients who under
go these procedures are probably
poor candidates in terms of nutri
tion and healing capability. Their
immune competence to deal with
infection is also probably depressed.
If satisfactory debulking can be
achieved, then a course of chemo
therapy given intraperitoneally, as
outlined by Dr. Sugarbaker, must
require a robust recipient indeed.
Such an undertaking is obviously
not suitable for anything but well-

equipped research departments with
trained oncologists and with patient
and aggressive surgeons who are
prepared to embark upon prolonged
surgical “tours de force” as part of
a research study. The aim of any
procedure should be to prolong life
which is of good quality. Patients
such as Sugarbaker describes run a
high risk of tumour recurrence, and
the masses may never be completely
or successfully removed. This raises
the questions, How much of their
remaining lives will these patients
spend in hospital undergoing re
peated surgical and oncologic treat
ment? and Can such a program
really achieve our desired aim?
On the other hand, progress is
made through people with courage
and the willingness to tilt at wind
mills and challenge problems from
which others turn. From such be
ginnings, new pathways may ap
pear, and it is good to realize there
are people prepared to undertake
what appears impossible. From
such beginnings the impossible may
become a reality.
The area covered by Dr. Sugar
baker in his Du Pont Lecture is just
part of a program he is undertak
ing. Most of us must await his
ongoing results and achievements
before embarking on what must be
a hazardous and rocky path for
both surgeon and patient.
References
1. Myers CE: The clinical setting and phar
macology of intraperitoneal chemothera
py: an overview. Semin Oncol 1985; 12 (3
suppl 4): 12-16
2. Myers CE, Collins JM: Pharmacology of
intraperitoneal chemotherapy. Cancer In
vest 1983; 1: 395-407

CORRESPONDENCE

Treatment of Genital Herpes:
an Option
To the editors. A number of welldocumented articles on the diagno
sis and management of genital her
pes have appeared recently,U6 the
treatment of both acute and chronic
herpatic lesions generally involving
the use of acyclovir. I would like to
suggest a further treatment option,
one that has been used effectively at
the University Health Services in
Edmonton for a number of years.
Liquid nitrogen as a freezing pro
cedure has met with excellent pa
tient acceptance and provided amaz
ing clinical healing within 1 week
of treatment, whether used for a
primary outbreak of herpes or for
recurrent lesions. The liquid nitro
gen is applied with a cotton-tipped
applicator to the involved area, no
matter how extensive, to freeze the
entire thickness of the lesions. Pa
tients who have widespread involve
ment of the vulvar area and are
obviously in severe distress are
most grateful for the immediate
relief and rapid healing. No other
medication is required.
This method is also used in the
treatment of condyloma acumina
tum, molluscum contagiosum and

ulcerative lesions of the vulva (e.g.,
Lipschutz ulcers).
I hope this alternative treatment
for genital herpes will prove helpful
to others who must deal with this
distressing condition.

Y. Yoneda, MD, FACS, FRCSC
University Health Services,
University o f Alberta,
Health Sciences Building,
111th Street and 88th Avenue,
Edmonton, Alta.
T6C 2R1
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Contributions to the Correspondence section
are welcome. They should be typewritten
and double spaced.

Primary Omental T orsion
To the editors. I read with interest
Appleby’s report on primary omen
tal torsion in the January 1989
issue (page 7). Having seen a num
ber of these cases in my surgical
career, I would like to add to Apple
by’s description.
First, these patients usually do
not present with nausea and vomit
ing, and the abdominal pain and
tenderness seem disproportionate to
their generalized symptoms. Sec
ond, most cases of primary omental
torsion that I have seen are associ
ated with an indirect inguinal her
nia on the right side. These are
noted in one of the classic descrip
tions of the condition.1
W.R. Ghent, MD, CM, FRCSC,
FACS, FICS
Department o f Surgery,
Hotel-Dieu Hospital,
Queen’s University,
10 Montreal St.,
Kingston. Ont.
K 7L 3G6

Reference
1. Aird I: A Companion in Surgical Studies,
2nd ed, Livingstone, Edinburgh, 1957

HOW I DO IT

Meatal-Based Tubularized Skin Flap For
Distal Hypospadias Repair
M. Gleave, MD; H.W. Johnson, MD, FRCSC; G.U. Coleman, MD, FRCSC;
M.G. McLoughlin, MD, FRCSC
istal or anterior hypospadias
accounts for approximately
70% of all cases of hypospadias,
including those in which the ureth
ral meatus opens proximal to its
normal position in either a glanular,
coronal or subcoronal position.
When possible, we use a meatal
advancement and glanuloplasty.1
However, when the urethral meatus
is either too proximal or is associat
ed with a ventral chordee, this
procedure will not produce the best
results. Our choice in these circum
stances is a modified Mustarde pro
cedure,2 using a meatal-based tubu
larized skin flap.

D

Patients
Since 1984, we have treated 40
boys for correction of distal penile
hypospadias using a meatal-based
tubularized skin flap. In 25, the
repair was the primary treatment,
and in 15, previous attempts (rang
ing from two to five procedures) at
repair had failed.
The group who underwent prima
ry repair ranged in age from 1 to 5
years. We prefer to operate when
the boys are between 12 and 18
months of age after a 1-week
course of androgens. The 15 boys
who had revision repairs ranged in
age from 5 to 15 years.

Surgical Procedure
A suture of 3-0 silk is placed
through the glans and secured to
the drapes cephalad. After the me
atus has been sounded to 12F, a
rectangular skin flap is outlined
proximal to the urethral meatus
(Fig. 1). The width of the flap
determines the urethral circumfer
ence and is approximately one-third
the circumference of the penile
shaft (12 to 14 mm). The length is
determined by the distance of the
meatus from the tip of the glans.
Any chordee between the corona
and the meatus is divided complete
ly before the proximal limit of the
flap is marked, because some proxi
mal migration of the meatus may
occur as the penis is straightened.
Saline erections are used to aid in
the excision of the chordee if neces
sary.
The flap is then incised sharply
down to Buck’s fascia and under
mined distally to the urethral me
atus. The base of the flap now lies
at the urethral meatus. The flap is
tubularized (Fig. 2) into the neoure
thra over a no. 8 feeding tube or
10F Silastic stent with running 6-0
polyglycolic acid sutures. This sin
gle suture line is buried facing
dorsally away from other surface
suture lines.

After the glans has been infiltrat
ed with 1 in 200 000 epinephrine,
the neourethra is extended to the
tip of the glans in one of two ways.
If the glans is flat, a glanular tunnel

FIG. 1. Rectangular skin flap is 12 to
14 mm wide and length is equal to
distance of meatus from tip of glans.

From the Division o f Urology, Department o f Surgery, University o f British Columbia,
Vancouver, B C
Accepted for publication Nov. 16, 1988
Reprint requests to: Dr. H. W. Johnson, Department o f Surgery, 3rd Floor - Rm. 3100, 910
West 10th Avenue, Vancouver, BC V5Z 4E3
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FIG. 2. Tubularization of skin flap
over 10F Silastic tube.

TUBULARIZED FLAP FOR HYPOSPADIAS REPAIR

is created between the ventral glans
and underlying distal corpora (18
patients) (Fig. 3a). If a ventral
groove is present, then glanular
flaps are raised (22 patients) and
sutured over the neourethra with
interrupted mattress sutures of 6-0
polyglycolic acid suture material
(Fig. 3b).
Byars’ flaps are then raised from
the dorsal hood of foreskin and
wrapped ventrally to cover the ven
tral defect (Fig. 4). A 10F silicone
stent or Silastic catheter is placed
for 5 to 7 days. The penis is
wrapped in a cling compression
dressing for 48 hours.

plained of a deflected or splayed
urinary stream.

Discussion
Several single-stage procedures
to repair distal hypospadias and
produce a meatus at the tip of the
glans have been described. When
meatal advancement and glanuloplasty are not applicable, we like to
use a meatal-based tubularized skin
flap, initially described by Mustarde3
and later modified by Belman.2
Other options include the Mathieu4
or Horton-Devine5 flip-flap proce
dures, various mobilized vascular

Results

I
►

►

:

The complication rate in boys
who had primary repair was low.
Two had small fistulas, one of them
in association with a meatal steno
sis. Both underwent a single surgi
cal repair of the fistulas on a day
care basis with good results.
The 15 boys who had revision
repairs did not fare as well. Five
(33%) had fistulas, associated with
meatal stenosis in three. One of the
five had a wound infection that
likely contributed to the fistula for
mation. All five had the fistulas and
stenoses corrected on a day-care
basis, although one required a sec
ond subsequent fistula repair.
Two boys required a day-care
procedure to remove redundant
skin tags.
Overall, nine patients (22.5%) re
quired additional surgical proce
dures, all carried out on a day-care
basis. No significant difference in
complications was seen between the
glanular tunnel technique and the
flap technique.
The early functional and cosmetic
results were good in 38 (95%) of
the boys. They had a good urinary
stream, straight erections and a
glanular meatus. In two boys, these
aims were not achieved; both com

FIG. 3. Extension of tubularized flap
to glanular tip via glanular tunnel
(top) or by raising glanular flaps (bot
tom).

flaps67 or free skin grafts.8 The last
two are usually reserved for midpenile or proximal hypospadias.
The flip-flap procedures cannot be
performed in one stage if there is
an associated chordee, but mea
tal-based tubularized flaps can be
used as a single-stage procedure
in distal to mid-penile hypospa
dias, with or without chordee.
The low incidence of complica
tions in primary repairs and the
overall good functional and cosmet
ic results in 38 of the 40 boys
reaffirms the effectiveness of the
modified Mustarde procedure re
ported by others.49 The higher
complication rate associated with
secondary or revision repairs (33%)
results from mobilizing flaps with

FIG. 4. Covering ventral defect with
Byars’ flaps.
CJS, VOL 32, NO. 3, M A Y 1989
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compromised blood supply from
previous operations. Despite this, a
good final result was still obtained
in 13 of these 15 problem patients.
The Mustarde meatal-based tubularized skin flap produces compara
ble results to other procedures used
in the repair of mid-penile to distal

hypospadias. The advantages in
clude some flexibility in construct
ing the glanular course of the
neourethra (flaps versus tunnel),
creation of a neourethra with a
single suture line that abuts the
corpora dorsally to reduce the risk
of fistulization and the ability to

excise associated chordee allowing
a single-stage repair.
We thank Dr. David Minninberg for
guidance in establishing this technique.
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CANADIAN ASSOCIATION OF GENERAL SURGEONS

Presidential Address, 1988. Surgical
Research: Its Importance in the Evolution
of the Specialty of General Surgery
Bernard Langer, MD, FRCSC, FACS
General surgery is a specialty that has gradually been defined by the evolution of
surgery in general, the major events being the identification and separation of
subspecialties. Advances in knowledge brought about by research have been the
major determinants in allowing the development of these subspecialties. Research
has played a major role in the redefinition of general surgery, which has now in its
own right become both the parent specialty and a subspecialty: the parent specialty
because of its continued concern with disease states of a general nature, such as
trauma, critical care, nutrition, transplantation, oncology; a subspecialty because of
its focus on specific areas of surgery, particularly gastrointestinal surgery. Future
developments in general surgery depend on fostering research in both the general
and specific areas, and also across the whole spectrum from the most basic to
applied clinical research.
La chirurgie generale est une specialite qui s’est definie progressivement avec
devolution de la chirurgie en general. Les principaux evenements qui ont marque
cette evolution sont l’identification, puis la separation des sous-specialites. La
recherche est a l’origine de l’avancement des connaissances, determinant majeur du
developpement de ces sous-specialites. La recherche a joue un role preponderant
dans la redefinition de la chirurgie generale, laquelle est devenue, a la fois, la
specialite mere et une sous-specialite en soi: la specialite mere, car elle continue de
s’interesser aux etats morbides de nature generale tels que traumatismes, reanima
tion, nutrition, transplantation, oncologie; une sous-specialite, parce qu’elle s’est
concentree sur des domaines specifiques de la chirurgie, particulierement sur la
chirurgie gastro-intestinale. Les developpements futurs de la chirurgie generale
dependront de l’encouragement accorde a la recherche, aussi bien dans ses aspects
generaux que specifiques, et allant de la recherche la plus fondamentale jusqu’aux
essais cliniques d’application.

ist general surgeon in an academic
institution. The association has
played an important role in estab
lishing new training standards for
general surgeons and in recogniz
ing and promoting the development
of new and special expertise in
general surgery. As you are all
aware, this is a constantly chang
ing game, and there has been
anxiety about the changes that
have taken place in general surgery.
When, for example, does specializa
tion become fragmentation, and
what will become of the specialty of
general surgery as we know it?
In my address today, I would like
to review some of the changes that
have taken place in the specialty of
general surgery, indicating the role
of research in bringing about these
changes and emphasizing the im
portance of maintaining strength in
research to continue this process of
evolution.

Pioneers of Surgical Research
he Canadian Association of
General Surgeons (CAGS) has
come a long way in only 11 years.
It has concerned itself with a num
ber of important issues. Education
has been a top priority and is most

T

apparent in the annual scientific
meeting. From the beginning, it
was the intention of this organiza
tion to appeal equally to the broadly
based surgeon in community prac
tice and the highly focused special-
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The birth of surgical research
occurred in the 18th century, the
landmark being the career of John
Hunter who “introduced a new spir
it of enquiry, a philosophy, which
not only transformed the medical
theory and practice of his epoch,
but profoundly influenced scientific
thinking everywhere down to our
own times.”1
A century later, Lord Lister intro
duced the principles of antisepsis
which made possible a remarkable
expansion of surgical potential.
Surgical research developed in the

RESEARCH IN GENERAL SURGERY

19th century, not only in anatomy
laboratories, but especially in the
developing field of physiology. The
chief figures were Heidenhain in
Germany, Eck and Pavlov in Russia
and Claude Bernard in France.
In the 20th century there was an
explosion of knowledge in all fields
of medicine as the scientific method
became established and universities
developed laboratories dedicated to
medical research. Alexis Carrel is a
premier example of the new breed
of 20th-century surgeon scientist.
He carried out some of the earliest
experiments using tissue culture of
cells. He was interested in organ
preservation and developed appara
tus for that purpose. His most
important work was in the area of
vascular surgery where he devel
oped the techniques for anastomo
sing blood vessels that are still in
use today.
W.E. Gallie lived at about the
same time as Carrel, and although
he is best known for organization
of a formal, structured, integrated
training program at the University
of Toronto, he was also a brilliant,
innovative thinker whose research
involved the autotransplantation of
tissues, particularly fascia in hernia
reconstruction and the use of xeno
graft bone material in the fixation
of fractures.
Other notable 20th-century re
searchers include Frances Moore, a
broadly based general surgeon who
had no specific organ interest, but
worked on the principle of studying
the whole patient. Jonathan Rhodes
at the University of Pennsylvania
and Stanley Dudrick developed a
system to provide all of the require
ments for maintenance of normal
nutrition to patients by the intrave
nous route. This research expanded
the capabilities of surgery and, par
ticularly, those of alimentary tract
surgeons.
Lloyd MacLean and his group at
McGill University focused on the

body’s response to injury, particu
larly immunologic responses. They,
along with Altemeier and others in
the United States, have emphasized
the importance of studying in detail
the host response to infection in
order to develop better strategies of
treating it, especially in the manipu
lation of nutrition and immunologic
factors.
In organ transplantation, no one
has contributed as much over as
long a time as Tom Starzl. He
almost single-handedly created the
field of liver transplantation, and
carried out fundamental studies of
factors involved in liver growth and
regeneration which have helped to
open up the field of liver surgery in
general.

The Surgical Specialties
The development of specific sur
gical specialties was occurring si
multaneously, partly as a result of
new capabilities for surgical treat
ment arising from research and
partly from expanding patient care
needs. Urology was built around the
cystoscope, a unique advance in
technology. Thoracic surgery was
made possible by the introduction
of endotracheal anesthesia and con
trolled ventilation. In the same way,
cardiac surgery did not develop as a
unique specialty until the extracor
poreal pump oxygenator was per
fected. In the course of all this,
general surgery has been defined by
a process of progressive amputa
tion, the field of general surgery
consisting of those parts of the
body left behind.

The Changing Face of General
Surgery
There have also been major re
ductions in general surgery as a
result of new scientific and techno
logic advances. In the upper gas
trointestinal tract, these include en

doscopic procedures such as scle
rotherapy for varices, papillotomy
for biliary stenosis and stone ex
traction, coagulation for upper gas
trointestinal bleeding and endoscop
ic removal of polyps in the lower
gastrointestinal tract. Lithotripsy
has been developed for the nonsurgical management of renal stones
and is in its early days of evolution
for treating biliary stones.
Pharm acologic developm ents
have also changed the face of sur
gery. They are best exemplified by
the development of H2 blockers and
other more advanced drugs which
can control gastric acid secretion
and have almost eliminated surgery
for the elective treatment of duode
nal ulcer disease. Chemotherapy for
cancer has not had the success
anticipated, but has modified our
approach to the treatment of some
malignant tumours.
Despite these developments, the
specialty of general surgery can be
kept strong by (a) buying into the
scientific and technologic develop
ments rather than worrying about
competing with them and (b) taking
advantage of the position we hold
as the surgical specialty which is
concerned about the whole patient.
With regard to technological ad
vances, general surgeons must be
involved where these advances are
applied to the treatment of surgical
diseases. Endoscopy, for example, is
an essential part of the alimentary
tract surgeon’s capability. The
CAGS and the general surgical
committee of the Royal College of
Physicians and Surgeons of Canada
have established endoscopy as an
essential part of the training of the
general surgeon. As endoscopy con
tinues to develop in the future, it is
essential that general surgeons be
involved in the advances related to
it, which also means in the research
related to it.
There are other areas where new
technology offers alternatives to
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surgery. Extracorporeal shock-wave
lithotripsy (ESWL) was developed
by physicists and engineers under
the leadership of a urologic sur
geon. In most centres, ESWL for
kidney stones has developed as a
team approach with the surgeon
playing a prominent or leading role
and considering this as one of the
options in the whole spectrum from
long-term medication to open surgi
cal procedures. The applications of
this technology to biliary stone dis
ease are currently under study and
the same approach must be taken.
Extracorporeal shock-wave litho
tripsy must develop as complemen
tary therapy to surgery, and stone
dissolution and the clinical trials
and subsequent treatment protocols
must involve general surgeons in
leadership roles. This is the rational
use of surgical expertise in a dis
ease which is, in its most lethal
form, a surgical disease.
Likewise, when other scientific
advances are made that may change
our own field, we must be sure to
develop appropriate expertise. We
must understand the pharmacology
of new drugs and their applications,
and be involved in the cutting edge
of science. This is obviously not for
every surgeon or surgical investiga
tor, but our surgical research ef
forts must include appropriate
training in this field so that we do
research that is current and com
petitive.
I emphasize that general sur
geons must take advantage of their
role in the diseases of the whole
body. In the area of cancer, new
developments in chemotherapy will
come from the large pharmaceutical
firms. The field of immunotherapy,
however, is open and requires an
innovative mind and understanding
of the fields of immunology and cell
biology. It is difficult, but not im
possible, for surgeons to compete
with pure basic scientists in this
area. Clinical research in cancer is
156
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the area in which we general sur
geons can be most competitive. The
ultimate testing of new therapy in
volves controlled clinical trials, and
we are the ones who have the
patients to carry out these studies.
Transplantation began as a pure
ly surgical specialty with technical
problems being predominant. Once
the technical problems were solved,
immunologic issues became the
major limiting factors, and a variety
of medical specialists now play a
major role in transplantation pro
grams. New immunosuppressive
drugs will be tested by pharmaceuti
cal companies, but immunologic
manipulation will be developed by
scientists with backgrounds in cell
biology and immunology. Surgeons
must be among those working in
the field. We, as surgeons, still tend
to be preoccupied with the technical
aspects of the operation and to
leave patient selection and prepara
tion, postoperative care and follow
up to others. This is a mistake.
Transplantation is an interdisciplin
ary field which has a common base
in science, and surgeons must play
a major role in every aspect of
transplantation programs. General
surgeons are particularly appropri
ate to this role.
Another area in which surgeons
must maintain an important interest
is that of critical care. This includes
polytrauma, nutrition, sepsis and
organ failure. The general surgeon
should be the key individual in
trauma centre organization, and in
actual resuscitation and manage
ment of critically ill patients after
injury and surgery. We must also
contribute to research in critical
care from basic studies of cellular
events in organ failure to clinical
trials of new therapies.

Universities and Surgical
Research
Having considered the role of

research in shaping the develop
ment of general surgery, I would
like now to examine what role the
universities play in this kind of
research, whether there is any role
for the surgeon in clinical practice,
and what function the CAGS has in
general surgical research.
The role of the university is to
train undergraduate students and
postgraduate specialists. Included
in every university’s mission is the
need to do research. As Malcolm
Brown, former president of the
Medical Research Council of Cana
da, has pointed out, the most im
portant role of research is to create
new knowledge. There are, howev
er, two other important reasons for
research in university hospital set
tings. First, research focuses atten
tion on the diseases being studied in
such a way that there is much
closer and more systematic assess
ment of patient selection, outcome
and follow-up; as a result, patient
care is better. The other important
role of research is in helping to
create an environment of critical
thinking and questioning, so that
students and residents will develop
better judgement, literature evalua
tion skills and appraisal of existing
dogma.

Role of the Practising General
Surgeon
This brings me to the role of
those of you who are surgeons in
busy clinical practice. You are obvi
ously not in a position to do re
search yourselves. It is important,
however, to maintain a sense of
enquiry and questioning of existing
practice. If those of you who are
over 50 years old remember how
you treated breast cancer during
your residency and compare that
with the way you treat it now, you
will recognize how important it is to
be aware of change and the need for
a good set of standards to evaluate
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what appears in the literature as an
advance in knowledge. Do you re
member the excitement about gastr
ic freezing and how large numbers
of freezing machines were sold, not
to mention the thousands of pa
tients who had their stomachs fro
zen, before it finally became appar
ent that not only did this new
treatment not work, but there were
serious complications as a result of
it?

Surgical Research and CAGS
The role of the CAGS in research
development is to support and pro
mote research in general surgery in
every way possible. This was recog
nized at the time our organization
was founded. In addition to our
advisory committee on research,
and under the leadership of Neil
Watters, we have created the Cana
dian Surgical Research Fund to
promote, lobby and raise money for
general surgical research — for
specific projects, for residents-intraining and to support research
training fellowships. Three potential
sources of funds include patients,
industry and our membership,
which is the major source of in
come. The contributions of our
members attest in a tangible way to
their commitment to supporting re
search. Much more is needed and
the members of the Board of the
research fund are seeking ways to
tap other sources. Our patients
have shown their willingness to
support research — but they have
to be asked. You, our members, can
help by approaching your patients
to support the Canadian Surgical
Research Fund. You will be pleas
antly surprised at the response.

The General Surgeon’s
Support for Surgical Research
The final question is, How are we
doing overall in relation to research

in general surgery? In a nutshell,
we are not doing as well as we
should. Interest in research has
increased in medical schools in
terms of numbers of summer stu
dents and research fellows, but
major problems exist.
Funding for research in general
has decreased in terms of real dol
lars, particularly in the area of
surgical research. This has oc
curred both in the US and Canada,
because of the increasing sophisti
cation of basic research and the
difficulty clinicians, especially sur
geons, have in competing with full
time basic scientists for limited re
search dollars. We have responded
by increasing the training period for
committed surgeon/scientists and
moving to develop within surgical
departments groups of investigators
that include dedicated basic scien
tists.
Another problem is the peerreview system in granting agencies
on whose committees, for a variety
of reasons, surgeons are often not
represented. The Canadian surgical
chairmen have formed the Canadian
Council on Surgical Research to act
as a lobby group and, it is hoped,
help to secure increased representa
tion of surgeons in the review proc
ess of scientific granting organiza
tions.
Another problem has been the
difficulty of maintaining the career
path of the surgeon/scientist in a
clinical department. This involves a
complexity of issues including time
protection, financial support and
image, all of which are now being
addressed.
Regarding the general surgical
community at large, there is a need
for support in terms of such bodies
as the Canadian Surgical Research
Fund. The CAGS has responded to
that need. Those dollars, however,
will always be a relatively small part
of the overall support required. Of
equal importance is the role of

surgeons in the community and of
the regional surgical societies in
recognizing the value of research,
in transmitting the knowledge
gained to their patients, and where
possible in helping to convince poli
ticians and other legislators of the
need for increased research support.

Future of General Surgery
What does the future hold for
general surgery? Perhaps the best
way to answer this is to look
through the window provided by
those currently working at the cut
ting edge in our medical schools. A
conference supported by the Cana
dian Surgical Research Fund was
held in Mississauga last June. The
topics covered by these young re
searchers included the following.
• “ Regulation of intracellular
pH in resident and activated perito
neal macrophages” . In this study
the researchers are trying to identi
fy the molecular mechanisms that
lead to activation of peritoneal mac
rophages. It is a very important
issue in our host defences in perito
nitis and of interest to every abdom
inal surgeon.
• “ 31P NMR spectroscopy of
liver and skeletal muscle in a model
of cancer cachexia”. New technolo
gy of surface coil spectroscopy is
being used to measure serially vis
ceral energy stores in an experimen
tal model of cancer cachexia. This
may provide a simple way to assess
nutritional deficits in cancer pa
tients.
• “Allotransplantation of single
donor purified canine islets into the
spleen or renal subcapsular space
using cyclosporine”. This very ex
citing piece of work won the CAGS
Resident’s Research Prize for 1988.
It is a study of transplantation of
highly purified islets in diabetic
dogs. Many investigators believe
that islet transplantation is more
likely to be successful in managing
CJS, VOL. 32. NO. 3. M A Y 1989
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the difficult human diabetic than
whole organ transplantation.
• “Islet cell differentiation and
proliferation induced by pancreatic
cytosol extract”. This important in
vestigation was carried out in ham
sters to study the factors that pro
mote growth and development of
islets. Such factors will be essential
in developing the ultimate tech
niques for islet transplantation in
the human.
• “Extracorporeal shock-wave
lithotripsy (ESWL): a valuable ad
junct in the management of difficult
biliary tract calculi”. This is a pre
liminary report of clinical experi
ence. It is the equivalent of a phase
II cancer trial and is very important
at present; ultimately, carefully con
trolled prospective studies will be
required.
• “The reversal of cyclosporine:

a mediated suppression of allogene
ic induced monocyte procoagulant
activity by H2 antagonists in vitro”.
Most transplant patients must take
multiple drugs. This study docu
ments the potentially detrimental
effect that H2 blockers may have on
cyclosporine immunosuppression in
transplant patients.
• “The critical injury of cold
preservation of liver allografts in
the rat is sinusoidal lining cell dam
age”. This is a careful morphologic
study in the rat, demonstrating the
typical endothelial cell injury char
acteristic of cold preservation of the
liver during transplantation. This
provides a simple model for the
study of better preservation tech
niques and focuses attention on an
important target cell in preservation
injury.
• “The effect of cisplatin on

SESAP VI Question

liver regeneration in the rat after
two-thirds hepatectomy”. The re
sults of this experimental study of
chemotherapy on liver regeneration
will have a bearing on the role of
adjuvant chemotherapy in patients
after resection of hepatic tumours.
These are some of the studies
which will change the way in which
we practise and will redefine the
specialty of general surgery. We
have come a long way since I
became a general surgeon 25 years
ago. I expect we will progress even
further in the next 25. I hope that I
will be around to see it and I know
that many of you, and certainly the
Canadian Association of General
Surgeons, by which 1 have been
honoured as president, will play an
important role in continuing to
shape the specialty of general sur
gery. ■

Corrections

Item 105
The most frequently encountered metabolic complication of urinary
diversion through an ileal segment is

(A) hyperkalemic, hypochloremic metabolic acidosis
(B) hyperchloremic metabolic acidosis
(C) hypokalemic metabolic alkalosis
(D) hypochloremic metabolic alkalosis

In the January 1989 issue, the arti
cle entitled “Acute scrotal pain in
children: prospective study of diag
nosis and management”, which ap
pears on pages 29 to 32, contains an
error. On page 31 the illustrations
for Figs. 1 and 2 are reversed, but
the legends are correct. The lefthand picture illustrates a case of
spermatic cord torsion and the righthand figure a case of epididymitis.
We apologize to both the authors
and our readers for this mistake.

(E) combined metabolic acidosis and respiratory alkalosis
For the incomplete statement above, select the one completion that is
best of the five given.
For the critique of Item 105 see page 170.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa
tion and Self-Assessment Program No. 6. For enrolment in the Surgical
Education and Self-Assessment No. 6, please apply to the American
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Also in the January 1989 issue, the
name of R.M. Baird, MD, FACS,
FRCSC, was inadvertently omitted
as one of the coauthors of the article
“The risk of occult invasive breast
cancer after excisional biopsy show
ing in-situ ductal carcinoma of com
edo pattern”, which appears on
pages 56 to 60.
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Carotid Body Tumours: the University of
Alberta Hospital Experience
F.A. Daudi, MD; O.G. Thurston, MD, FRCSC
At the University of Alberta Hospital between 1950 and 1988, 17 patients who had a
diagnosis of carotid body tumour were seen; 15 of them were followed up for an
average of 8 years (range from 1 to 38 years).
In 14 patients the tumour was removed surgically. There were no operative
deaths and no strokes occurred. The most frequent complication was cranial nerve
deficit. Of the 15 patients followed up, 10 (67%) manifested a deficit of the facial,
vagus or hypoglossal nerve.
The primary tumour was diagnosed histologically as a benign neoplasm in all 14
patients operated on, but in 3 distant metastases developed or there was invasive
local recurrence. Patients with malignant tumour were significantly (p < 0.01)
younger than those with a benign tumour.
Carotid body tumours can be managed safely with respect to stroke complications,
but cranial nerve injuries continue to be a problem. Malignant tumours are difficult
to distinguish from benign tumours except that they tend to occur in younger
patients. Prompt surgery and close follow-up is particularly important in patients
with carotid body tumour.

►
►
►

►

Entre 1950 et 1988, 17 patients de l’hopital de TUniversite d’Alberta ont re?u un
diagnostic de tumeur du glomus carotidien; 15 d’entre eux ont ete suivis pendant
une periode moyenne de 8 ans (ecart de 1 a 38 ans).
Chez 14 patients, la tumeur fut enlevee chirurgicalement. II n’y eut pas de
mortality peroperatoire et aucun accident cerebrovasculaire n’est survenu. La
complication la plus frequente fut un deficit des nerfs craniens. Des 13 patients qui
ont survecu et qui ont fait l’objet d’un suivi, 10 (77%) manifestaient un deficit des
nerfs facial, vague ou hypoglosse.
La tumeur primitive fut diagnostiquee histologiquement comme tumeur benigne
chez chacun des 14 patients operes bien que, dans 3 cas, il y eut metastase a
distance ou recidive avec envahissement local. Les patients porteurs de’tumeurs
malignes etaient significativement plus jeunes (p < 0.01) que ceux qui souffraient
de tumeurs benignes.
Les tumeurs du glomus carotidien peuvent etre traitees sans crainte d’un accident
cerebrovasculaire, mais les lesions des nerfs craniens sont une complication
courante. Les tumeurs malignes se distinguent difficilement des tumeurs benignes,
sauf qu’elles semblent survenir chez des patients plus jeunes. Une chirurgie precoce
et une surveillance etroite des suites therapeutiques sont particulierement importantes chez les patients souffrant d’une tumeur du glomus carotidien.
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arotid body tumour is an un
common neoplasm which arises
from paraganglionic cells at the
bifurcation of the common carotid
artery. The tumour is extremely
vascular. However, in the follow-up
of patients operated on for carotid
body tumours we have noted that
cranial nerve complications have
been more numerous and more seri
ously disabling than vascular com
plications. We believe that because
surgeons are preoccupied with po
tential vascular complications, vas
cular control is well handled, but
neurologic complications, because
of cranial nerve damage, remain a
challenge. In this study of 17 pa
tients with carotid body tumours we
have attempted to demonstrate the
importance of cranial nerve compli
cations.

C

Patients and Methods
Between 1950 and 1988, 17 pa
tients seen at the University of
Alberta Hospital in Edmonton had a
diagnosis of carotid body tumour.
The medical records of these pa
tients were reviewed and data tabu
lated with particular attention to
duration of symptoms, methods of
investigation, operative findings and
techniques, postoperative complica
tions and histologic features of the
tumours. Fifteen patients were fol
lowed up by clinic visit or letters
from other physicians with particu
lar attention paid to persisting disa
bilities and tumour recurrence.
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Findings
The 17 patients (7 men and 10
women) ranged in age from 15 to
79 years (mean 48 years). All pre
sented with a neck mass which had
been present from 2 months to 13
years. Three patients had bilateral
tumours and three had a family
history of carotid body tumour.
Diagnosis was confirmed by arteri
ography in 12 patients; computed
tomography was also done in 2 of
these. In four patients the diagnosis
was made at the time of neck
exploration and in one patient by
computed tomography alone, car
ried out just before surgery. Four
teen patients underwent surgical re
section of the tumour. In 13 of
these, an adventitial dissection and
resection was carried out after se
curing proximal and distal vascular
control. In one patient, the carotid
bifurcation was resected and common-to-internal carotid artery conti
nuity was restored with a saphe
nous vein graft. Three patients were
not operated because of advanced
malignant disease not related to the
carotid body tumour, previous
stroke and pending resection of an
adrenal pheochromocytoma. Imme
diate postoperative complications
were hematoma requiring re
exploration of the neck in two
patients. There were no operative
deaths. Pathological examination of
excised tumours confirmed the di
agnosis of benign carotid body tu
mour in all 14 patients.
The mean follow-up of the 15
patients was 8 years (range from 1
to 38 years). At the time of writing,
eight patients were alive and free of
recurrent tumour. Four patients
died of unrelated causes. One pa
tient died of metastatic carotid body
tumour in bone. One patient was
alive with metastatic carotid body
tumour to the spine and associated
paraplegia. One patient was alive
with locally recurrent carotid body
160
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tumour extending to the base of the
skull. Thus, in 3 of the 15 patients
the tumour behaved in a malignant
fashion, although this was not an
ticipated from the histologic appear
ance of the primary tumour. The
age of these 3 patients was 25 ± 9
years (mean ± SD) whereas the age
of the 14 other patients was 53 ±
15 years (p < 0.01, Student’s ftest).
The 15 patients available for fol
low-up showed a high incidence of
persisting cranial nerve deficits.
Voice changes, including hoarse
ness and inability to raise the voice
to a loud level, were noted in six
patients. Three patients had a uni
lateral (and ipsilateral) hypoglossal
nerve palsy and one patient had a
palsy of the marginal mandibular
branch of the facial nerve. Thus, 10
of 15 patients (67%) had a localized
deficit of the facial, vagus or hypo
glossal nerve.

Discussion
In this series, postoperative vas
cular complications were confined
to two postoperative hematomas,
which required evacuation. No pa
tient suffered a stroke either intraoperatively or postoperatively,
and there were no operative deaths.
However, postoperative complica
tions related to cranial nerve lesions
were noted frequently, and this has
been a consistent finding in series
of patients with carotid body tu
mours reported from other institu
tions.1-3 Surgeons operating on pa
tients with carotid body tumours
have become increasingly aware of
the devastating effects of interrup
tion of carotid blood flow. As a
result, the perioperative mortality
and stroke rates have fallen dramat
ically in the last 20 years4 as vascu
lar techniques have been refined.
Unfortunately, the rate of cranial
nerve injuries has not fallen corre

spondingly. Low death and stroke
rates for carotid body tumour resec
tion should result in patients being
operated on sooner for carotid body
tumours when they are relatively
small (stage I in the classification of
Shamblin and colleagues5). Small
tumours, an awareness of potential
cranial nerve injury and refinement
of technique6 should result in a
decline in the incidence of cranial
nerve injuries resulting from the
removal of carotid body tumours.
There is general agreement that
it is difficult to predict the malig
nant potential of carotid body tu
mours from the histologic appear
ance of the primary tumour, al
though cellular pleomorphism has
been observed to be an indication of
malignancy.2 In our series, one pa
tient had local recurrence of the
primary tumour after what was con
sidered to be a complete excision
and two patients had frank metastases to bone. In each case, the
primary tumour was thought to be
benign pathologically. This is in
keeping with the findings of Meyer
and colleagues6 who noted a meta
static rate of about 5% for carotid
body tumours regardless of histo
logic appearance. In this series of
patients, young age at the time of
diagnosis was a more reliable index
of aggressive tumour behaviour
than the histologic appearance of
the tumour. This finding argues for
early surgery and close follow-up
for patients in the second, third and
fourth decades of life, who have a
carotid body tumour.
The majority of patients with
carotid body tumours present with
a unilateral lesion and have no
family history of this condition.
However, familial occurrence and
bilateral lesions have been docu
mented. Bleker and Wereldsma7
noted a 25% incidence of bilateral
tumours in patients with a family
history compared with 5% other
wise. Three patients in our series
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had a family history and one of
them had bilateral tumours. The
other patient with bilateral carotid
body tumours had no family histo
ry. The patient with bilateral carotid
body tumours and a positive family
history of the tumour was also
found to have an adrenal pheochromocytoma. This association
has been noted8 and represents an
additional consideration in the
work-up preoperatively of patients
with carotid body tumours.
Carotid body angiography has
been the gold standard for the
diagnosis of carotid body tumours,
its accuracy approaching 100%.3
Computed tomography shows a
well-circumscribed, strong contrast
enhancing mass at the bifurcation
of the common carotid artery and
these findings appear to be typical
of this lesion.9 In one of our most

recent patients, the combination of
clinical assessment and computed
tomography accurately defined the
lesion, and this patient was operat
ed on without difficulty. We believe
that as more experience is gained
with computed tomography, it will
replace angiography in the diagno
sis of carotid body tumours, except
in special situations in which carot
id body stenosis is suspected or in
the rare situation when emboliza
tion is contemplated before surgery.
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NOTICES
Annual Meeting of American Soci
ety of Colon and Rectal Surgeons
More than 1000 surgeons are expected
to attend the 88th annual meeting of
the American Society of Colon and
Rectal Surgeons which will be held in
Toronto, June 11-16, 1989. The pro
gram features workshops, guest lec
tures, exhibits and, of particular inter
est, a panel discussion on the optimal
surgical technique for colorectal cancer.
For further information contact: Execu
tive Office, The American Society of
Colon and Rectal Surgeons, Ste. 1080,
800 East Northwest Highway, Palatine,
IL, 60067, USA; (312) 359-9184.

Continuing Education at Univer
sity of Toronto
A course entitled “Hepatic Surgery:
New Anatomy, New Techniques” is
being offered by the Faculty of Medi
cine at the University of Toronto. Fur
ther information about the course,

which is scheduled for Sept. 18, 1989,
can be obtained from the Department of
Continuing Education, Faculty of Medi
cine, University of Toronto, Medical
Sciences Building, Toronto, Ont.
M5S 1A8; (416) 978-2718.

Urologic Oncology
Toronto will also be the setting for a
conference Oct. 12-14, 1989 entitled
“Urologic Oncology: Today & Tomor
row”. Dr. John Trachtenberg of Toron
to is the conference chairman. More
information can be obtained from Jeanie
McGoldrick, Conference Coordinator,
Stratagem Communications, Ste. 604, 2
Sheppard Ave. E, Willowdale, Ont.
M2N5Y7; telephone (416) 229-2331;
fax (416) 229-6443.

Royal College Annual Meeting
The 58th annual meeting of the Royal
College of Physicians and Surgeons of
Canada will be held Sept. 22-25 in

Edmonton. The program includes post
graduate courses, poster sessions,
workshops, symposia, free communica
tion sessions and medical and surgical
exhibits. Over 2500 specialists, interns
and residents are expected to attend.
For further information contact Anna
Lee Chabot, Head - Meetings and As
semblies Section, Office of Fellowship
Affairs, The Royal College of Physi
cians and Surgeons of Canada, 74 Stan
ley Ave., Ottawa, Ont. KIM 1P4; (613)
746-8177.

CMA Annual Meeting
The Canadian Medical Association’s
122nd annual meeting is scheduled for
Aug. 20-25, 1989 in Quebec City. In
conjunction with the meeting, a scien
tific program on “highway traumatolo
gy” is being offered by the CMA and
the “ Regie de Tassurance automobile
du Quebec”. Further information can
be obtained from the CMA Meetings
Department, PO Box 8650, Ottawa,
Ont. K1G 0G8; (613) 731-9331.
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Surgical Treatment of Peritoneal
Carcinomatosis: 1988 Du Pont Lecture
Paul H. Sugarbaker, MD, FACS*
Tumour spread onto peritoneal surfaces is frequent in patients who have recurrent
gastrointestinal cancer. In this study the author describes (a) a cytoreductive
surgical technique of ball-tipped electrocautery dissection, which can rapidly and
definitively remove large volumes of intra-abdominal tumour, (b) a procedure for
immediate postoperative lavage of the abdominal cavity to remove blood and tissue
debris, and (c) a regimen of early and delayed intraperitoneal chemotherapy to
destroy small quantities of residual cancer cells on intra-abdominal surfaces.
Forty-seven patients underwent cytoreductive surgery to remove large volumes of
adenocarcinoma widely disseminated through the abdomen. Most patients had
intraperitoneal chemotherapy to destroy small volumes of cancer remaining within
the abdomen. In the absence of previous radiotherapy, one patient died and the
morbidity was acceptable. In eight patients who received radiotherapy, seven had
bowel perforation and one died. Surprisingly, the majority of patients who had
cytoreductive surgery plus intraperitoneal chemotherapy had disease-free long-term
survival. In patients with peritoneal carcinomatosis, long-term disease-free survival
correlated with low tumour aggressiveness, adequate cytoreductive surgery and the
use of intraperitoneal chemotherapy.
Chez les patients souffrant de cancer gastro-intestinal, l’envahissement tumoral des
surfaces peritoneales est frequent. L’auteur decrit a) une technique de dissection a
l’electrocautere a pointe mousse permettant de reduire rapidement et definitivement
de telles tumeurs, b) une technique de lavage postoperatoire immediat de la cavite
abdominale pour eliminer le sang et les debris tissulaires, et c) un regime
therapeutique compose d’une chimiotherapie intraperitoneale immediate et retardee,
destinee a eliminer de petites quantites de cellules cancereuses residuelles sur les
surfaces intra-abdominales. Quarante-sept patients ont subi une chirurgie cytoreductrice d’importantes masses d’adenocarcinomes largement dissemines dans l’abdomen.
La plupart des patients refurent une chimiotherapie pour detruire de petites masses
tumorales qui restaient dans l’abdomen. En l’absence de radiotherapie prealable, un
patient est decede et la morbidity fut acceptable. Des huit patients qui refurent de la
radiotherapie, sept subirent une perforation intestinale et un mourut. On a constate
avec etonnement que la majorite des patients qui eurent une chirurgie cytoreductrice
accompagnee d'une chimiotherapie intraperitoneale, a beneficie d’une survie a long
terme, exempte de rechute. Dans les cas de carcinomatose peritoneale, une survie
libre de maladie, de longue duree, correspond a une tumeur peu agressive, a une
chirurgie cytoreductive adequate et a une chimiotherapie intraperitoneale.
From the Department o f Surgery, Emory University School o f Medicine, Winship Clinic and
Cancer Center, Atlanta, Ga.
Presented as the Du Pont Lecture at the annual meeting o f the Southern Ontario Surgical
Society, Stratford, Ont., June 3, 1988
*Sponsored as visiting professor by Du Pont Canada Inc., Mississauga, Ont.
Accepted fo r publication Nov. 15, 1988
Reprint requests to: Dr. Paul H. Sugarbaker, Winship Cancer Center, 1327 Clifton Rd. NE,
Atlanta, GA 30322, USA
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he surgical treatment of cancer
is dictated by the anatomic lo
cation of the tumour and its histo
logic grade of malignancy. In le
sions of low-grade malignancy,
such as mucinous adenocarcinoma
which may appear in the colon or
appendix, resection including mini
mal margins (less than 1 mm) of
healthy tissue has resulted in cure.
Unfortunately, when this tumour
extends through the bowel wall,
mucin-producing cells disseminate
throughout the peritoneal cavity.
The resulting clinical entity is com
monly referred to as cystadenocarcinoma, malignant pseudomyxoma
peritonei or mucinous peritoneal
carcinomatosis. In the past, it was
considered impossible to render pa
tients who had peritoneal carcino
matosis clinically free of tumour.
I shall describe a technique for
cytoreductive surgery and in
traperitoneal chemotherapy and re
port the results to date in a group
of patients who had these treat
ments for peritoneal carcinomatosis
from colonic and appendiceal can
cer.

T

Surgical Problems Posed by
Peritoneal Carcinomatosis
Peritoneal carcinomatosis is char
acterized by an “omental cake” of
tumour attached to stomach and
colon (Fig. 1). It can usually be
removed by a combined omentectomy-splenectomy; however, if the
colon is encased by tumour, an
en-bloc resection of omentum,
spleen and abdominal colon may be
necessary. Next to stomach and
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colon, the pelvic peritoneum is most
frequently affected; the cul-de-sac is
generally filled by tumour. Also
involved are the undersurfaces of

FIG. 1. “Omental cake” is characteris
tic of peritoneal carcinomatosis. It in
volves omentum, spleen and may en
case abdominal colon.

FIG. 2. Small-bowel sparing by perito
neal implants. Even though thick lay
ers of tumour are present on most
abdominal surfaces, small-bowel sur
face is relatively spared of tumour.
Portions of small bowel fixed to ab
dominal wall are at ligament of Treitz
and terminal ileum. These sites may be
encased in mucinous tumour.

the right and left hemidiaphragm,
the right suprahepatic space be
tween the diaphragm and liver and
the inferior aspect of the liver (right
subhepatic space) just above the
right kidney. Tumour beneath the
right hemidiaphragm may fix liver
and diaphragm together. The right
and left paracolic gutters may be
filled by tumour adherent to perito
neum. The fatty tissue of the porta
hepatis, falciform ligament and less
er omentum are often involved; the
gallbladder and porta hepatis are
commonly a single mass of cancer.
One aspect of this condition, not
previously appreciated, is the rela
tive sparing of small-bowel surfaces
by tumour implants (Fig. 2), be
lieved to be due to peristalsis. Only
after several laparotomies will the
small bowel become encased by tu
mour, because tumour emboli ad
here to abraded peritoneum and are
trapped within fibrous adhesions on
small-bowel surfaces. Continued
growth of tumour within smallbowel adhesions makes cytoreduction unsafe.1 However, early in the
disease, removal of tumour from
peritoneal surfaces can be accom
plished without trauma to the small
bowel. There are two exceptions to
this tumour-sparing effect. The ter
minal ileum and ligament of Treitz
are both anchored to the retroperitoneum. These anatomic
sites are much less mobile than the
remaining small bowel and may be
encased by tumour. The terminal
ileum must often be resected with
the cecum. Wedge excision of small
bowel at the ligament of Treitz may
also be necessary.
The optimal timing for the cy
toreductive procedure may not be
the same in all patients. Ideally,
removal of bulky tumour, including
greater omentum, and opening up
of all abdominal adhesions should
be accom plished
before intraperitoneal chemotherapy is start
ed. Some patients will be referred

for definitive treatment of peritoneal
carcinomatosis shortly after explor
atory laparotomy. They are often
not capable, physically or emotion
ally, of enduring a major abdominal
procedure at that time. Placement
of a peritoneal access device and
several cycles of intraperitoneal che
motherapy are used to preserve gas
trointestinal function and reduce
small-volume disease on peritoneal
surfaces. If the disease does not
disseminate to distant sites and the
patient’s physical status improves
over 4 to 6 months, then definitive
treatment of peritoneal carcinoma
tosis with cytoreductive surgery is
indicated.

Surgical Technique for
Cytoreduction
With sufficient courage, knowl
edge of anatomy, patience and per
sistence, the surgeon can dissect all
peritoneal surfaces within the abdo
men free of tumour using balltipped electrocautery on pure cut
and at high voltage (Table I). Dis
section with the ball tip just be
neath the tumour leaves visceral
structures intact, removing only the
lesion and involved peritoneal sur
faces. An important aspect of this
technique is strong traction and
countertraction between tumour
and normal tissue (Figs. 3 to 5).
This will expose vascular and ductal
structures and avoid damage to
them as the dissection proceeds.
Electrocautery on pure cut evapo
rates tumour tissue and does little
damage to fibrous tissue and nor
mal fat, so normal anatomic struc
tures encased in fat but covered by
mucinous tumour should not be
affected. Tissues rich in collagen,
such as ureters, large blood vessels,
common duct and intestinal wall
may be severely damaged unless the
surgeon’s technique is meticulous
and these structures are irrigated
CJS. VOL. 32. NO. 3. M A Y 1989
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frequently with cool water during
the procedure.
The undersurface of the dia
phragm poses special problems. If
the ball-tipped electrocautery con
tacts diaphragmatic muscle, marked
unpredictable contractions occur;
the cautery tip may perforate the
hemidiaphragm or pericardium. Tu
mour in this area is best removed
using a combination of blunt dissec
tion and contact yttrium-aluminumgarnet (YAG) laser. The latter will
maintain hemostasis and a margin
of dissection but will not cause
contractions of diaphragmatic mus
cle. An essential piece of equipment
for this procedure is the laser
smoke evacuator, which minimizes
the foul odour and excessive
smoke, thus maintaining the sur
geon’s view of the operative field,
and eliminates the possible inhala
tion hazard to operating-room per
sonnel.
In patients who must undergo
reoperation, tumour within fibrous
adhesions must be removed from
small-bowel surfaces, and this can
be hazardous. Frequent irrigation
of the operative site with saline will
minimize the possibility of full
thickness thermal damage to bowel
wall. If multiple areas of the bowel
are damaged, then a high, diverting
loop jejunostomy should be
brought out through a transverse
incision in the left upper quadrant.
This will prevent the formation of
small-bowel fistulas and associated
intraperitoneal sepsis. When pelvic

tumour implants are removed there
may be trauma to the large bowel,
requiring temporary exteriorization
of the sigmoid colon. The ostomies
are closed when bowel integrity is
demonstrated radiologically.
Cytoreduction of tumour in the
porta hepatis presents a special
problem. Cystadenocarcinoma char
acteristically implants and grows in
the “nooks and crannies” of the
abdomen. The recesses created by
the gallbladder, falciform ligament
and common-duct structures are
usually heavily involved by tumour.
An ultrasonic dissector has been a
valuable tool by which to remove
the mucinous cancer (high in water
content) from around the vital tubu
lar structures (high in collagen con
tent) that constitute the porta hepa
tis.2
Gross tumour within the lesser
omentum may require a lesser
omentectomy with sacrifice of the
right branch of the vagus nerve and
a portion of the left gastric artery.
If this is needed, a gastric drainage
procedure (pyloroplasty or gas
trojejunostomy) should be per
formed.

Technique for Immediate
Postoperative Intraperitoneal
Lavage
When the dissection is complet
ed, a Tenckhoff catheter is placed
through the abdominal wall at a
convenient location lateral to the

rectus muscles and anchored at the
peritoneal level by a pursestring
suture.
Postoperatively, the abdominal
cavity is lavaged for 24 hours with
a dialysis solution containing antibi
otics. This will remove blood and
tissue debris, which may plug the
catheter, and will help prevent in
fection and the formation of adhe
sions (Table II).

FIG. 3. Mucinous tumour implant on
peritoneal surface overlying pancreas.

FIG. 4. Traction at tumour-normal
tissue interface. Ball-tipped electrocau
tery on pure cut at high voltage is
used to evaporate tumour and separate
it from normal tissue.

Table I. Requirements for Dissection of Gastrointestinal Tumour From Peritoneal Surfaces
1. Meticulous bowel preparation, removing bacteria and fungus from the gastrointestinal tract.
2. Electrocautery machine placed on high voltage, pure cut, with the ball tip employed for tissue
contact.
3. Strong traction-counter traction placed at the tumour-healthy tissue interface.
4. Use of laser smoke evacuator.
5. Frequent irrigation for cooling nearby tissues when the dissection is used adjacent to a vital
structure such as small bowel, ureter or common duct.
6. Wide exposure using a self-retaining retractor.
7. Postoperative peritoneal lavage to remove tissue debris. Large-volume instillations in the
immediate postoperative period should contain antibiotics.
8. Intraperitoneal chemotherapy to minimize the recurrence of microscopic residual disease.
Lavage fluid should contain antibiotic agents.
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FIG. 5. Tumour-free abdominal surface
following electrocautery dissection.
Damage to underlying pancreatic tis
sue is minimal.
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To minimize catheter-related
complications, there must be meti
culous hemostasis, and the perito
neal cavity must be irrigated clear
of blood and clots before the abdo
men is closed. Cytotoxic agents
used for intraperitoneal chemother
apy prevent neutrophil replication
within the abdominal cavity for the
first week postoperatively, so antibi
otics are needed in the lavage solu
tion to control bacterial growth.
Drains in the abdomen should be
of the closed suction type, placed
low in either flank so that they can
be used for dependent drainage if
peritonitis occurs (Fig. 6). When
early postoperative intraperitoneal
chemotherapy is completed and in
traperitoneal drainage ceases, the
Romel tourniquets, used to provide
a watertight seal, are removed. This
allows gravity drainage of any re
curring intra-abdominal fluid, which
will help to prevent late abscess
formation. It also facilitates removal
of the suction drains, which are
usually placed beneath the left hemidiaphragm and occasionally with
in the pelvis.
Peritoneal lavage can be per
formed postoperatively in patients
who have ostomies, but leakage of
intraperitoneal fluid will be exces
sive unless the bowel wall is se
cured circumferentially with individ
ual sutures to the peritoneum plus
fascia.3

Intraperitoneal Chemotherapy
Cytoreductive surgery to remove
malignant tumour usually results in
limited short-term benefit to pa
tients. Bowel obstruction can be

relieved and bulk tumour removed.
Yet long-term disease-free survival
cannot be achieved unless the ex
tensive tumour contamination of
intra-abdominal surfaces can be
controlled. The use of early and
delayed postoperative intraperito
neal chemotherapy has been used
successfully to eliminate from the
abdominal cavity single cancer cells
and tumour emboli. These malig
nant foci become imbedded in the
fibrinous exudate that accumulates
on raw tissue surfaces within the
abdomen after surgical trauma.4
They develop into recurrent peri
toneal carcinomatosis over time no
matter how complete the surgical
cytoreduction.
Intraperitoneal chemotherapy has
been used to combat the regrowth
of cancer within the fibrous adhe
sions that form after cancer sur
gery. Optimally, the drugs should
be instilled in a large volume of
fluid to distend the abdomen and
reach all exposed surfaces. The che
motherapy does not penetrate tu
mour masses of appreciable size but
should destroy all small-volume dis
ease. It is best utilized in the first 5
postoperative days when drug dis
tribution to all intra-abdominal sur
faces is complete. Delayed postoper
ative intraperitoneal chemotherapy
is designed to augment the effects
of the surgery and the early postop
erative intraperitoneal chemothera
py. Drug distribution is less uni
form after abdominal adhesions
have formed and retroperitoneal fi
brous reaction has occurred. The
current plan for early and late in
traperitoneal chemotherapy for
large bowel tumours is shown in
Table III.

Patient Groups

Forty-seven consecutive patients
with advanced primary or recurrent
colorectal or appendiceal tumours
underwent laparotomy and cytore
ductive surgery; none were merely
explored surgically, the abdomen
closed and no further action con
templated. They ranged in age from
16 to 74 years. They were divided
into four groups. Group 1 (18 pa
tients) represented the ideal situa
tion in which patients had grade 1
or less mucinous cancer. All had
malignant pseudomyxoma perito
nei; no patient had benign mucocele
of the appendix.1 Group 2 patients
(17) had moderate- to high-grade
mucinous colonic or rectal adeno
carcinoma implanted on peritoneal
surfaces, but had no hematogenous
or distant lymphatic metastases.
Group 3 patients (eight) had either
high- or low-grade tumour that had
been treated with radiation (abdomi
nal or pelvic) or intraperitoneal iodine-131 monoclonal antibody.
Group 4 (four) had peritoneal carci
nomatosis and, subsequently, dis
tant metastases.
In each group of patients, some
were treated with intraperitoneal
chemotherapy and some were not.
In patients who did not receive
intraperitoneal chemotherapy, ab
dominal infection or an adhesive
process developed that prevented

Table II. Abdominal Lavage Instilled Immediately After Completion of Surgery
1. Instill 1 litre 1.5% dextrose peritoneal dialysis fluid as rapidly as possible. The fluid should
contain antibiotics for broad-spectrum coverage.
2. One hour dwell time, drain fluid as rapidly as possible.
3. Repeat instillations every 1 hour four times, then every 4 hours four times, then every 8 hours
until chemotherapy begins.

FIG. 6. Romel tourniquet used to pro
vide watertight seal around closed suc
tion drains inserted through generous
stab incisions.
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drug delivery by a peritoneal access
device.
Results
All of the low-grade mucinous
tumours were of appendiceal origin.
Moderately differentiated but clini
cally nonmetastasizing tumours
originated in the appendix (six) and
other parts of the colon (eleven).
Nearly all of the 47 patients were
symptomatic before they were treat
ed for peritoneal carcinomatosis.
The asymptomatic patients had le
thal seeding of peritoneal surfaces,
established by a previous laparoto
my and a rising carcinoembryonic
antigen level.
The short-term results of the
ball-tipped electrocautery technique
were surprisingly good. All patients
but one had at least transient relief
of intestinal obstruction. Patients
who seemed to profit most over the
long term had three clinical features
in common (Table IV). First, and
most important, they did not have
distant lymphatic or hematogenous
spread of the disease. Of four pa

tients with metastases (group 4),
only one remains disease free, and
he underwent a pneumonectomy for
lung metastases. Second, patients
who were made clinically disease
free by cytoreductive surgery
seemed to be in a favourable group,
even though some required several
staged surgical procedures to reach
this status. Of course, a larger
proportion of low-grade cancers
were completely removed. Finally,
only patients who had intraperitoneal chemotherapy or im
munotherapy, in addition to sur
gery, remained well for long peri
ods. Over half of the patients with
mucinous adenocarcinoma may be
expected to have prolonged diseasefree survival. They represent the
first report of cure after treatment
for peritoneal carcinomatosis.
Unfortunately, in these early clin
ical studies, these favourable results
were not obtained without cost. The
majority of patients who had cy
toreductive surgery after abdominal
radiotherapy had bowel perforation
postoperatively. A similar complica
tion occurred in four of the patients

who did not have preoperative ab
dominal radiotherapy. There were
no cases of anastomotic breakdown.
Of the patients who did not have
radiotherapy preoperatively, six had
peritonitis in the presence of an
intact bowel. The organisms were
Staphylococcus epidermidis and
Candida albicans. There were two
postoperative deaths, one from
staphylococcal pneumonia and the
other from the formation of multi
ple fistulas in a patient who had
irradiated bowel.

Discussion
Complications of cytoreductive
surgery are frequent, the most se
vere being seen in patients who
have previously undergone abdomi
nal or pelvic radiotherapy. I recom
mend that such patients be exclud
ed from this treatment plan unless
all of the irradiated tissue can be
resected.
If this procedure is attempted in
the presence of invasive tumours,
there may be dangerous hemorrh-

Table III. Early and Delayed Postoperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Large-Bowel Cancer
Cycle
Time
1
2*
3*
4*
Day of surgery Abdominal lavage only
Postop day 1
Mit C 10 mg/m2 in 1 L 1.5%
5-FU 900 mg/m2 plus 50
Mit C 12 mg/m2 in 2 L
5-FU 900 mg/m2 plus 50
dextrose dialysate solution.
mmol sodium bicarbonate
mmol sodium bicarbonate
Infuse as rapidly as
in 2 L 1.5% dextrose
in 2 L
possible; 23-hour dwell
dialysate solution. Infuse as
time. Maximum dose 20
rapidly as possible; 24-hour
mg. Drain abdomen
dwell time and no drainage
completely before next
instillation
Postop day 2
5-FU 800 mg/m2 plus 50
Same dose of 5-FU in 1 L
5-FU 900 mg/m2 plus 50
Same dose of 5-FU in 1 L
to 5
mmol sodium bicarbonate
solution. The soft tube used
mmol sodium bicarbonate
in 1 L 1.5% dextrose
for peritoneal access is
in 1 L
dialysate solution. Infuse as
removed after instillation
rapidly as possible; 23-hour
on day 5
dwell time. Maximum dose
1600 mg. Drain abdomen
completely before next
instillation
Postop day 6
Drain abdominal cavity as
completely as possible and
remove Tenckhoff catheter.
‘ Approximately 4 weeks separate cycles of intraperitoneal chemotherapy; drugs are instilled through a soft catheter positioned by paracentesis. Mit C =
mitomycin C, 5-FU = 5-fluorouracil.
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age, damage to vital structures and
an unsatisfactory surgical result.
When tumours are invasive, dissec
tion must be carried onto normal
tissue. For low-grade lesions, it is
adequate and safe, constituting ac
ceptable principles of surgical on
cology, to remove the tumour
through the interface of normal and
tumour tissue. However, when the
tumour is of moderate- or highgrade malignancy, reasonable pallia
tion can sometimes be achieved and
long-term survival may result if
distant metastasis does not occur.
Cytoreductive surgery should be ac
companied by intraperitoneal che
motherapy because satisfactory pal
liation or long-term disease-free
survival was not achieved without
it.
The Roswell Park group5 had
excellent results when they used
intraperitoneal cis-platinum chemo
therapy in patients with ovarian
cancer who had intra-abdominal
tumour nodules 1 cm in diameter or
smaller. A group from the Nether

►

Tab le IV .

Malignant pseudomyxoma perito
nei will never metastasize, so, if the
tumour is removed from the abdom
inal cavity, these patients can be
cured; the indication for cytoreduc
tive surgery is the presence of the
tumour itself, not any associated
symptoms. Patients with pseudo
myxoma peritonei may be expected
to have a good prognosis with this
treatment plan.
Patients with colonic adenocarci
noma of the mucinous histologic
type were also treated in this series.
This tumour is locally more inva
sive, so that a complete cytoreduction is more difficult. Also, residual
tumour is more solid and has a
well-developed vasculature. This
means that tumour penetration by
chemotherapy will not be as great
as with malignant pseudomyxoma
peritonei. When tumour cells are
suspended in an avascular protein
gel (mucinous ascites), the chemo
therapy diffuses into the mass, is
not metabolized or removed and
may be expected to exert maximal

lands6 obtained good responses in
patients treated with mitomycin C
when there were only small tumour
nodules in the abdominal cavity.
We7 had good results with cytore
ductive surgery plus intraperitoneal
5-fluorouracil and mitomycin C in
patients who had malignant mucin
ous adenocarcinoma of colonic or
appendiceal origin. Intraperitoneal
chemotherapy in the presence of
small-volume tumour may benefit
patients with malignant disease dis
seminated throughout the peritone
al cavity.1
In selecting patients for cytore
ductive surgery, certain factors
must be considered. With moderateor high-grade tumour, the long
term disease-free survival is usually
limited and metastases may occur at
other sites, causing death. In these
patients, the standard surgical indi
cations for palliative surgery (intes
tinal obstruction or uncontrollable
abdominal distension from tumour
or ascites) should be the indications
for surgery.

Results of Treatment of Patients With Peritoneal Carcinomatosis

►

G roup
Result

►

►
►
►
►
►

►

►
►
►
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No. of patients
NED after operation
Primary site
Appendix
Colon
Unknown
Symptoms/signs
Bowel obstruction
Massive ascites
Abdominal mass
Rising CEA
Complications after cytoreductive surgery*
Peritonitis
Bowel perforation
Prolonged ileus
Abscess
Intraperitoneal chemotherapy/no intraperitoneal chemotherapy
NED
AWD
DOD
DOC

1

2

3

4

18

17
7

8

4

3

1

6
11

1

1

7

3

11
17

0
1
3

8
3
4

_

_

_

5
5
4
3

5

2
0
1

2
0
1
1

0
6
1
0

0
0
0
0

3/5
3/0

4/0

3

3

2
2
2

2
3

0

13/5
9/ 2T

14/3

2/0
0/2
2/1

5/1
3/2

0/0

0/0

0/11

6/0

0/4

1/0
0/0
2/0
1/0

NED = no evidence of disease, CEA = carcinoembryonic antigen, AWD = alive with disease, DOD = died of disease, DOC = died of other causes.
'One patient died of staphylococcal pneumonia.
tBoth patients received 15 cycles of 7-interferon intraperitoneally; they were the only ones in the series who had no evidence of disease in the absence
of intraperitoneal chemotherapy.
JDied with multiple small-bowel perforations.

►

►
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cell kill. Well-vascularized tumour
nodules and normal structures rap
idly remove chemotherapeutic
agents by lymphatic channels and
the capillary network. In summary,
one expects intraperitoneal chemo
therapy to produce its greatest cell
kill when the tumour is avascular.
This is just the opposite of chemo
therapy given by the intravenous
route.
Even though mucinous colonic
adenocarcinoma may invade intra
abdominal structures and implant
widely on all peritoneal surfaces, it
rarely metastases by lymphatic or
hematogenous routes. By the theo
ries of metastases suggested by
Weiss,8 this tumour would have a
metastatic inefficiency of infinity.
One may question the use of the
ball-tipped electrocautery on pure
cut at high voltage. Its advantages
are speed, accuracy of dissection
and hemostasis. A large amount of
tumour tissue can be removed rap
idly at one session, without the
extensive blood loss that results
from sharp dissection. Even the
smallest amount of blood in the
operative field will interfere with
exposure and may result in damage
to vital structures. Unless large ves
sels are transected, the electrocau
tery maintains absolute hemostasis
and cleanly defines the plane of
dissection between tumour and nor
mal tissue. Early in the course of
his experience, the surgeon will
recognize the characteristic features
seen when transecting tumour, fat,
abdominal adhesions or vital struc
tures.
Long-term (3 years) disease-free
survival was seen in the majority of
patients with nonmetastasizing tu
mour in this series. These clinical
data suggest that a combination of
cytoreductive surgery with the balltipped electrocautery on pure cut at
high voltage followed by in
traperitoneal chemotherapy can
cure selected patients with malig
170
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nant large-bowel cancer on perito
neal surfaces.
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SESAP VI Critique
Item 105
Hyperchloremic metabolic acidosis is a recognized complication of
diverting urine through an ileal segment. The problem occurs with
varied incidence after construction of an ileal or colonic conduit, a
continent ileal pouch, or a ureterosigmoidostomy. It may be seen in
patients with normal renal function and in the absence of systemic
electrolyte changes. Hyperkalemic, hypochloremic metabolic acidosis
can occur when jejunal rather than ileal segments are used for urinary
diversion.
Physiologic explanations of hyperchloremic metabolic acidosis in
clude: selective reabsorption of urinary chloride by the ileal mucosa; a
renal acidifying defect; reabsorption of ammonium chloride, and bicar
bonate secretion by the colon in response to local introduction of urine.
The absence of significant changes in serum chloride or total C02
should not be equated with an absence of metabolic abnormalities after
urinary diversion. Therapy for hyperchloremic metabolic acidosis must
include restriction of chloride intake, because of the relationship
between chloride reabsorption and acid reabsorption.

m
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Periosteal Neochondrogenesis for
Biologically Resurfacing Joints: Its
Cellular Origin
Rick Zarnett, MD, MSc;* Robert B. Salter, OC, MD, FRCSCt
The purpose o f this study was to determine if the hyaline-like cartilage produced in
major full-thickness defects o f a joint surface, treated by a free periosteal graft and
subjected to continuous passive motion (CPM), originated exclusively from the
progenitor cells o f the cambium of the graft. Free periosteal grafts were raised from
the tibia of both hind legs of eight male New Zealand rabbits and transplanted into
full-thickness defects across the entire width of the patellar groove of 15 female
rabbits. Postoperatively, CPM was instituted and the animals were sacrificed after 3
weeks. Cells from the regenerated tissue were grown from tissue explants and their
karyotypes determined. In 33% of the rabbits, all cells contained a Y (male)
chromosome, indicating that regenerated tissue originated exclusively from the
progenitor cell of the periosteal graft. Karyotypes of the cells from the other 67%
were mosaics (both female and male); thus, their cellular origin was from both the
periosteal allograft and the pluripotential mesenchymal cells in the subchondral
tissues.

Le but de la presente etude consistait a determiner si le cartilage de type hyalin, qui
apparait quand des dysplasies interarticulaires majeurs sont traitees par greffe
periostique libre et soumises a une mobilisation passive continue (MPC), provient
exclusivement des cellules souches du cambium du greffon. Ces greffons ont ete
obtenus a partir des tibias des membres inferieurs de huit lapins New Zealand
males. Its ont ete transplants chez 15 lapines, dans des dysplasies completes sur toute la
largeur de la gouttiere rotulienne. Apres l’operation, une MPC fut mise en place et les
animaux furent sacrifies apres 3 semaines. Les cellules du tissu regenere furent mises en
culture et leurs karyotypes furent determines. Chez 33% des lapines, toutes les cellules
contenaient le chromosome Y (male), indiquant que le tissu de regeneration provenait
exclusivement des cellules du greffon periostique. Le karyotype des cellules des 67%
restant etait constitue d’une mosai'que (male et femelle); en consequence, leur origine
cellulaire venait, a la fois, de l’allogreffe periostique et des cellules mesenchymateuses
pluripotentes du tissu sous-chondral.
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rosthetic joint replacement is a
major advance in the treatment
o f degenerative joint disease, but
possible residual loosening and in
fection make the procedure unac
ceptable in the young or active
person.
Recent investigations1"3 at our
research laboratory demonstrated
that major, full-thickness defects in
a joint surface can be “ biologically
resurfaced” by stimulating the cam
bium o f free periosteal grafts with
continuous passive motion (CPM).
In a previous study,4 free autoge
nous periosteal grafts were labelled
with tritiated thymidine to deter
mine if the cellular origin o f the
hyaline-like cartilage was progeni
tor cells o f the periosteal graft. This
method enabled us to follow the
pluripotential cells o f the cambial
layer o f the grafts as they passed
through the stages o f neochon
drogenesis. We were able to con
clude that the thymidine-labelled
cells in the regenerated tissue had
originated from the periosteal graft.
We were, however, unable to com 
ment on the origin o f the entire
mass o f regenerated tissue.
The rabbit has 22 pairs o f chro
mosomes.56 The 21 pairs o f autosomes can be arranged in descend
ing order o f length and numbered
serially (Fig. 1). Chromosome pairs
20 and 21 are the shortest
acrocentric chromosomes, corre
sponding to group G in the human
karyotype. The acrocentric Y chro
mosome is the smallest o f the ka-
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ryotype and can be placed in a
morphologic group with chromo
some pairs 20 and 21.56 Thus, it is
possible to differentiate between the
karyotype of a female and a male
cell by establishing if four or five
small acrocentric chromosomes are
present.
If an allograft of periosteum
could be transplanted from a male
to a female rabbit, the cells derived
from the pluripotential cells of the
cambial layer of the periosteum
would carry a recognizable label
(i.e., the Y chromosome). This label
would not become diluted as the
cells underwent subsequent mitosis.
This experiment was designed to
answer the following question: Does
the entire regenerated hyaline-like
tissue originate from the progenitor
cells of the periosteal graft or do
the subchondral tissues provide plu
ripotential cells which contribute to
the “biological resurfacing” of
these major, full-thickness defects?

Tissue Culture

individual layers of periosteum a
blue 5-0 polypropylene suture was
placed in the fibrous layer of each
graft. The grafts were placed in
0.9% sterile saline solution until
transplantation.
Each female rabbit was anesthe
tized and the appropriate limb pre
pared as in the donor. A medial
arthrotomy of one knee joint was
performed on each rabbit. The pa
tella was dislocated laterally and the
allograft of periosteum transplanted
into a 5-mm full-thickness defect
across the entire patellar groove, as
previously described34 (Fig. 2).
While under anesthesia, the ani
mals were placed on the CPM appa
ratus where they remained until
they were killed 3 weeks later.7

The involved knee joints were
exposed under sterile conditions. A
portion of the newly formed tissue
from the patellar groove was re
moved and placed in a Petri dish
containing cold sterile phosphatebuffered saline (PBS). The sample
was obtained from the centre of the
defect, well above the underlying
subchondral bone, in order to avoid
contamination by the surrounding
host (female) tissue.
To confirm the biopsy location,
50% of the knees (randomly select
ed) were fixed, decalcified and
stained as previously described.4
This allowed us to observe any
signs of graft rejection.

Material and Methods
Twenty-three (15 female, 8 male)
adolescent, New Zealand rabbits,
weighing between 2.2 and 2.8 kg,
were used as models. The surgical
procedures were performed under
general anesthesia induced by an
intravenous injection of sodium
pentobarbital (25 m g/kg body
weight) and maintained by an inha
lation mixture of 1% halothane,
60% nitrous oxide and 39% oxygen.
In the male rabbit, the skin of the
hind limbs was shaved from the hip
to the ankle and prepared with
povidone-iodine. A medial skin inci
sion (6 cm long) was made over the
proximal tibia, and a rectangular
incision 7.5 X 15 mm was made in
the underlying periosteum of both
hind limbs. The periosteal graft was
carefully elevated from the underly
ing tibia by sharp subperiosteal dis
section, and to distinguish the two
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FIG. 1. Karyotype of rabbit contains 22 pairs of chromosomes. As in human, male
contains five small acrocentric chromosomes (pairs 20 and 21 plus Y). In contrast,
female has only four small acrocentric chromosomes (pairs 20 and 21).
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FIG. 2. (Left) Transverse section through male periosteal allograft lying or
subchondral bone. Cambium of graft faces into joint. Base of defect is flat in
contrast to contour of patellar groove. (Right) Lateral view of periosteal graft
sutured to periosteum of femur. Depth of defect varied from 2 mm in centre of
groove to 5 mm at edge.

PERIOSTEAL NEOCHONDROGENESIS

The tissue sample was trans
ferred to a sterile Petri dish with 3
to 4 ml of medium, consisting of
alpha minimal essential medium
(MEM) supplemented with 15% fetal
calf serum (FCS), penicillin (100
un its/m l), streptom ycin (100
mg/ml) and amphotericin B (2.5
Mg/ml). The tissue was then cut
into pieces approximately 0.5 mm2
and 6 to 10 pieces were transferred
to each of four Falcon plastic cul
ture flasks. The flasks were placed
upright for 30 minutes in the incu
bator to allow the tissue explants to
attach firmly to the flasks. With 10
ml of medium the explants were
incubated at 37°C in 95% humidi
fied air plus 5% carbon dioxide. The
medium was changed twice weekly.

peated three times. The cells were
spread and flattened on the glass
slides and the chromosomes were
then stained with Giemsa solution.

Examination for Chromosomes
The slides were screened under
low power (125X) and chromosome
spreads identified for counting and
photography. When a cell in which
all the chromosomes were clearly
defined was identified, it was exam
ined further under high power
(1250X) and the number of
acrocentric chromosomes (four indi
cating a female karyotype and five
indicating a male karyotype) docu
mented.

Subculture Technique

Results

At 4 to 6 weeks, the cells were
separated from the flasks with
0.25% trypsin/ethylene diamine
tetra-acetic acid, and secondary cul
tures were established on sterile
glass microscope slides, which were
placed in culture dishes and incu
bated for a further 48 hours.

Tissues from the transplanted
knees of the 15 female rabbits were
studied. The first four rabbits made
up a pilot group; their knees were
examined for evidence of graft re
jection. Of the remaining 11 rab
bits, 1 was excluded because of a
dislocated patella and 1 because the
periosteal graft had become de
tached from the subchondral bed.
This left nine animals for chromo
somal analysis of the regenerated
tissue.

Harvesting of Chromosomes
After the 48 hours, colcemid
(concentration 0.67 Mg/ml) was
added to the medium and the Petri
dishes were incubated for 3 more
hours, after which the medium was
removed and the cells were hypotonically expanded using 0.075 M
potassium chloride.

Fixing the Cells
Ten millilitres of a 3:1 mixture of
ice-cold methanol and glacial acetic
acid were slowly added to the dish
es, allowing the cells to fix for 15
minutes. This procedure was re

Gross Findings
In all rabbits, the patellar groove
was fully restored; the defects were
filled in by smooth tissue resem
bling hyaline articular cartilage.
There was no evidence of graft
rejection.

Histologic Findings
The surface of the regenerated
tissue was smooth and resembled
hyaline articular cartilage. Round
chondrocytes were contained in

well-formed lacunae. The extracel
lular matrix stained well with Safranin O, indicating glycosaminoglycan production.
After 3 weeks of CPM there was
no histologic evidence of graft re
jection or cellular infiltration in the
regenerated tissue.
Tissue samples from four knees
were examined histologically. The
sample was always taken from the
central and superficial area of the
graft, thus avoiding both the regen
erated tissue in the base of the
defect and the normal articular car
tilage.

Chromosomal Analysis
The tissue explants grew slowly;
it took 4 to 6 weeks for a sufficient
number of cells to be available for
subculture. A minimum of two
flasks containing between 6 and 10
tissue explants each were examined
to give a wide sampling of tissue.
The karyotypes of 194 cells were
determined (average 21.6 cells/rabbit).
In three of the nine female rab
bits, 100% of the cells examined
carried the male karyotype, proving
that all these cells had differentiated
from the pluripotential cells in the
cambium of the periosteal graft
(Fig. 3). In the other six rabbits, the
karyotypes were sexual mosaics,
containing both female (host) and
male (graft) cells (Fig. 4).

Discussion
In their original investigation on
the “biological resurfacing’’ of
joints, O’Driscoll and colleagues3
reported that in 20% of the control
animals (i.e., those that did not
receive a periosteal graft), hyaline
cartilage was the predominant tis
sue formed. In addition, 1-mm full
thickness defects are capable of
CJS, VOL. 32. NO. 3. M A Y 1989
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healing with hyaline-like cartilage
when stimulated by CPM.8 There
fore, the subchondral tissues can
produce hyaline-like cartilage, al
though it is inferior in quantity and
quality to the tissue formed when
full-thickness defects are grafted
with periosteum.9
The present investigation demon
strated that the hyaline-like carti
lage produced when free periosteal
grafts are transplanted into full
thickness defects is not derived en
tirely from the periosteal graft; in
67% of rabbits the regenerated tis
sue had a cellular origin from both
periosteal graft and the subchondral
tissues. In the remaining 33% the
periosteal graft was exclusively re-

m
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FIG. 3. Photomicrograph of chromo
somal spread contains five small
acrocentric chromosomes (arrows),
proving that it originated from perios
teal graft.

sponsible for the cellular origin of
the regenerated tissue.
Early attempts at “biological re
surfacing” failed because the tis
sues underwent either necrosis and
degeneration or, at best, conversion
to fibrous tissue.10 Hoover and Cov
entry11 believed that the various
interposition materials acted only as
a culture medium and had no effect
on the ultimate repair tissue on the
joint surface. Ruback and associ
ates9 placed a cell-impenetrable fil
ter between the cancellous bone and
a periosteal graft in an attempt to
demonstrate the origin of the carti
lage-like tissue regenerated in their
experimental model. At 4 to 8
weeks, all the filters had fractured,
making the contribution to the re
pair tissue from the underlying
bone difficult to assess. Because the
cells represented clonal outgrowths
from tissue explants, the proportion
of male and female cells is an
unreliable indicator of the actual
proportion of tissue derived from
each of the two sources.
We demonstrated that the hya
line-like cartilage, either totally or
in part, originates from the perios
teal graft. Thus, the periosteum is
of primary importance in this “bio
logical resurfacing” model.

Conclusions

FIG. 4. This cell contains four small
acrocentric chromosomes (arrows) and
is therefore female. It has its origin
from undifferentiated mesenchymal
cells in subchondral tissues.
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The hyaline-like cartilage pro
duced when a free periosteal graft is
transplanted into a major full-thick
ness articular defect in a joint sur
face and subjected to continuous
passive motion, is derived either
totally or in part from the periosteal
graft. In two-thirds of the animals
in this study, the subchondral tis
sues provided pluripotential cells
contributing to neochondrogenesis.
We thank Mr. Ajai Kumar and Mrs.
Chin Ho for technical assistance. This
research project was approved by the

Animal Experimentation Committee at
The Research Institute, The Hospital
for Sick Children, Toronto.
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D oes Endoscopy Really Help the Surgeon
Evaluate Gastric Cancer?
Nadey S. Hakim, MD, FRCS; Michael G. Sarr, MD, FACS; Jon A. van Heerden, MD, FRCSC
To determine whether gastroscopy helps the surgeon in preoperative planning and
decision-making in patients with gastric cancer, the authors reviewed the charts of 100
consecutive patients with surgically proven gastric cancer. The findings from
gastroscopy, upper gastrointestinal series and computed tomography were evaluated for
their ability to define the anatomic site of the lesion, proximal and distal extent of gastric
involvement, presence of a mass or ulceration and the sensitivity of diagnosis. The
sensitivity of endoscopic biopsy and brush cytology were also determined. Gastroscopy
was found to be the most sensitive diagnostic test, both in recognizing the presence of an
abnormality (100% versus 86% versus 76% respectively) and the possibility of a malignant
condition (88% versus 71% versus 76%); in addition, endoscopic biopsy and brush
cytology were diagnostic in 90% and 70% of patients, respectively. Gastroscopy and upper
gastrointestinal series were equally accurate in determining proximal or distal extent of
tumour. The authors concluded that gastroscopy is the most sensitive diagnostic test in
patients with gastric cancer; upper gastrointestinal series does not add significantly
useful information to the preoperative evaluation. Computed tomography can assess
regional and distant metastasis, but its contribution as to the local extent of the tum our is
limited.

Les auteurs ont etudie les dossiers medicaux de 100 patients consecutifs porteurs de
cancers gastriques demontres a la chirurgie, afin d’etablir si, dans le cancer gastrique, la
gastroscopie aidait le chirurgien dans sa planification preoperatoire et dans sa prise de
decision. Les resultats des examens de gastroscopie, des cliches en serie des voies
digestives hautes et de la tomodensitometrie ont ete mis en parallele pour etablir leur
capacity de definir le siege de la tumeur, l’etendue proximale et distale de l’atteinte
gastrique, la presence d’une masse ou d’ulceration et la sensibilite diagnostique. On a
aussi determine la sensibilite de la biopsie endoscopique et de l’examen cytologique par
brassage. La gastroscopie s’est averee le test diagnostique le plus sensible, tant pour
reconnaitre la presence d’une anomalie (100% contre 86% et 76%, respectivement), que
pour prevoir la possibility qu’il s’agisse d’une affection maligne (88% contre 71% et 76%);
la biopsie endoscopique et la cytologie par brassage avaient une valeur diagnostique chez
90% et 70% des patients, respectivement. La gastroscopie et les cliches en serie des voies
digestives superieures etaient d’une egale precision pour determiner l’etendue proximale
et distale de la tumeur. Les auteurs concluent que la gastroscopie represente l’instrument
diagnostique le plus sensible dans les cas de cancer de l’estomac; les cliches en serie des
voies digestives n’ajoutent pas vraiment d’information utile a 1’evaluation preoperatoire.
La tomodensitometrie peut evaluer les metastases regionales et a distance, mais sa
contribution a 1’evaluation de l’etendue locale est limitee.
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Reprint requests to: Dr. Michael G. Sarr, Department o f Surgery, Gastroenterology Research Unit,
Mayo Clinic, Rochester, MN55905, USA
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lexible fiberoptic gastrointestinal
endoscopy has become a wellestablished procedure for evaluating
the esophagus, stomach and duode
num. In several studies'-4the diagnos
tic accuracy of radiologic contrast
examination of the upper intestine has
been compared with endoscopic tech
niques. Contrast roentgenography
was found to be accurate in at least
90% of patients, and several authors3-4
have advised that endoscopic exami
nation be reserved for patients in
whom the results of radiologic assess
ment are inconclusive or when a
histologic diagnosis of malignancy is
required.
The purpose of this study was to
compare, retrospectively, the accura
cy of gastroscopy, conventional upper
gastrointestinal roentgenography and
computed tomography and to corre
late results with surgical findings and
the final pathology report, in patients
with proven gastric carcinoma. Our
aim was to determine if any of the tests
provide more information than others
to assist the surgeon in planning
operative strategy.

Methods
One hundred consecutive patients
seen at the Mayo Clinic between 1985
and 1987 with surgically confirmed
gastric cancer were studied retrospec
tively. Only those who underwent
preoperative gastroscopy carried out
by a member of our group were
included. The results of endoscopy
and the histopathologic report of bi
opsies or cytologic study were taken
from the original records. The find
ings of upper gastrointestinal con
trast roentgenography and computed
CJS, VOL. 32, NO. 3, M A Y 1989
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tomography, when performed in addi
tion to the endoscopy, were also re
viewed. Each diagnostic investigation
was assessed for its ability to recog
nize one or more of the following: a
gastric abnormality defining accurate
ly the macroscopic appearance (be
nign versus malignant); the presence
or absence of mass or ulceration; the
site (upper third or lower third of
stomach) and size of the lesion; the
gross margins of the lesion (proximal
extension in relation to the eso
phagogastric junction and distal ex
tension in relation to the pylorus) and
the distensibility of the stomach. Bi
opsies and brush cytologic samples
taken during endoscopy were re
viewed for diagnostic sensitivity.

Results
The mean age of the group was 69
years and the ratio of men to women
was 4 to 1. Thirty-five patients under
went an upper gastrointestinal series
and 34 abdominal computed tomogra
phy, in parallel with the gastroscopy.
Ninety-eight patients underwent
gastrectomy, 1 had a bypass for pallia
tion and in the other the tumour was
deemed unresectable. All had an ade
nocarcinoma of the stomach.
The results of the three diagnostic
procedures are shown in Table I.
With respect to gastroscopy, the
distensibility of the stomach was men
tioned in only seven reports and was
correct in all cases. Multiple biopsies
were performed in all cases and the
accuracy in diagnosing malignancy
T a b le

P ro c e d u re

Gastroscopy
(n = 100)
Upper gastrointestinal
contrast roentgenography
(n = 35)
Computed tomography
(n = 26)
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was 90%; thus, 10% of biopsy results
were false negatives. Brush cytology,
performed concomitantly in 25% of
cases, gave positive results in 70%.
Of the 35 upper gastrointestinal
series, 5 (14%) were interpreted as
being normal (false negative). The
orientation (anterior, posterior, lesser
and greater curvature) was rarely
mentioned and the distensibility of the
stomach was never mentioned.
Of the 34 computed tomograms,
abnormal features suggestive of a
malignant lesion were detected in 26
(76%). Thickening of the gastric wall
was noted in 15 patients (45%) and
was the most common indication of
malignant disease. The other abnor
mal scans showed, in addition, a mass
within the stomach. Although the
examination was accurate in defining
the site of the lesion, its extent was
poorly assessed. In patients with
metastatic nodal disease the positive
scans revealed local lymph-node en
largement in nine. Thus, the sensitivi
ty of recognition of nodal metastases
was 9 of 20 (45%), whereas the speci
ficity approached 100%. Liver metas
tases were incorrectly suggested in
one patient.

Discussion
Our study clearly demonstrates
that gastroscopy with biopsy is a
sensitive diagnostic procedure (90%),
which provides an objective diagnosis
of gastric cancer in patients with
proven carcinoma of the stomach.
Endoscopy identifies mucosal abnor

1. Diagnostic Procedures for Evaluating Gastric Carcinoma
P resen ce or
absence of
u lc e r a tio n , %

P r e s e n c e or
a b s e n c e of
m ass, %

P r o x im a l/d is ta l
e x te n t of
m a lig n a n c y , %

95

96

82

89

71

77

95

77

91

76

100

A b n o rm a l
fin d in g s , %

M a c r o s c o p ic
im p r e s s io n of
c a r c in o m a , %

100

88

86
76
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malities related to gastric cancer with
greater sensitivity (100%) than either
gastrointestinal contrast studies
(86%) or computed tomography
(76%). Gastroscopy and gastrointesti
nal contrast studies were equally ac
curate in determining proximal and
distal extent of the malignant disease.
Computed tomography may provide
information concerning the presence
or absence of liver metastases and
nodal involvement, but did not pro
vide additional information on the
local extent of the tumour.
In the past, the upper gastrointesti
nal series has been the “ gold stan
dard” against which to judge the
diagnostic accuracy of tests for gastr
ic cancer; introduction of the air con
trast technique in Japan further im
proved its sensitivity, often allowing
the diagnosis of superficial, early
gastric cancers. However, the advent
and rapid adoption of gastroscopy in
the 1970s added a new dimension to
the diagnostic armamentarium; sur
geons are now asked to see many
patients with endoscopically suspect
ed (or proven) gastric cancer who have
not undergone conventional contrast
roentgenography. Before we carried
out this study, our hypothesis, based
on a subjective impression and now
proven incorrect, was that upper gas
trointestinal contrast studies were
more accurate in determining the
extent of the malignant disease, and,
therefore, were helpful in aiding the
planning of the operative procedure.
Also, we confirmed the findings of
several other studies235 that gastros
copy was a very sensitive method for

S ite a n d
o r ie n ta tio n ,

%

76

B io p s y ,

%

B ru s h
c y to lo g y , %

100
(90 +ve)

25
(70 +ve)
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diagnosing gastric carcinoma. It is, in
our experience, superior to contrast
studies in sensitivity and equally effi
cacious in delineating the proximal
and distal extent of the lesion. More
over, gastroscopy provides the ability
to obtain an objective diagnosis of a
malignant condition through direct
biopsy or by cytologic examination.
Biopsies were diagnostic in 90% of
cases, a rate similar to the sensitivity
reported by others,6 and brush cytolo
gy was diagnostic in 70%, which is
substantially less than the 83% report
ed by Pilotti and colleagues.6
Whether, by combining endoscopy
and conventional radiologic contrast
study, diagnostic sensitivity is im
proved markedly and is thus cost
effective, is difficult to answer. Of the
10 patients in whom the endoscopic
biopsy gave a false-negative result, 6
had lesions that the endoscopist de
scribed as highly suggestive of a
malignant condition, and in the other
4 the lesions were abnormal but equiv
ocal with respect to malignancy. Of
these four patients, three had abnor
malities on radiologic contrast study
which could have been considered
suggestive of a malignant lesion;
therefore the combined use of the two
diagnostic tests might have benefited
only three patients. Moreover, since
radiologic contrast studies are no
more accurate in delineating proximal
or distal tumour extension, we con
clude that they offer little additional
preoperative information of impor
tance to the surgeon when gastric
cancer is suspected on endoscopic
examination or proven by additional
biopsy.
Two fundamental types of gastric

computed tomography are performed
in clinical practice: (a) the directed
examination, prompted by a history of
known or suspected gastric disease
based on previous surgery, endoscopy
or barium study and (b) the incidental
examination in which the stomach is
studied as part of a more general
search for intra-abdominal disease,
when no known gastric disease exists.
In our study, all such scans were
directed studies, ordered when there
was a suggestion of an abnormality on
endoscopy or contrast roentgenogra
phy. In spite of this, there were false
negative results in 24% of cases. Had
they not been “directed” tests, the
sensitivity most likely would have
been less. In several reported series,7-9
wall thickness 1 cm or greater has
been a reliable indicator of gastric
malignant disease. Little information
was available to assess the local extent
of the tumour. None of the 26 patients
who had computed tomography
were found to have liver metastases
at surgery and in only one scan was
there a suspicion of hepatic involve
ment.

Conclusions
Our study suggests that in the
investigation of gastric disease, the
routine use of upper gastrointestinal
contrast roentgenography with only
selective use of gastroscopy may re
duce the number of endoscopic exam
inations but sacrifices diagnostic sen
sitivity and would be unacceptable.
Gastroscopy, therefore, is the exami
nation of choice in the patient with
suspected gastric cancer; contrast ro

entgenography should be performed
as a second choice. On the other hand,
gastroscopy is not necessarily indicat
ed in the patient who has a mass that
appears malignant on contrast study,
unless operation will only be under
taken if there is objective documenta
tion of malignancy (i.e., biopsy proof).
Computed tomography can assess the
presence of regional node metastases,
with a sensitivity of 45%, and possibly
the absence of liver metastases but
does not add important information
on the local extent of the tumour.
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Comparison of Processed Bovine Internal
Mammary Arteries and Autologous Veins
as Arterial Femoral Substitutes in Dogs:
Blood Compatibility and Pathological
Characteristics
F.J. Teijeira, MD, PhD; Yves Marois, MSc; L. Aguiar, MD; R. Guidoin, PhD;
R. Bauset, MD; G. Lamoureux, MD; A. Downs, MD, FRCSC;* M. Marois, MD;
D. Boyer, MSc
This study was undertaken to compare the chemically processed internal mammary
artery (BIMA) and the autologous femoral vein as arterial grafts. The BIMA
prosthesis was implanted as a left femoral artery bypass and the femoral vein as a
right femoral artery bypass graft in 27 dogs. In groups of three dogs the grafts were
implanted for predetermined durations: 4, 24 and 48 hours (short term), 1, 2 and 4
weeks (medium term) and 3, 6 and 9 months (long term). All autologous veins were
patent when the dogs were killed. The patency rates of the BIMA grafts were 100%
in the short-term group, 67% in the medium-term group and 29% in the long-term
group. The deposition of labelled fibrinogen and platelets on flow surfaces, the
structural preservation of the wall of the BIMA prosthesis and accumulation of
thrombi during the period of implantation were studied.

Cette etude a ete entreprise dans le but de comparer l’artere mammaire interne
bovine traitee chimiquement (BIMA) et la veine femorale autologue utilisees comme
greffons arteriels. La prothese BIMA a ete greffee chez 27 chiens comme derivation
de l’artere femorale gauche alors que la veine femorale etait utilisee pour ponter
l’artere femorale droite. Les animaux, repartis par groupes de trois chiens, ont re?u
les greffes pour des durees predeterminees de 4, 24 ou 48 heures (le court terme),
de 1, 2 ou 4 semaines (le moyen terme) et de 3, 6 ou 9 mois (le long terme). Quand
les animaux furent sacrifies, toutes les veines autologues etaient permeables. Le
taux de permeabilite des greffons BIMA etait de 100% a court terme, de 67% a
moyen terme et de 29% a long terme. Ont aussi fait l’object d’une etude, le depot de
fibrinogene marque et de plaquettes sur la surface luminale, la preservation de la
structure de la paroi de la prothese BIMA et l’accumulation de thrombi durant la
periode d’implantation.
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hemically processed grafts are
used as substitute blood con
duits in peripheral vascular surgery
when autologous vein is not avail
able. Although human umbilical
veins have performed satisfactorily
for some 12 and outstandingly for
others ,3 several authors4-5 have
questioned their durability. Bovine
heterografts (originating from ca
rotid arteries) are now used only as
a secondary vascular access ;6-8 their
primary use in peripheral vascular
surgery was practically abandoned
after reports of early thrombosis
and aneurysm formation.9-11 Their
secondary use is now being chal
lenged by the polytetrafluoroethylene graft. 1213
Despite marginal improvements,
bovine grafts have been disappoint
ing clinically . 14-16 Nevertheless,
chemically processed biologic grafts
of small diameter are still being
investigated. New ideas led Malone
and colleagues 17 to develop an acel
lular matrix biograft, and Loisance
and colleagues 18 described a new
biochemical processing of human
placental arteries. In Brazil, Biocor
Industrias19 explored the possibili
ties of a chemically processed bo
vine internal mammary artery (BI
MA) as a vascular substitute for
small- and medium-sized arteries.
Although results in humans were
satisfactory , 19 more, thorough in
vestigation must be done before its

ARTERIAL FEMORAL SUBSTITUTES

final commercial release. We report
our in-vivo evaluation of this new
graft as a femoral artery substitute
in the dog. The BIMA prosthesis
was compared with the autologous
femoral vein with respect to paten
cy, morphologic features and plate
let and fibrinogen deposition on the
luminal surface of the graft placed
for predetermined periods.

Materials and Methods

The Grafts
The BIMA prostheses (Fig. 1)
were obtained from Biocor Industrias Ltda of Nova Lima, Brazil.
The bovine internal mammary ar
tery graft is chemically processed
with glutaraldehyde for 3 months,
then stored in sterile buffered 3%
formaldehyde solution. It must
therefore be abundantly and care
fully rinsed in heparinized saline
before implantation.
Autologous femoral veins were
dissected during surgery in each
dog and were interposed as arterial
femoral substitutes.

weighing on average 20 kg, were
selected as stipulated by the Canadi
an Council on Animal Care. After a
24-hour fast, they were anesthe
tized with 25 m g/kg of intrave
nous Pentothal and then mechani
cally ventilated. Under strict sterile
conditions, segments from both
right and left femoral arteries were
removed and the right femoral vein
was harvested. In each case, a few
minutes after injection of 1 m g/kg
of heparin intravenously, 5 cm of
autologous femoral vein was inter
posed as a graft in the right femoral
artery and the 5 cm of BIMA graft
in the left femoral artery. End-toside or end-to-end anastomoses
were performed using Prolene
(Ethicon Ltd., Peterborough, Ont.)
6-0 or 7-0 suture. The dogs were
given 15 000 units of prolongedeffect antibiotic (Penlong S; Rogar
STB Inc., Montreal, PQ), returned
to their cages and fed a normal diet.
A second operation was carried out
at predetermined intervals — 4, 24
and 48 hours (short term), 1, 2 and
4 weeks (medium term) and 3, 6
and 9 months (long term) — for
exposure to labelled platelets and
fibrinogen. Overall, nine groups of

three dogs per duration of implanta
tion were evaluated. Those in the
long-term group underwent angiog
raphy before the second operation.
Investigations
The dogs remained anesthetized
for 4 hours after intravenous injec
tion of platelets, labelled in the
laboratory, and 125 nCi of label
led 125I fibrinogen. The grafts were
then removed. Both venous and
prosthetic grafts were gently rinsed
in heparinized physiologic saline
and immediately cut into five seg
ments of equal length, the first and
fifth segments including the anasto
motic areas and the other three
segments located in between. Each
segment was counted separately for
deposition of labelled platelets and
fibrinogen in a well counter (Compu
Gamma 1282; LKB-Wallac, Broma,
Sweden). The measured activity,
corrected for time and background,
was expressed as net counts per
minute to give a relative measure of
the platelet and fibrinogen deposits
along grafts.
The specimens were then fixed in
a 1.5% buffered solution of glutar-

Platelet Labelling
Whole blood (50 ml) was with
drawn from each study dog after a
24-hour fast. Platelets were isolated
by double centrifugation and la
belled with indium-111 oxinate
(Mallinkrodt Canada Inc., Montreal,
PQ) using a method that was modi
fied from the one described by Thakur and colleagues.20 The platelets
were labelled with 300 to 700 /uCi
o f m In by incubation. They were
washed in saline and resuspended in
autologous plasma. Labelling effi
ciency was typically around 85%,
but no viability test was done.
Graft Implantation and Reoperation
Twenty-seven

mongrel

dogs,

FIG. 1. Processed bovine internal mammary artery (BIMA) prosthesis (external
diameter 6 mm, wall thickness 0.4 mm).

►

►

CJS, VOL 32, NO. 3, M AY 1989

181

TEIJEIRA, ET AL.

aldehyde and processed for light
microscopy and scanning electron
microscopy according to a previous
ly described protocol.21

apparently related to the vascular
surgery. Consequently, only 24
dogs were available for examination
of patency, quantification of platelet
and fibrinogen deposition and
pathological investigation.

Statistical Analysis

Statistical analysis of the results
was by analysis of variance, for
repeated measures, using Fischer’s
LSD (least significant difference) for
a posterior two-by-two comparison.

Fibrinogen and Platelet Uptake
Patency

The patency rates are summa
rized in Table I. Patency of the
BIMA grafts decreased with length
of implantation, but all venous
grafts were patent at the time of
removal. Three dogs were with
drawn from the study because of

Results
Three dogs died for reasons not

Table 1. Patency Rates of Bovine Internal Mammary Artery (BIMA) and Autologous Femoral Vein
Grafts at Different Time Intervals After Implantation
Patency, % (no./total no.)
Group
Short term
Medium term
Long term

generalized thrombosis: one in the
short-term group and two in the
long-term group. No aneurysmal
formation was visible either in the
BIMA grafts or the autologous
veins.

BIMA

Femoral vein

100 (8/8)
67 (6/9)
2 9 (2 /7 )

100 (8/8)
100 (9/9)
100 (7/7)

FIG. 2. Graphic representation of fibrinogen uptake along graft segment by BIMA
grafts and autologous femoral veins for short- (diamonds), medium- (squares) and
long-term (triangles) implantations. Kcpm = net counts per minute.

Fibrinogen accum ulation is
shown in Table II. Analysis of fi
brinogen uptake revealed signifi
cant increases (p < 0.05) in autolo
gous vein grafts over the first 48
hours, and when compared with
BIMA over the same period the
latter finding was evident in every
segment analysed except the proxi
mal one, for which the difference
was not significant. The fibrinogen
uptake in the autologous vein
grafts of the medium- and long
term groups was significantly (p <
0.001) lower than in the short-term
group, but not statistically different
from the uptake in the BIMA
grafts.
Figure 2 illustrates the pattern of
fibrinogen uptake by graft seg
ments for each period of implanta
tion. Uptake by autologous vein
grafts was substantial at the distal
anastomoses and along the middle
segments in the short-term group,
compared with the proximal anasto
moses. Fibrinogen uptake by the
BIMA grafts showed a selective in
crease at both distal and proximal
anastomoses in the short-term
group compared with the middle
segments.
Platelet accumulation followed a
similar pattern in that the increase

Table II. Fibrinogen Uptake (Net cpm) by BIMA and,Autologous Femoral Vein Grafts
Implantation
group

Gratt
Femoral vein
BIMA
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Short term
Medium term
Long term
Short term
Medium term
Long term
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_________________________________ Gratt se9menl
Distal
2
3
37 788
3 893
5119
20 091
4 976
5 705

29 269
4 453
6 953
10111
3 439
8 686

30 531
6817
9175
8 320
7 997
8 843

4

Proximal

30 662
6 633
4 893
8 488
6 086
4 644

16 891
5 932
4 858
22 962
7 185
5 689
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was much greater in the autologous
veins in the short-term group (Table
III). Differences in pattern and in
tensity between the two materials
were not statistically significant,
probably because of the extreme
variation in the viability of the
platelets for each dog in the study.
Figure 3 demonstrates clearly the
accumulation of platelets at both
anastomoses of the BIMA grafts in
the short-term group.

Pathological Investigations

The structure of virgin BIMA
grafts was observed by both light
and scanning electron microscopy.
The latter revealed a carefully pro
cessed graft whose defect-free sur
face was smooth, with a number of
endothelial cells no longer viable.
The basement membrane appeared
to be well preserved, thus separat
ing the blood flow from the under

lying collagen matrix (Figs. 4 to 6).
The wall was also well preserved
and the tunica externa appeared
normal.
After short-term implantation, ac
cumulation of thrombotic matrix
was visible for up to 2 weeks adja
cent to the sutures at both anasto
moses (Fig. 7). The middle segment
of the flow surface was smooth with
scattered deposits of fibrin platelets
and erythrocytes. A discrete fibrosis
of the media occurred with occa
sional displacement and restructur
ing of the internal elastic lamina.
After 1 month of implantation,
the thrombi at the anastomoses of
the BIMA grafts were organized
and extended along the artery; the
surface of the pannus exposed to
the blood flow showed early reendothelialization. A few blood de
posits were still evident in the medi
al part of the smooth luminal sur
face (Fig. 8). In the adventitia,
granulomatous inflammatory tissue

FIG. 3. Graphic representation of platelet uptake along graft segment of BIMA
grafts and autologous femoral veins for short- (diamonds), medium- (squares) and
long-term (triangles) implantations.

reacted to become incorporated
with vasa vasorum.
In the patent grafts after long
term implantation, the pannus at
both anastomoses exhibited a veil
of newly formed endothelial-like
cells. Flow surface appeared similar
to that seen 1 month after implan
tation. Mild medial fibrosis was not
noticeable, the elastic lamina was
not always apparent and a granulo
matous inflammatory reaction with
foreign-body giant cells in the ad
ventitia was seen (Figs. 9 and 10).
The structure of the femoral
veins altered slightly shortly after
implantation. For 2 weeks, throm
botic debris was visible at the anas
tomoses and over the flow surface
(Fig. 11). Forty-eight hours later,
intimal fibrosis occurred at both
anastomoses where a partial denu
dation of the luminal surface was
perceptible.
Between 1 week and 1 month,
the subendothelial fibrosis became
dense, with displacement and local
ized ruptures of the elastic network.
Also, peripheral sclerosis was ob
served along the anastomoses after
1 month of implantation, at which
time the thrombi had almost disap
peared and the sutures were totally
incorporated in the newly grown
pannus, coated with endothelial
cells. The middle portion of the
graft still had some debris and was
still partially denuded. Over the
long term, surface cells proliferated
sufficiently to cover the whole lumi
nal surface (Fig. 12). The wall be
came thicker as a result of progres
sive fibrosis (Fig. 13).

Table III. Platelet Uptake (Net cpm) by BIMA and Autologous Femoral Vein Grafts
Graft
Femoral vein
BIMA

Implantation
group
Short term
Medium term
Long term
Short term
Medium term
Long term

_________________________________ Graft segment
Distal
2
3
15 202
892
291
9 845
1 501
393

10 552
588
403
4 966
1 240
429

13 200
920
463
3 343
1 542
571

4

Proximal

18 953
1 885
265
3 621
1 724
387

2 540
1 300
206
8 488
2 993
412
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Discussion
Bovine heterografts have not
evolved as outstanding blood con
duits when used as primary vascu
lar replacements.2223 Despite some
enthusiastic reports,24- 26 there are

widely recognized weaknesses. 7
Even the Solco prosthesis, an inter
esting model, did not meet clinical
needs and was wisely abandoned
after biodegradation became evi
dent.27 Caution is indicated before
introducing any new chemically

processed bovine heterograft and
the following questions must be
asked:
• Is the BIMA a valuable graft
in terms of patency?
• How stable biologically is this
chemically processed artery?

FIG. 4. Scanning electron micrographs of external tunica of FIG. 5. Scanning electron micrographs of virgin BIMA graft.
virgin BIMA graft (original magnification, A X 20, B X 200). Luminal surface was smooth with no sign of rupture (original
magnification, A X 20, B X 200).

FIG. 6. Flow surface of BIMA graft is still covered with
endothelial cells. However, because of processing, those cells
are no longer viable (original magnification, X 720).
184
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FIG. 7. Thrombus matrix is still present at anastomotic sites
of BIMA graft 2 weeks after implantation (original magnifica
tion, X 60).

ARTERIAL FEMORAL SUBSTITUTES

• What are the likely failure
mechanisms?
Compared with autologous vein,
the patency rates achieved with the
BIMA are much lower, 2829 which is
not unexpected, since the vein is
the gold standard of arterial substi
tutes .30 Yet, the patency rates com
pare favourably with any synthetic
blood conduit tested in our labora
tories and the BIMA is second to
homologous vein either fresh or
frozen.31' 33 Moreover, fibrinogen
and platelet retention are lower
than that of alternative arterial sub
stitutes. Healing is limited, howev
er, to the development of a pannus
over the anastomotic areas; the rest
of the conduit should, therefore,

present an antithrombogenic sur
face whose in-vivo properties
should not be altered in order to
maintain this blood compatibility.
The BIMA graft has demonstrat
ed structural strength with preser
vation of the elastic network during
processing. A mild fibrosis was
present in the media soon after
implantation. The usefulness of this
graft lies in its capacity to preserve
the smoothness of the flow surface,
and on the development of an exter
nal fibrotic capsule. Quality control
should be exacting to ensure that
defect-free grafts are implanted. We
are unconvinced that the currently
accepted standards constitute a suf
ficient guarantee.34 Additional test

ing, involving endoscopy35 and mea
surement of the electrical imped
ance of the graft wall36 should be
mandatory. It is evident that han
dling should be atraumatic in order
to maintain the integrity and anti
thrombogenic characteristics of the
graft material.
Experiments to date do not per
mit researchers to predict the future
failure mechanisms of the BIMA in
humans; the dog remains a poor
model for evaluating chemically
processed grafts . 37 Usually, in dogs,
the grafts develop fibrous hyperpla
sia, which rapidly becomes occlu
sive, and fail because of thrombo
sis. Administration of acetylsalicylic
acid contributes to better patency

FIG. 9. Light microscopic view of BIMA prosthesis implanted
for 3 months. Elastic lamina is no longer visible (original
magnification, X 100).

FIG. 8. Scanning electron micrographs of BIMA graft 1 month
after implantation. Presence of endothelial cells along anasto
mosis is limited to pannus (A) (original magnification, X 200).
Luminal surface remained smooth with some nonviable origi
nal cells (B) (original magnification, X 540).

FIG. 10. Light microscopic view of BIMA prosthesis implanted
for 6 months. Fibrosis is mild and elastic lamina is still visible
(original magnification, X 100).
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rates for chemically processed
grafts.38 In humans, with the ab
sence of complete endothelialization
of the flow surface, failure mecha
nisms are very different and proba
bly related to lipid uptake. Lipids
are retained on the luminal surface
and then penetrate the wall and
cannot be drained off because lym
phatic vessels are absent. The colla
gen bundles become plasticized and
stretched; they may rupture, lead
ing to tissue resorption.39 Dilatation
is accompanied by additional cho
lesterol uptake and any bacteremia,
however transient, may permit colo
nization of the glycocalyx biofilm.40
Because of its patency rates and
firm structure, we believe that clini

cal trials using the BIMA graft can
be undertaken for specific purposes
in selected patients. Its use in aor
tocoronary bypass is not recom
mended since results remain inferior
to the autologous vein graft be
cause neo-endothelialization is ab
sent, and this leads to an unfavou
rable prostacyclin-thromboxane bal
ance. We would be reluctant to use
the BIMA graft in peripheral vascu
lar surgery where frequently associ
ated lipid abnormalities and ulcers
are likely to cause bacteremia.
Thus, the recommended application
for BIMA is as a secondary access
for arteriovenous fistulas. Should
the material prove highly success
ful, its use might be extended.

Conclusions
The new bovine internal mamma
ry artery heterograft has some in
teresting features and is an accept
able blood conduit in terms of pat
ency rates and structural stability.
The luminal surface of the graft is
blood compatible, and the deposi
tion of a thrombotic matrix is limit
ed to both anastomotic areas. How
ever, autologous vein is still the
material of choice for aortocoronary
bypass and in peripheral vascular
surgery. Although the dog is a poor
model for evaluating the BIMA
prosthesis, encouraging results
should stimulate researchers to pur
sue clinical trials.

FIG. 11. Thrombus matrix is still present at anastomotic sites
of autologous femoral vein 2 weeks after implantation (origi
nal magnification, X 60).

FIG. 12. Fragile development of veil of endothelial cells on
luminal surface 3 months after implantation (original magnifi
cation, X 600).
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FIG. 13. Light microscopic views of femoral vein implanted for
3 months with important parietal fibrosis (A) and granuloma
tous reaction in adventitia (B) (original magnification, X 100).
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Effect of a Direct Current Field on Axons
After Experimental Spinal Cord Injury
Michael G. Fehlings, MD;* Tat H. Wong; Charles H. Tator, MD, PhD, FRCSC; Michael Tymianski, MD
There is evidence that direct current (DC) stimulation promotes neurologic recovery
in spinal cord injury. The authors conducted a morphometric analysis of axons at
the site of spinal cord injury in adult rats treated with a DC field. Ten rats received a
17-g and 15 rats a 53-g clip compression injury and were treated with either a sham
(control) or a functioning DC stimulator for 8 weeks. Five normal rats were also
assessed.
T here was a significant relation (p < 0.0001) between the severity of injury and
the num ber of axons at the injury site. After the 17-g injury, there was no
significant difference in the number of axons between control and treated rats.
However, after the 53-g injury, there were significantly (p < 0.05) more axons in
treated than control rats. Both degrees of injury caused preferential destruction of
large-calibre axons. Subsequent analysis showed that the axon diameter of treated
rats with 17-g or 53-g injury was significantly greater (p < 0.05) than that of
control rats with 17-g or 53-g injury. These data, for the first time, show that the
application of a DC field increases the number and calibre of axons at the site of a
spinal cord injury and enhances the survival or regrowth of axons following spinal
cord injury in the rat.

II existe des preuves que, dans les cas de lesion spinale, la stimulation a l’aide de courant
direct (CD) favorise la guerison neurologique. Les auteurs ont mene une analyse
morphometrique des axones au siege des lesions spinales, chez des rats adultes traites a
1 aide d’un champ de CD. Les lesions ont ete provoquees chez 10 rats par une compression
de 17 g appliquee a l’aide d’une pince, et chez 15 autres rats par une compression de 53 g.
Les animaux furent ensuite traites pendant 8 semaines soit par stimulation simulee
(groupe temoin), soit par stimulation reelle a l’aide de CD. Cinq rats normaux furent aussi
evalues.
On a constate une relation significative (p < 0.0001) entre la gravite des lesions et le
nombre d’axones au siege des lesions. Dans les cas de lesions de 17 g, aucune difference
significative n ’a ete observee dans le nombre d’axones entre les animaux temoins et les
animaux traites. Toutefois, apres une lesion de 53 g, il y avait significativement plus
d’axones (p < 0.05) chez les rats traites que chez les temoins. Quelle que soit leur gravite,
les lesions causaient une destruction preferentielle des axones de gros calibres. L’analyse
subsequente a revele que le diametre des axones des rats traites etait significativement
plus gros (p < 0.05) que celui des temoins, qu’il s ’agisse de lesions de 17 g ou de 53 g.
Pour la premiere fois, des resultats demontrent que l’application d’un champ de CD
augmente le nombre et le calibre des axones au siege d’une lesion spinale et favorise la
survie ou la regeneration des axones apres une lesion spinale chez le rat.

irect current (DC) fields have
been shown to enhance the
proliferation of neurites in cul
ture,12 to promote axonal sprouting
and decrease retrograde axonal
degeneration3 7 and to promote re
covery89 and regeneration45 of in
jured spinal cord axons in mam
mals. In this study, we investigated

D
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the effect on axon counts and other
morphometric parameters, includ
ing myelination index and axon
diameter, of DC stimulation of
axons at the site of cord injury,
using a computer-assisted line-sam
pling technique. Our aim was to
provide insight into the cellular
effects and mechanisms of action of

DC fields on injured spinal cord
axons.

Methods
Experimental Procedures
A total of 30 rats were used in
the study (25 with spinal cord inju
ries and 5 normal controls). Twen
ty-five adult rats underwent lami
nectomy at C7-T1 and were sub
jected to a 1-minute clip compres
sion injury of the cord at C8. The
rats were randomly allocated to one
of two severities of cord injury by
using a modified aneurysm clip to
exert a force of either 17 g (10 rats)
or 53 g (15 rats).10 They were
further blindly randomized to re
ceive either DC stimulation (14 pA)
or act as controls (0 g.A) (Table I).
The design, manufacture, electrical
characteristics and method of im
plantation of the DC stimulators
have been described elsewhere.9
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Briefly, immediately after cord inju
ry, the electrodes, attached to the
stimulator by insulated platinum
wire, are placed epidurally with the
anode proximal and the cathode
distal to the injury site.
Postoperatively, clinical neuro
logic function was assessed each
week by the inclined plane tech
nique.11 After 8 weeks, motor and
somatosensory evoked potentials
were recorded, and the axonal trac
er, horseradish peroxidase (HRP),
was introduced into the cord at T6.
Coronal sections through the brain
stem and motor cortex were exam
ined, and the number of neurons,
retrogradely labelled by HRP, were
counted.
The injury site was sectioned
transversely at 400 /urn with a vibrotome, postfixed in a 2% osmium
tetroxide/3% sodium ferrocyanide
solution, immersed in 2% aqueous
uranyl acetate and embedded in
araldite plastic. The blocks were
sectioned serially on an ultrami
crotome for light and electron mi
croscopy. A quantitative assessment
of axons at the injury site was then
performed. The spinal cord of five
normal rats was similarly evaluated.

lesion from each rat, determined by
inspection, was selected. A Zeiss
photomicroscope attached to a cam
era lucida was used to measure the
number, minor axis and myelin
thickness of axons intercepted by
48 radial sample lines (drawn from
the centre of the cord at even
intervals of 27r/48 radians) at
1000X magnification with the aid
of a digitizing tablet interfaced to a
microcomputer. Myelination index
(MI) was calculated according to the
following formula: MI = a /a + 2m,
where a = minor axis and m =
myelin thickness.12 The estimated
total number of axons within a
section was derived using an algo
rithm based on line-sampling theo
ry.12
To confirm the accuracy of the
line-sampling technique, area
counts were performed in the five
normal rats. The total number of
axons in a quadrant of the cord (the
area bounded by 12 of the 48 radial
sample lines) was compared with
the total number of axons in the
same sector estimated by line sam
pling.

Line-Sampling Technique

The data were analysed on the
University of Toronto IBM 4381
mainframe computer using the Sta
tistical Analysis Systems (SAS ver
sion 5.16) statistical programming
language. Analysis of variance and
linear regression were used to ana

Two independent, blinded observ
ers (M.G.F. and T.H.W.) evaluated
the spinal cord sections using the
line-sampling technique of Blight.12
The section with the most severe

Statistical Analysis

lyse continuous data. Later compar
isons were made using Tukey’s
HSD test.13 The results were ex
pressed as mean ± SEM; differences
were considered significant at p <
0.05.

Results
This study is part of a larger
investigation on the effects of DC
fields in experimental spinal cord
injury. In it, we document the de
tailed quantitative analysis of axons
at the injury site. Results of the
inclined plane assessment, electrophysiologic recordings and axonal
tracing studies have been reported
elsewhere.9 They showed that DC
stimulation promoted clinical recov
ery of neurologic function, en
hanced axonal function in the
motor tracts of the cord and in
creased the number of HRP-labelled
axons traversing the injury site.
The axonal morphometric data
are summarized in Table I. The
number of axons in the cord of
normal rats was 458 000 ± 50 000.
Spinal cord injury resulted in a
significant (p < 0.0001) decrease in
the number of axons at the injury
site. Although there were no signficant differences in the number of
axons between control and treated
rats with 17-g injuries, for 53-g
injuries the treated rats had signifi
cantly (p < 0.05) more axons at the
injury site than controls. When we

T a b le 1. A xon M o rp h o m e try (Mean ± S E M )*

Group

N orm al
17-g injury
Treatm ent
C ontrol
53-g injury
Treatm ent
C ontrol

No. of
rats

Axon
counts

Axon
d ia m e te r, ^ m

M y e lin a tio n
in d e x t

5

458 0 0 0 ± 50 000

A

1.94 ± 0 .0 7

A

0 .6 2 ± 0.01

A

6
4

55 100 ± 23 200
52 200 ± 23 200

B
B

1.46 ± 0 .0 1
1.31 ± 0 .0 2

B
C

0 .6 6 ± 0.01
0 .6 7 ± 0.01

B
C

7
8

51 700 ±
25 3 0 0 ±

B
C

1.39 ± 0 .0 1
1.17 ± 0.02

D
E

0 .6 7 ± 0.01
0 .7 2 ± 0.01

C
D

8 300
8 500

’ M eans w ith d iffe re n t letters beside each c o lu m n are s ig n ifica n tly d iffe re n t (p < 0.05) by an alysis o f varia nce and T u ke y 's HSD te st,
t The ratio o f axon diam eter to fib re diam eter. Data fro m axons s m a lle r th an 3 ^ m are excluded due to lim ite d pre cisio n o f th e m e a su re m e n t ap pa ratu s.
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examined the distribution of axons
in the various cord funiculi, we
found that there were significantly
(p < 0.05) more axons in the
ventral and ventrolateral funiculi of
the cord in 53-g injury treated rats
than in controls; in contrast, there
were no differences between axon
counts in the dorsal and dorsolater
al funiculi between control and
treated rats. The axon counts of
control and treated rats with 17-g
injuries were similar in all funiculi,
although treated rats showed a 60%
increase in axon counts in the ven
trolateral funiculus (29 100 ±
11 100 versus 18 200 ± 9100, p >
0.05).
We noted a preferential destruc
tion of large-calibre axons (Table I).
For example, there was a significant
difference (p < 0.0001) in the mean
axon diameter between normal
(1.94 ± 0.07 ^m) and injured cord
(1.35 ± 0.10 nm, pooled data).
Furthermore, the mean axon diame
ters of 17- and 53-g treated rats
were significantly greater than
those of their respective controls
(Table I).
Marked post-traumatic demyelination resulted from the spinal cord
injury. It was reflected by a signifi
cant (p < 0.05) difference in the
myelination index between axons in
normal and injured cord (Table I).
The demyelination was generally
more severe in rats having 53-g
injuries than in those with 17-g
lesions. Furthermore, DC stimula
tion was associated with less demy
elination in axons larger than 3 /xm
for both 17- and 53-g treated rats
compared with their respective con
trols (Table I).
Axon counts derived using 48
sample lines showed an excellent
correlation with the total counts of
a cord quadrant. For example, the
counts based on line sampling and
the total counts differed by approxi
mately ± 5% (t = 1.21, p > 0.05),
confirming the validity and robust
te)

CJS, VOL. 32, NO. 3, M A Y 1989

ness of the line-sampling technique.

Discussion
This study is the first to evaluate
quantitatively the effect of an ap
plied DC field on axon counts and
other morphometric parameters
after spinal cord injury in a mam
mal. The data show that the DC
field is associated with an increased
number of surviving myelinated
axons at the injury site, particularly
large-calibre axons, and that it de
creases the extent of post-traumatic
demyelination.
The data are consistent with our
previous demonstration9 that DC
stimulation of the injured mamma
lian cord results in an increased
number of axons, retrogradely la
belled by HRP, which traverse the
site of cord injury. Furthermore,
the effects on axon number, diame
ter and myelination index provide a
structural basis for the clinical neu
rologic and electrophysiologic ef
fects of DC fields on cord injured
rats.89
Although it is unclear why axon
counts were not increased in treated
rats with 17-g injuries, the results
are consistent with our previous
finding of a lack of clinical, electrophysiologic or anatomical improve
ment at this severity of injury. It is
possible that the failure to detect a
difference in axon counts in the
17-g injury group may represent an
artifact of the relatively small sam
ple size (n = 10). For example,
treated rats with 17-g injuries,
when compared with controls, had
a 60% increase in the number of
axons in the ventrolateral funiculus.
A post hoc calculation of sample
size13 affirmed that this difference
would have achieved statistical sig
nificance had the sample size been
approximately doubled. In future
studies, it may prove fruitful to
re-examine whether DC fields can

effect functional and anatomical re
covery in mild or moderate spinal
cord injuries.
Spinal cord injury resulted in a
preferential loss of large-calibre ax
ons, similar to the findings of
Blight12 and Blight and Decrescito,14 who suggested that axonal
shearing may be a major mecha
nism of axonal injury after cord
compression. The modulus of rigidi
ty, defined as the amount of stress
required to produce a unit of shear,
varies inversely as the fourth power
of the radius of a cylinder,15 and
may explain the selective loss of
large axons which would be more
vulnerable to shear forces. We
showed that the applied DC stimu
lation enhanced the survival of
large-calibre axons in treated rats
with both 17-g and 53-g injuries. It
is possible that DC stimulation
equally enhances the survival of all
axons, regardless of size, but be
cause cord injury results in the
preferential loss of large-calibre ax
ons, the stimulation effect is most
apparent in large spinal cord axons.
Although the mechanism of ac
tion of DC fields on injured axons is
incompletely understood, there is
evidence that modulation of transcellular ionic fluxes may be in
volved. For example, around sev
ered axons there exists an extracel
lular field which is associated with a
strong inward “injury current”, due
mainly to Na+ and Ca++ ions.16 It
has been proposed6 that the distal
placement of the cathode of an
applied electrical field should drive
this “injury current” in the oppo
site direction. Since Ca++ is known
to disrupt neurofilaments and to
promote axonal degeneration,17 one
major effect of applied DC fields
might be to reduce retrograde axo
nal degeneration, which in turn
might facilitate recovery and regen
eration. We are studying this hy
pothesis.
In conclusion, in this investiga

ELECTRICAL STIMULATION OF AXONS

tion we have demonstrated that DC
fields promote the survival of myeli
nated spinal cord axons and reduce
the extent of demyelination follow
ing experimental spinal cord injury.
We thank D. Wilken and M. Moncada
for their technical assistance.
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Nonoperative Management of
Complications of Percutaneous Renal
Nephrostomy
Susan Dian Goldberg, MD, FRCSC;* Robin R. Gray, MD, FRCPC;t Eugene L. St. Louis, MD, FRCPC;t
John Mahoney, MD; Michael A. Jewett, MD, FRCSC;* Ara G. Keresteci, MD, FRCSC*
Between 1984 and 1986 at the Wellesley Hospital in Toronto, 210 percutaneous
renal nephrostomies were performed for drainage and 140 were done to provide
access for nephrolithotomy. Less than 2% of the patients experienced complications
requiring intervention and less than 0.5% required an open surgical approach for
the management of procedure-related problems. Complications that were managed
conservatively included splenic puncture, false aneurysm, laceration of the renal
artery, arteriovenous fistula, hemorrhage requiring transfusion, pneumothoraxempyema, urinoma, septic shock and the hemolysis-hyponatremia-renal
shutdown syndrome.

Entre 1984 et 1986, 210 nephrostomies renales percutanees ont ete pratiquees pour
fins de drainage a THopital Wellesley de Toronto, et 140 autres ont ete effectuees
pour offrir une voie d’acces pour une nephrolithotomie. Moins de 2% des patients
ont souffert de complications necessitant une intervention chirurgicale et moins de
0.5% ont necessity un abord chirurgical ouvert pour corriger un probleme cause par
1’intervention. Parmi les complications traitees de fa?on conservatrice, on compte:
perforation splenique, faux anevrisme, laceration de l’artere renale, fistule arterioveineuse, hemorragie necessitant une transfusion, empyeme de pneumothorax,
urinome, choc septique et le syndrome hemolytique, hyponatremique et oligo-anurique.

ver the past decade, percutane
ous nephrostomy has emerged
as the primary therapeutic approach
for retained renal calculi. In combi

O

nation with extracorporeal shockwave lithotripsy, percutaneous ne
phrolithotomy has virtually elimi
nated the need for an open proce

From the *Department o f Surgery and fDepartment o f Radiology, The Wellesley Hospital,
University o f Toronto, Toronto, Ont.
Accepted fo r publication Sept. 14, 1988
Reprint requests to: Dr. S.D. Goldberg, Ste. 206, E.K. Jones Building, 160 Wellesley St. E,
Toronto, Ont. M 4Y1J3
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dure. Likewise, the need for an
open approach to obstruction at the
ureteropelvic junction has been
markedly reduced by using percuta
neous pyeloplasty (endopyelotomy).
Whether access is obtained under
fluoroscopic or ultrasonic guidance,
morbidity, mortality and convales
cence time are decreased compared
with an open surgical procedure.

Patients and Methods
Between January 1984 and De
cember 1985, 350 percutaneous
renal nephrostomies were per
formed for drainage (210) or ne
phrolithotom y (140). Patients
ranged in age from 21 to 81 years,
with a 2:1 male predominance. Du
ration of hospital stay ranged from
3 to 28 days (mean 11 days).
Renal access was achieved in all
cases under fluoroscopic guidance.
Retrograde placement of a ureteric
occlusion balloon catheter for injec
tion of contrast medium, or as an
aid to dilation of the renal system,
preceded percutaneous puncture in
most nephrolithotomy cases. All
procedures were performed using

PERCUTANEOUS RENAL NEPHROSTOMY

local anesthetic, supplemented by
analgesics administered intrave
nously. The following five brief case
reports illustrate the problems en
countered and their management.

the occlusion balloon, after 8 min
utes, the hemorrhage had ceased
and normal perfusion was noted
through the main renal artery.

Case 2

r

Case Reports

Case 1
One patient suffered laceration of
the right renal artery. This was
managed by temporary balloon oc
clusion of the main renal artery
(Figs. 1 and 2), after which the
percutaneous tract was embolized
with Gelfoam (Fig. 3). On release of

A renal artery pseudoaneurysm
(Fig. 4) formed after a percutaneous
access procedure. It was successful
ly managed nonoperatively by selec
tive cannulation of the involved
vascular branch and by emboliza
tion with autologous clot and Gianturco coils.

Case 3
One patient suffered perforation

of the upper ureter complicated by
an obstructive clot in the lower
ureter. This resulted in the forma
tion of a massive urinoma. Nephros
tomy drainage was by placement of
a ureteric stent from above, paren
teral administration of antibiotics
and intravenous administration of
furosemide. The urinoma resolved
completely within 24 hours.

Case 4
During attempted placement of a
left internal ureteric stent this pa
tient suffered laceration of the
spleen (Fig. 5). After receiving
blood transfusion the patient re
mained hemodynamically stable and
was discharged 14 days later. There
were no late sequelae.

Case 5
After routine dilatation of a per
cutaneous tract, established for ne
phrolithotomy, the balloon could
not be deflated. A second percuta
neous nephrostomy provided access
to the balloon which was punc
tured, permitting the entrapped di
lator to be removed.
FIG. 1. Case 1. Balloon tamponade of
renal artery laceration before applica
tion of Gelfoam.

FIG. 3. Case 1. Bleeding tamponaded
with Gelfoam.

Results
Complications requiring active in
tervention occurred in less than 2%
of the 350 patients; they included
hemorrhage requiring transfusion
(8), pneumothorax-empyema (2),

►
►

►

►

►

►

FIG. 2. Case 1. Massive extravasation.
Balloon catheter is in place.

FIG. 4. Case 2. False aneurysm in
branch of renal artery.

FIG. 5. Case 4. Splenic perforation.

►

►
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NEW FROM MILES
TABLETS

A REVOLUTIONARY
ORAL ANTIBIOTIC
THE POWER OF PARENTERALS.
THE FREEDOM OF TABLETS.
“ CIPRO"
Ciprofloxacin Hydrochloride
THERAPEUTIC CLASSIFICATION
Antibacterial Agent
p r e s c r ib in g

ACTIONS
Ciprofloxacin, a synthetic fluoroquinolone, has a bactericidal mode of action. This action is
achieved through inhibition of DNA gyrase, an essential component of the bacterial DNA
replication system. Inhibition of the alpha subunit of the DNA gyrase blocks the reseafing of
the nicks on the DNA strands induced by this alpha subunit, leading to the degradation ofthe
DNA by exonucleases. This bactericidal activity persists not only during the multiplication
phase, but also during the resting phase of the bacterium.
Ciprofloxacin retained some o f its bactericidal activity after inhibition of RNA and protein
synthesis by rifamycin and chloramphenicol, respectively. These observations suggest
ciprofloxacin may possess two bactericidal mechanisms,, one mechanism resulting from
the inhibition o f DNA gyrase and a second mechanism which may be independent on RNA
and protein synthesis.
INDICATIONS AND CLINICAL USES
CIPRO' (Ciprofloxacin Hydrochloride Monohydrate, may be indicated lor the treatment of patients
with the follow ing infections caused by susceptible strains of the indicated microorganisms.
RESPIRATORY TRACT INFECTIONS:
Acute bronchitis and acute pneumonia caused by

Enterobacter cloacae
Escherichia coli
Haemophilus influemae
Klebsiella pneumoniae

Proteus mirabilis
Pseudomonas aeruginosa
Staphylococcus aureus
Streptococcus pneumoniae

Due to the nature ot the underlying conditions which usually predispose patients to

Pseudomonas infections of the respiratory tract, bacterial eradications may not be achieved
in patients who display clinical improvement despite evidence of in vitro sensitivity. In
patients requiring subsequent courses of therapy, CIPRO® should be used alternately with
other anti-pseudomonal agents. Some strains of Pseudomonas aeruginosa may develop
resistance during treatment. Therefore, susceptibility testing should be performed periodi
cally during therapy to detect the emergence of bacterial resistance.
URINARY TRACT INFECTIONS:
Upper and lower urinary tract infections, such as complicated and uncomplicated cystitis,
pyelonephritis, and pyelitis, caused by

C itrobacterdivetm
Citrobacter freundii
Enterobacter cloacae
Escherichia coli
Klebsiella pneumoniae
Klebsiella oxytoca
Morganella morganii

Proteus mirabilis
Pseudomonas aeruginosa
Serratia mamescens
Staphylococcus dureus > ;
Staphylococcus epidermidis
Streptococcus faecalis

SKIN AND SOFT TISSUE INFECTIONS:
caused by:

Enterobacter cloacae
Escherichia coli
Klebsiella pneumoniae
Proteus vulgaris
Proteus mirabilis

Pseudomonas aeruginosa
Streptococcus pyogenes
Staphylococcus aureus
Staphylococcus epidermidis

BONE AND JOINT INFECTIONS:
caused by:

Enterobacter cloacae
Pseudomonas aeruginosa

Serratia marcescens
Staphylococcus aureus

INFECTIOUS DIARRHEA: (When antibacterial therapy is indicated)
caused by:

Escherichia coli (enterotoxigenic strains)
Campylobacter jejuni

Shigella flexneri
Shigella sonnei

Appropriate culture and susceptibility tests should be performed prior to initiating treatment
in order to isolate and identify organisms causing the infection and to determine their
susceptibilities to ciprofloxacin. Therapy with CIPRO® may be initiated before results ot
these tests are known. However, modification of this treatment may be required once results
become available or if there is no clinical improvement. Culture and susceptibility testing
performed periodically during therapy will provide information on the possible emergence or
bacterial resistance.
CONTRAINDICATIONS
CIPRO" (Ciprofloxacin Hydrochloride Monohydrate) is contraindicated in patients who have
shown hypersensitivity to ciprofloxacin or other quinolone antibacterial agents.
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WARNINGS
Children
The safety of CIPRO® (Ciprofloxacin Hydrochloride Monohydrate) in children has not yet
been established. Damage to juvenile weight-bearing joints and lameness were observed
both in rat and dog studies out not in weaned piglets (see Product Monograph: TOXI
COLOGY). Histopatnological examination of the weight-bearing jo in ts of immature dogs
revealed permanent lesions of the cartilage. Consequently. CIPRO" should not be used in
prepubertal patients.
Pregnancy
The safety of CIPRO" in the treatment ot infections in pregnant women has not yet been
established (see PRECAUTIONS).
PRECAUTIONS
General
Anaphylactic reactions including cardiovascular collapse have occurred rarely in patients
receiving therapy with CIPRO" (Ciprofloxacin Hydrochloride Monohydrate). These reactions
have occurred within the first 30 minutes following the first dose and may require epineph
rine and other emergency measures.
CIPRO" may cause central nervous system (CNS) stimulation which may lead to tremor,
restlessness, light-headedness, confusion, and very rarely to hallucinations or convulsive
seizures. Therefore, CIPRO" should be used with caution in patients with CNS disorders,
such as severe cerebral arteriosclerosis or epilepsy. Patients with known convulsive seizure
disorders should only be treated with CIPRO" if anticonvulsive therapy has been initiated.
Crystalluria related to ciprofloxacin has been reported only rarely in man because human
urine is usually acidic. Patients receiving ciprofloxacin should be well hydrated and alkalinity
of the urine should be avoided. The recommended daily dose should not be exceeded.
Crystals ot ciprofloxacin have been observed rarely in the urine of human subjects but more
frequently in the urine of laboratory animals.
Prolonged use of CIPRO" may result in the overgrowth of nonsusceptible organisms. Careful
observation of the patient is therefore essentia), and if superinfection should occur during
therapy, appropriate measures should be taken.
Pregnancy
The safety of CIPRO" in pregnancy has not yet been established. CIPRO® should not be used
by pregnant women unless tne likely benefits outweigh the possible risk to the fetus. CIPRO'"
has been shown to be non-embryotoxic and non-teratogemc in animal studies.
Nursing Mothers
It is not known whether ciprofloxacin is excreted in human milk. However, it is known that
ciprofloxacin is excreted in the milk of lactating rats and that other drugs of this class are
excreted in human miik. A decision should be made to discontinue nursing or to discontinue
the administration of CIPRO® taking into account the importance of the drug to the mother
and the possible risk to the imant.
Drug Interactions
Concurrent administration of ciprofloxacin with theophylline may lead to an elevated plasma
concentration and prolongation of elimination half-life of theophylline. This may result in
increased risk of theophylline-related adverse reactions. If concomitant use cannot be
avoided, plasma concentrations of theophylline should be monitored and dosage adjust
ments made as appropriate
Ciprofloxacin has been shown to interfere with the metabolism and pharmacokinetics of
caffeine. Excessive caffeine intake should be avoided.
Probenecid blocks renal tubular secretion of ciprofloxacin and has been shown to produce an
increase in the level ot ciprofloxacin in the serum.
Concomitant administration of a nonsteroidal anti-inflammatory drug with ciprofloxacin has
been reported to increase the risk of CNS stimulation and convulsive seizures.
Antacids containing aluminum or magnesium hydroxide have been shown to reduce the
absorption of ciprofloxacin. Concurrent administration with these agents should be avoided.
Renal Impairment
Since ciprofloxacin is eliminated primarily by the kidney. CIPRO* should be used with
caution and at a reduced dosage in patients with impaired renal function (see DOSAGE AND
ADMINISTRATION).
ADVERSE REACTIONS
CIPRO ‘ (Ciprofloxacin Hydrochloride Monohydrate) is generally well tolerated. During worldwide
clinical investigation, 8,861 courses ot ciprofloxacin treatment were evaluated tor drug
safety. (Included in this evaluation were data from 283 patients who received ciprofloxacin
only intravenously and 169 patients who received sequential rntravenous/oral ciprofloxacin
therapy.)
Adverse events, whether drug-related or not, occurred in 10.2% of patients. These adverse
events occurred in the following frequencies: Gastrointestinal System (5.0%), Central
Nervous System (1.6%), Skin/Hypersensitivity (1.4%), and Adverse Laboratory Changes
(5.6%).
’
",
!
The most frequently reported events, drug-related or net were nausea (.}.#%> and diarrhea
Additional events that occurred in less than 1% of ciprofloxacin courses are listed beibw:
Gastrointestinal vomiting, dyspepsia, abdominal pain, anorexia
Central Nervous System: dizziness, light-headedness, headadtfe, Cervoustless, anxiety,
agitation, restlessness, tremor, lethargy, drowsiness, somnolence
Skin/Hypersensitivity: rash, pruritus, local edema, urticaria, increased perspiration,
photosensitivity
Most of the adverse events were described as only mild or moderate in severity.
There have been 9 reports of arthropathy associated with CIPRO". Three of these reports
involved children. Arthralgia was usually the first symptom which led to rapid assessment
and withdrawal of the drug. No irreversible arthropathies have been observed.
Adverse Laboratory Changes
Changes in laboratory parameters listed as adverse events without regard to drug relationship (5.6%):
Hepatic:
Elevations of: SGPT (1.3%), SGOT (1.4%),
Alkaline Phosphatase (0.4%), y glutamyl transpeptidase (0.3%),
LDH (0.3%), Serum bilirubin (9.1%)
Hematologic: Eosinophilia (0.6%), leukopenia (0.2%)
Renal:
Elevations of: Serum creatinine (0.3%), BUN (0.3%)
Other changes occurring in less than 0.1% of courses were: elevated uric acid, elevated
cholesterol, increase in blood platelets, monocytes, and leukocytes.
SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO" (Ciprofloxacin Hydrochloride Mono
hydrate). In the event of acute overdosage, the stomach should be emptied by inducing
vomiting or by gastric lavage. The patient should be carefully observed and given sup
portive treatment.
DOSAGE AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the
severity and nature ot the infection, the susceptibility of the causative organism and the
status ot renal function.
CIPRO® (Ciprofloxacin Hydrochloride Monohydrate) may be taken before or after meals.
Absorption is faster on an empty stomach. Patients should be advised to drink fluids liberally
and not take antacids containing magnesium or aluminum.

Adult

DOSAGE FORMS
Availability

The recommended dosages of CIPRO*' are:

Location of
Infection

Type/Severity

Unit
Dose

Fre
quency

Daily
Dose

Urinary Tract

Mild/Moderate
Severe/Complicated

250 mg
500 mg

q 12h
q 12h

500 mg
1000 mg

Lower Respiratory
Tract
Bone & Joint
Skin 8 Soft Tissue

Mild/Moderate
Severe/Complicated*

500 mg
750 mg

q 12h
q 12h

1000 mg
1500 mg

Infectious Diarrhea

M i Id/Moderate/Severe

CIPRO® 250-each tablet contains ciprofloxacin hydrochloride monohydrate
equivalent to 250 mg ciprofloxacin.
CIPRO® 500-each tablet contains ciprofloxacin hydrochloride monohydrate
equivalent to 500 mg ciprofloxacin.
CIPRO® 750-each tablet contains ciprofloxacin hydrochloride monohydrate
equivalent to 750 mg ciprofloxacin.
STORE BELOW 30 ° C (86° F).

Strength
500 mg

q 12h

1000 mg

* e.g. hospital-acquired pneumonia, osteomyelitis.
Depending on the severity of the infections, as well as the clinical and bacteriological
responses, the average treatment period should be approximately 7 to 14 days. Generally,
treatment should last 3 days beyond the disappearance of clinical symptoms or until
cultures are sterile. Patients with osteomyelitis may require treatment for a minimum of 6
to 8 weeks and up to 3 months. With acute cystitis, a five-day treatment may be sufficient.

Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabo
lized and partially cleared through the biliary system of the liver and through the intestine
(see Product Monograph: HUMAN PHARMACOLOGY). This alternate pathway of drug
elimination appears to compensate for the reduced renal excretion of patients with renal
impairment. Nonetheless, some modification of dosage is recommended, particularly for
patients with severe renal dysfunction. The following fable provides dosage guidelines for
use in patients with renal impairment. However, monitoring of serum drug levels provides
the most reliable basis for dosage adjustment. Only a small amount of ciprofloxacin (< 1 0%)
is removed from the body after hemodialysis or peritoneal dialysis.

Creatinine Clearance
mL/min (mL/s)

Dose

> 3 0 (0 .5 )
< 30 (0.5)
and patients on hemodialysis
or peritoneal dialysis

No dosage adjustment
Use recommended dose
once daily or half
the dose twice daily

Bottles of 50

250
500
750
500
750

Unit Dose Package of 100

mg
mg
mg
mg
mg

Tablet
Identification
Miles
M iles
M iles
Miles
M iles

512
513
514
513
514

Rpfprpnrpc-
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2. Product monograph.
3. Ball AP, E urJV lin Microbiol 1986; 5(2):214-19.

MILES

MILES CANADA INC.
PHARMACEUTICAL DIVISION
77 BELFIELD ROAD, ETOBICOKE, ONTARIO M 9W 1G6

© MILES CANADA INC., 1989
® Registered Trademark
MILES CANADA INC. is the Registered User of the
Trademark CIPRO", the original brand of ciprofloxacin hydrochloride.
TM The trademark of the CIPRO tablet, consisting of its
colour, shape and size, is a trademark of MILES CANADA INC.

[ paab
| ccpp

When only the serum creatinine concentration is available, the following formula (based on
sex, weight and age of the patient) may be used to convert this value into creatinine
clearance. The serum creatinine should represent a steady state of renal function:
Males:
Weight (kg) x (140 - age)
72 x serum creatinine(mg/1 OOmL)
Females:
0.85 x the above value
To convert to international units, multiply result by 0.01667

CHILDREN
The safety and efficacy of CIPRO1" in children have not been established. CIPRO® should not
be used in prepubertal patients (see WARNINGS).

nephrostomy dislodgement (1), fail
ure of a dilated balloon catheter to
deflate (1), formation of a urinoma
(1), retroperitoneal hematoma (1),
pleural effusion (2), delayed he
morrhage (3), splenic laceration (1),
renal artery pseudoaneurysm (1),
renal artery laceration (1) and septic
shock (10).

Discussion
Since percutaneous renal access
has become a routine urologic pro
cedure, the incidence of related
complications has increased. Those
reported include bleeding requiring
transfusion, infection, urinoma, pel
vic laceration, ureteral avulsion, ob
struction at the ureteropelvic junc
tion or ureteral stricture, pneumo
thorax or hemothorax, bowel inju
ry, renal vein thrombosis, arteriove
nous fistula formation, renal or pe
rirenal abscess, and death second
ary to myocardial infarction, sepsis

or respiratory failure.1-7 Most of
these complications can be man
aged conservatively1-6 as we have
illustrated.
With improved angiographic ex
pertise, vascular complications such
as pseudoaneurysm, laceration of a
branch of the renal artery and arte
riovenous fistulas can be managed
by techniques of vascular access
and embolization.4-6 Case 1, in
which Gelfoam embolization in the
percutaneous tract was used, is a
recent variation of previous tech
niques.4-6
Advances in intensive care medi
cine have permitted successful man
agement of septic shock and hemol
ysis-hyponatremia-renal shutdown
syndrome, conditions that are po
tentially fatal. Increasing expertise
has resulted in percutaneous ne
phrolithotomy and extracorporeal
shock-wave lithotripsy virtually re
placing open surgical lithotomy and
permits nonoperative management
of associated complications.
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Natural History of Vertical Abdominal
Parietal Closure: Prolene Versus Dexon
R.T. Lewis, MD, FRCSC, FACS;* F.M. Wiegand, MD, FRCSCf
The long-term outcome of laparotomy incisions after mass closure (taking large
tissue bites through all layers) with continuous polypropylene (Prolene) in 95
patients or interrupted poly glycolic acid (Dexon) sutures in 105 patients was
compared by randomized prospective study. Of the 200 patients, 194 incisions were
median and 2 were paramedian (4 patients were excluded). There was one wound
dehiscence (0.51%) due to slippage of a polypropylene knot. At 5-year follow-up,
4 hernias were found in incisions repaired with polypropylene, compared with 11
in the polyglycolic acid group; 10 of the 11 occurred after the first year (p = 0.01).
Wound infections were slightly more frequent in patients whose incision was closed
with polypropylene. Only two hernias in each group occurred in patients who had
had wound infections. Polypropylene and polyglycolic acid both allow rapid and
secure closure of vertical laparotomy incisions, but late herniation is more common
when polyglycolic acid sutures are used.

Dans une etude prospective et randomisee, on a compare 1’evolution a long terme
des incisions de laparotomie, soit apres fermeture large chez 95 patients (en prenant
de larges piqures a travers toutes les couches de tissus) a l’aide de polypropylene
continu (Prolene), soit apres suture a points separes chez 105 patients a l’aide de fil
d’acide polyglycolique (Dexon). Chez ces 200 patients, on a compte 194 incisions
medianes et 2 paramedianes (4 cas ayant ete elimines). On a enregistre une seule
desunion de suture de plaie (0.51%) due au lachage d’un noeud de polypropylene.
Apres 5 ans de surveillance des suites therapeutiques, on a denombre 4 hernies
d’incisions reparees avec du polypropylene, comparativement a l l dans le groupe
acide polyglycolique; 10 des 11 sont survenues apres la premiere annee (p = 0.01).
Les infections de plaie ont ete legerement plus frequentes chez les patients dont
l’incision avait ete refermee avec le polypropylene. Seulement deux hernies dans
chaque groupe ont ete notees chez des patients qui avaient subi des infections de
plaie. Le polypropylene et l’acide polyglycolique assurent, tous deux, une fermeture
rapide et solide des incisions verticales de laparotomie, mais les hernies tardives
sont plus frequentes avec les sutures d’acide polyglycolique.

From the Department o f Surgery, Queen Elizabeth Hospital and McGill University, Montreal, PQ
Presented at the 92nd annual meeting o f the Canadian Association o f Clinical Surgeons, eastern
division, Toronto, Ont., May 5-8, 1988
*'Associate Professor o f Surgery, McGill University. Surgeon-in-Chiet, Queen Elizabeth Hospital,
Montreal

lthough the incidence of
wound dehiscence has de
creased to nearly 1% with the use of
mass closure (through and through,
taking large tissue bites) and proper
surgical technique,1'4 wound failure
because of incisional hernia remains
a problem.5 In addition to a 5% to
7% incidence of herniation in the
first year after laparotomy,1 just as
many hernias appear again later,6'8
and the results of repair by conven
tional methods are still poor.910
The main causes of herniation
are wound dehiscence1Land postop
erative complications, such as
wound infection, pulmonary compli
cations and abdominal disten
sion.112 The role played by the type
of suture material in causing post
operative herniation is uncertain.
Many studies13-17 have shown no
difference in the incidence of her
niation with either absorbable or
nonabsorbable sutures, but the fol
low-up has been short. Others1819
have noted more hernias when ab
sorbable sutures were used.
We conducted a prospective ran
domized study of patients who had
mass closure of vertical laparotomy
wounds to identify and compare the
outcomes of incisions closed with
absorbable and nonabsorbable su
tures.

A

tAssistant Professor o f Surgery. McCill University

Patients and Methods
Accepted for publication Nov. 9, 1988
Reprint requests to: Dr. Ronald T. Lewis, Department o f Surgery, Queen Elizabeth Hospital,
2100 Marlowe Ave., Montreal, PQ H4A 3L6
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Two hundred consecutive vertical
laparotomy wounds longer than 10

1

SUTURE MATERIAL FOR LAPAROTOMY CLOSURE

cm were randomized at operation
by the last digit of the patient’s year
of birth. Patients born in even years
had the wound closed with inter
rupted Smead-Jones sutures20 of
no. 1 polyglycolic acid (Dexon;
Davis and Geek, Markham, Ont.),
and patients born in odd years had
the wound closed with continuous
simple sutures of no. 1 poly
propylene (Prolene; Ethicon Ltd.,
Peterborough, Ont.). In each case,
care was taken to include musculoaponeurotic tissue bites at least
1 cm from the wound edge. Sutures
were not pulled tight and they were
placed 1 to 2 cm apart. The subcu
taneous fat was approximated with
interrupted sutures of 4-0 poly
glycolic acid and the skin with
simple sutures of 5-0 nylon (Ethilon; Ethicon Ltd.).
For each patient, the age, sex,
weight and height and preoperative
blood concentrations of hemoglo
bin, urea nitrogen and bilirubin
were recorded. Values of ideal body
weight for height and body build
were obtained from standard ta
bles,21 and the percentage actual of
ideal body weight was derived for
each patient. The operative diagno
sis, type of operation, degree of
wound contamination,22 presence of
a previous abdominal wound, ur
gency of operation and periopera
tive use of antibiotic prophylaxis
and steroids were noted. For some
patients, we measured the time
taken to close the fascia and the
length of the wound.

After operation, the patients were
followed up daily by physiotherapy
personnel for development of pul
monary complications. Sputum cul
ture and chest x-ray films were
obtained as indicated clinically. A
scoring system was used to evaluate
postoperative pulmonary complica
tions, four or more points being
regarded as significant.23 The
wounds were inspected by infection
control personnel 5 days after oper
ation and before the patient was
discharged. A further follow-up was
made 1 month later.
A wound infection was diagnosed
when pus drained from the
wound.24 A sample of the draining
material was cultured. Wounds that
were erythematous or tender were
monitored until they drained pus or
the signs subsided. The surgeon
evaluated clinically any gross ab
dominal distension caused by uri
nary bladder, bowel or ascites dur
ing the first week postoperatively.
After discharge from hospital,
the patients were followed up by a
single surgeon at 1, 3, 6, 12, 24
and 60 months. The end-points for
wound failure were wound dehis
cence, diagnosed only when eviscer
ation occurred, and incisional her
nia, defined as a defect with sharp
fascial margins and presenting as a
bulge when the patient strained
while standing. The outcomes with
respect to these end-points were
analysed by the life-table meth
od.2526
Statistical analysis was performed

T a b le 1. Patient Data

Mean age, yr (± SEM)
Sex (male/fem ale), no.
Weight, actual/ideal, %
Hemoglobin (< 100 g/L), no.
Blood urea nitrogen
(> 10.7 m m ol/L urea), no.
Bilirubin (> 34.2 Mm ol/L), no.
Malignant disease, no.
Steroid use, no.
Prim ary/repeat incisions, no.

Dexon
(n = 103)

Prolene
(n = 9 3 )

56.8 ± 17
44 /59
111.5 ± 20
8

55.8 ± 18
48/45
111.6 ± 24
13

10
6
29
6
80 /23

5
6
21
4
73/20

when necessary by Student’s f-test,
Fisher’s exact test and x 2 analysis
with the Yates modification, and
the outcomes derived from life-table
data were compared by the log rank
X 2 equivalent.

Results
Of the 200 patients who entered
the study, 105 had fascial closure
of the laparotomy wound with
Dexon and 95 with Prolene. Two
patients from each treatment group
were excluded from further analy
sis. Two died within a week of
surgery, a third required reopera
tion on the first postoperative day
and in the fourth the protocol was
violated by the use of retention
sutures in addition to fascial clo
sure. Thus, 196 incisions were eval
uated; 194 were median and 2 pa
ramedian. Fifty-two incisions were
confined to the lower abdomen. In a
few patients in each group, the
incision was made through a previ
ous laparotomy scar. Table I com
pares the treatment groups and
shows that they were similar in
mean age, sex distribution and pa
tient weight, and in the frequency
of anemia, jaundice, uremia, malig
nant disease and preoperative ste
roid usage.
Wound infections were slightly
more frequent in incisions closed
with Prolene, which was used more
for emergency operations, than in
incisions closed with Dexon, but the
difference was not significant. Pro
phylactic use of antibiotics and
wound class were also similar in the
two groups (Table II). Table III
shows the frequency of wound in
fection and type of operation per
formed in each treatment group.
Respiratory complications devel
oped in 26 wounds closed with
Prolene and in 21 closed with Dex
on. Abdominal distension was re
corded postoperatively in 33 paCJS. VOL. 32. NO. 3. M AY 1989
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tients in the Prolene group and in
27 in the Dexon group (not signifi
cant). Fascial closure time was 49
s/c m for Dexon and 41 s/cm for
Prolene (p < 0.05).
The only case of wound dehis
cence was caused by slipping of a
Prolene knot. Incisional hernias
were more frequent in the Dexon
group, and the majority were seen
after the first year of follow-up
(Table IV). In each group, only two
hernias developed in patients who
had had wound infections. In Fig.
1, the outcomes in the two treat
ment groups are evaluated by the
life-table method (p < 0.05).

Discussion
The ideal suture for fascial clo
sure should not cause infection or
irritation; it should achieve its pur
pose in holding the wound edges
together but disappear when its
work is done.27 This implies that an
absorbable suture should be ideal.
However, studies have shown that
when catgut, the natural absorbable
suture, is used to close median and
standard paramedian laparotomy
wounds, the incidence of wound
dehiscence is unacceptably high.3
The reason is that catgut loses its

tensile strength after only 10 days,
well before healing fascia has
gained sufficient strength. This is
not a problem when modern syn
thetic sutures are used. Synthetic
nonabsorbable sutures and absorb
able sutures have markedly de
creased the incidence of wound de
hiscence, particularly when the
technique of mass closure is ap
plied.20 In addition, Jenkins2 and
others,161728 have shown that for
mass closure a continuous suture is
as effective as interrupted sutures
in preventing wound dehiscence,
and can be placed more quickly.
The present study, then, is an ethi
cal and valid comparison of mass
closure comparing polypropylene
with polyglycolic acid sutures.
In our trial, the rate of wound
dehiscence was 0.51%. Thus, we
have confirmed that mass closure
using either of these suture materi
als effectively prevents abdominal
wound dehiscence. In mass closure,
large tissue bites avoid the zone of
increased collagenase activity that
extends up to 5 mm from the
wound margin,29 and, compared
with small bites, they distribute the
tension in the suture over a large
area, making tissue necrosis less
likely.4'30 As in previous studies,1617
continuous suture closure in our

T a b le II. C o m p a ris o n o f F a c to rs R e la tin g to W o u n d S ep sis

W o u n d in fe c tio n
E m e rg e n c y /e le c tiv e la p a ro to m y
P ro p h y la c tic use o f a n tib io tic s
W o u n d c la s s
C le a n
C le a n -c o n ta m in a te d
C o n ta m in a te d

Dexon

P rolene

11
2 1 /8 2
67

19
3 0 /6 3
64

31
53
19

26
51
16

trial was completed more quickly
than closure with interrupted su
tures.
We have also shown that Dexon
sutures are associated with more
late herniations through laparoto
my incisions than Prolene. This
preponderance of late herniation in
the polyglycolic acid group was not
due specifically to postoperative
complications, for only two hernias
in each group developed after
wound infections; also, pulmonary
complications and abdominal disten
sion were less frequent in the
Dexon group than the Prolene
group.
It seems likely that most hernias
were caused by failure of the poly
glycolic acid suture material. Apo
neurotic incisions of the abdominal
wall are much less vascular and
heal more slowly than skin wounds.
They require about 120 days to
regain strength.31 Unfortunately,
polyglycolic acid loses 80% of its
tensile strength within 2 weeks of
operation,32 and more than 90%
within 3 weeks.3334 At that time,
aponeurotic wounds have reached
only 20% of the preoperative
strength of the fascia. It is assumed
that the tensile strength of poly
glycolic acid is sufficient to prevent
wound dehiscence, but that the su
ture fails during the collagen matu
ration phase of wound healing.35
The resulting weakness presents
later as an incisional hernia. Playforth and colleagues,36 found that 1
month after operation radiopaque
markers placed on the fascial mar
gins at surgery showed a separation
of more than 10 mm, predicting

T a b le III. W o u n d S e p s is b y T y p e o f O p e ra tio n
Dexon

T y p e of
o p e ra tio n
B ilia ry
U p p e r g a s tro in te s tin a l
C o lo re c ta l
V a s c u la r
M is c e lla n e o u s

198

P rolene

G roup

In fe c te d

U ninfected

Infected

U ninfected

8
2
1
0
0

40
21
29
7
6

4
8
5
0
2

31
30
19
7
6
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S eq u e la
W o u n d in fe c tio n
W o u n d d e h isc e n ce
In c is io n a l h e rn ia
E arly
Late

Dexon

P rolene

11
0
11
1n
0.01
io lp_

19
1
4
?
2

SUTURE MATERIAL FOR LAPAROTOMY CLOSURE

incisional herniation that may not
be clinically apparent until more
than 1 year after operation.
What, then, can be done to pre
vent postoperative incisional hernia
tion? It remains to be seen whether
more durable absorbable sutures
such as polydioxanone (PDS; Ethicon),37 or polyglactin 910 (Vicryl;
Ethicon) will be more effective than
polyglycolic acid in preventing late
herniation. But it seems unlikely
that they will, because Leese and
Ellis38 found that 20% of laparoto
my wounds closed with PDS su
tures developed incisional hernias
compared with 8.5% closed with
nylon. Moreover, of seven h
ial
hernias found by Wasiljew
Win
chester39 during a mean
ionth
follow-up of 244 pat:
whose
laparotomy wounds
closed
with continuous m
uture of
polyglactin 910, or
e followed
a wound infectioalternative
course is to accept Hie thesis of
Douglas31 that all aponeurotic
wounds are potential sites of her
niation. If this is so, delayed hernia
tion can only be prevented by repair
with nonabsorbable sutures, or by
operating through muscle-sparing

incisional hernia repair: a twelve year
review. Ann R Coll Surg Engl 1986; 68:
185-187

incisions in which intact muscle
helps to buttress the repair.4041

Guiney DJ, Morris PJ, Donaldson GA:

11.

References

Wound dehiscence. A continuing prob
lem in abdominal surgery. Arch Surg
(Chicago) 1966; 92: 47—
51
12 P ollock AV: Laparotomy. J R Soc Med
1981; 74: 480-484
13. Irvin TT, Koffman CG, Duthie HL:
Layer closure of laparotomy wounds
with absorbable and non-absorbable su
ture materials. B r J Surg 1976; 63:
793-796
14. Cameron AE, Gray RC, T albot RW, et
al: Abdominal wound closure: a trial of
Prolene and Dexon. B r J Surg 1980; 67:
487-488
15. Corman ML, Veidenheimer MC, Coller
JA: Controlled clinical trial of three
suture materials for abdominal wall clo
sure after bowel operations. Am J Surg
1981; 141: 510-513
16. R ichards PC, Balch CM, Aldrete JS:
Abdominal wound closure. A random
ized prospective study of 571 patients
comparing continuous vs. interrupted
suture techniques. Ann Surg 1983; 197:
238-243
17. McN eil PM, Sucerman HJ: Continuous
absorbable vs interrupted nonabsorbable
fascial closure. A prospective, random
ized comparison. Arch Surg 1986; 121:
821-823
18. P ollock AV, Greenall MJ, E vans M:
Single-layer mass closure of major lapa
rotomies by continuous suturing. J R
Soc Med 1979; 72: 889-893
19. B ucknall 'TE, E llis H: Abdominal
wound closure — a comparison of mo
nofilament nylon and polyglycolic acid.
Surgery 1981: 89: 672-677
20 J ones TE, N ewell ET jr , B rubaker RE:
Use of alloy steel wire in closure of
abdominal wounds. Surg Gynecol Obstet
1941; 72: 1056-1059
21 . New weight standards for men and
women. Metropol Life Insur Co Stat
B u ll 1959; 40: 1-4
2 2 . Report of an Ad Hoc Committee of the
Committee on Trauma, Division of Medi
cal Sciences, National Academy of
Sciences-National Research Council:
Postoperative wound infections: the in
fluence of ultraviolet irradiation of the
operating room and various other fac
tors. Ann Surg 1964; 160 (suppl 2): 1192
23. L eaper DJ, P ollock AV, Evans M:
Abdominal wound closure: a trial of
nylon, polyglycolic acid and steel su
tures. B r J S u r g 1977; 64: 603-606
24. Ljuncqvist U: Wound sepsis after clean
operations. Lancet 1964; 1: 1095-1097
25. Cutler SJ, E derer F: Maximum utiliza
tion of the life table method in analyzing
survival. J Chronic Dis 1958; 8: 699712
26. P eto R, P ike MC, Armitace P, et al:
.

1. Bucknall TE, Cox PJ, E llis H: Burst
abdomen and incisional hernia: a pro
spective study of 1129 major laparoto
mies. B r Med J [ Clin Res] 1982; 284:
931-933
2. Jenkins TP: The burst abdominal
wound: a mechanical approach. B r J
Surg 1976; 63: 873-876
3. Golicher JC, Irvin TT, Johnston D, et
al: A controlled clinical trial of three
methods of closure of laparotomy
wounds. B r J Surg 1975; 62: 823-829
4. S anders RJ, DiClementi D, I reland K:
Principles of abdominal wound closure.
1. Animal studies. Arch Surg 1977; 112:
1184-1187
5. E llis H: Midline abdominal incisions (E).
B r J Obstet Gynaecol

1984; 91: 1-2

6. Akman PC: A study of five hundred
incisional hernias. J In t Coll S u rg 1962;
37: 125-142
7. E llis H, Gajraj H, Georce CD: Incision

al hernias: when do they occur? B r J
Surg 1983; 70: 290-291
8. Mudce M, Hughes LE: Incisional hernia:
a 10 year prospective study of incidence
and attitudes. B r J Surg 1985; 72: 7071
9. Lancer S, Christiansen J: Long-term
results after incisional hernia repair.
Acta ChirScand 1985; 151: 217-219

10. George CD, E llis H: The results of

.

1031_01_95_ 83

'L—

100h “

80

90

58

152

l74____ A _______

Polypropylene
j69

C=
13
O

T3

O03

__J_____

Polyglycolic Acid

80

70

60

12

18

_L
24

_i
60

Months

FIG. 1. Outcome in incisions closed with polypropylene (Prolene) and polyglycolic
acid (Dexon). Vertical bars represent standard error of mean for interval.
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BOOK REVIEWS

ABO INCOMPATIBILITY AND
TRANSPLANTATION. Edited by
Aaron D. Bannett, Hans Brynger, Bo
Samuelsson, Robert F. McAlack and
Michael Breimer. 246 pp. Illust. Grune
& Stratton, Inc., Philadelphia; W.B.
Saunders Company Canada Limited,
Toronto, Ont., 1988. $81.95. ISBN
0-8089-1951-2.

ABO-incompatible transplantation is be
coming an important issue as the limita
tions of our pool of donor organs are
reached. This book is a Transplanta
tion Proceedings reprint from December
1987. It includes papers from the com
bined proceedings of the First Interna
tional Symposia on ABO Incompatibility
and Transplantation (Philadelphia,
March 1987 and Gothenburg, Sweden,
June 1987).
The book is divided into three sec
tions. The first, on the basic science of
the ABH system, emphasizes new devel
opments in solving its underlying com
plexity. Papers on the current under
standing of ABH antigen structure and
tissue distribution are presented. In
their paper, Socha and colleagues dis
cuss the analogous animal blood-group
systems and their place on the evolu
tionary scale.
The next section is on experimental
transplantation. Because the ABO200
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incompatible transplant represents a
model for acute humoral rejection,
many of the papers are on xenografting. Indeed, many of the techniques
presented for removal of pre-formed
natural antibodies are applicable to the
ABO-incompatible transplant. Cerilli
presents an interesting paper on the
importance of vascular endothelial anti
gen matching in kidney allografts,
based on monocyte cross-matching.
Paul’s review of humoral rejection
mechanisms is excellent. In several pa
pers, Romano and colleagues discuss
the removal of anti blood group A
antibodies using synthetic trisaccharide
analogues of the A antigen. The results
of a limited trial of intravenous adminis
tration of these trisaccharides to human
volunteers and their therapeutic use in
three infants with hemolytic disease due
to ABO incompatibility are presented.
In the last section, the clinical as
pects of transplantation are discussed.
It is divided into sections on the major
transplant organs — kidney, liver,
heart-lung and bone marrow. A clinical
overview of ABO-incompatible trans
plantation is provided in two separate
papers, by Starzl and colleagues and
Rappaport and Dausset. The majority of
the papers include results of ABO-mismatched kidney allografts, with particu
lar emphasis on the A2 to O graft.

Different techniques for dealing with
the anti blood group antibodies are put
forward, including the use of immunoadsorbent columns produced by
Chembiomed in Edmonton. Finally, the
importance of Lewis blood-group
matching in kidney allografts is re
viewed in two articles presenting oppo
site viewpoints.
The section on liver transplantation
deals primarily with survival following
ABO-identical, ABO-compatible but
nonidentical and ABO-incompatible
transplants. Papers on hyperacute rejec
tion, the importance of the Lewis bloodgroup system in liver transplantation
and hemolysis after nonidentical trans
plants are presented.
The section on ABO-incompatible
heart-lung transplantation includes
only two case reports. The first involves
hemolysis after ABO-incompatible but
nonidentical heart-lung transplant and
the second, acute humoral rejection
after an ABO-incompatible transplant.
The section on bone-marrow trans
plantation includes papers that compare
techniques for dealing with the prob
lems of delayed or acute hemolysis,
delayed hemopoiesis and graft rejection
in ABO-incompatible bone-marrow
transplants. Techniques discussed
continued on page 206
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Ketoconazole in the Treatment of
Osteomyelitis Due to Candida albicans
R.M. Bannatyne, MB, ChB, Dip Bact, MRCPath, FRCPC;* H.M. Clarke, MD, PhD, FRCSCt
Osteomyelitis caused by Candida albicans is a rare condition. The authors report its
occurrence as an infective complication in the fractured phalanx of a 3-year-old boy.
The infection was first thought to be due to Staphylococcus aureus, but a course of
doxacillin was unsuccessful, and when cultures of the injured finger grew C.
albicans, a 3-month course of ketoconazole orally was begun. Ketoconazole was
prescribed because, unlike amphotericin B, the antibiotic usually used in such cases,
it is not nephrotoxic, it can be taken orally and it has proved successful in other
reported cases of osteom yelitis due to C. albicans. The boy’s infection resolved and
fracture healing was confirmed radiologically.

L’osteomyelite a Candida albicans est une affection rare. Les auteurs en decrivent un cas
qui est survenu comme complication infectieuse de la fracture d’une phalange chez un
garf on de 3 ans. Au debut, l’infection fut attribuee a Staphylococcus aureus, mais un
traitement a la cloxacilline s’avera inefficace. Quand les cultures du doigt blesse mirent en
evidence le C. albicans, une therapie de 3 mois au ketoconazole par voie orale fut m ise en
route. On a present le ketoconazole parce que, contrairement a l’amphotericine B qui est
habituellement employee dans ces cas, cet antibiotique n’est pas nephrotoxique et il peut
etre pris par voie orale. De plus, il s ’est deja montre efficace dans d’autres cas
d’osteomyelite a C. albicans. L’infection du gareonnet disparut et la radiographie vint
confirmer la guerison de la fracture.

steomyelitis caused by Candida
albicans is rare, and its optimal
treatment is unknown. The toxicity
of amphotericin B and the develop
ment of resistance to 5-fluorocytosine limit the use of these custom
ary antifungal agents. We report a
case of osteomyelitis due to C. al
bicans affecting the middle phalanx
of an index finger; it was success
fully treated with a 3-month course
of ketoconazole taken orally.

O

Case Report

middle phalanx of the injured fin
ger, with a suggestion of superim
posed infection (Fig. 1). The boy
was admitted to hospital and started
on an empirical 1-week course of
doxacillin (200 m g /k g daily intra
venously, given every 6 hours) for
infection assumed to be caused by
Staphyloccus aureus. There was no
evident improvement, so explorato
ry surgery with open debridement
was performed. No pus was found.
Easy mobility of the fracture indi
cated lack of healing. A deep swab
and two curettage specimens were
taken from the fracture site. Cefo
taxime (100 m g /k g daily given
every 6 hours) was administered
intravenously for several days.
When the culture results from the
operative specimens all indicated C.
albicans a 3-month course of keto-

A 3-year-old boy sustained a cut
to his left index finger at play.
Within a week the digit became red
and swollen. An x-ray film was
made and amoxicillin was pre
scribed. The laceration healed over
the next 7 days but the swelling
and redness remained. Review of
the x-ray film revealed a transverse
fracture of the distal shaft of the

From the *Department o f Bacteriology and fD ivision o f Plastic Surgery, The Hospital fo r Sick
Children, Toronto, Ont.
Accepted fo r publication Sept. 28, 1988
Reprint requests to: Dr. R.M. Bannatyne, Department o f Bacteriology, The Hospital for Sick
Children. 555 University Ave., Toronto, Ont. M5G 1X8

FIG. 1. Infected fracture of distal shaft
of middle phalanx of left index finger.
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conazole taken orally (50 mg/d in
a single dose) was begun. During
this period, progressive healing was
observed both clinically and radiologically (Fig. 2). No serious side
effects of the drug were encoun
tered, and the infection did not
recur on 2-year follow-up.
Antifungal susceptibility tests
showed that the Candida isolate
was resistant to ketoconazole, but
we decided to persist with the thera
py in view of the boy’s early clinical
improvement.

Discussion
A recent review1 uncovered only
58 cases of osteomyelitis due to C.
albicans in the English literature.
Our case, which meets the diagnos
tic criteria of Edwards and col
leagues2 — radiologic evidence of
osteomyelitis plus isolation of C.
albicans from deep tissue — was
unusual in several respects. First,
the infection involved a digit,

ANTIBIOTIC

whereas C. albicans usually affects
single long bones, contiguous verte
bral bodies or the sternum. Second,
the infection appeared to be prima
ry, following trauma, rather than
secondary to bloodstream involve
ment or a surgical procedure. Final
ly, we used ketoconazole in place of
the more widely favoured am
photericin B.
This decision was based on the
success of ketoconazole in blasto
mycosis,3 another yeast-like fungal
infection in which bone involvement
is a prominent part. The relative
resistance of our patient’s isolate
did not deter us from persisting
with the drug, since previous inves
tigators4-5 have noted a poor corre
lation between its in-vitro activity
and clinical performance. In addi
tion, ketoconazole has been used as
the primary agent in five reported
cases of osteomyelitis due to C.
albicans with favourable clinical re
sponses.1 It is not associated with
the undesirable, nephrotoxic side
effects of intravenously adminis
tered amphotericin B and its ease of
administration is an attractive fea
ture.
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ACTION
In vitro studies demonstrate that the bactericidal
action of cefoxitin, a cephamycin derived from
cephamycinC, results from the inhibition of
bacterial cell wall synthesis. Evidence suggests
that the methoxy group in the 7a position is
responsible for the resistance of cefoxitin to
degradation by bacterial beta-lactamases.
INDICATIONS AND CLINICAL USES
TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by S erratia m arcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and joint infections caused by
Staphylococcus aureus

7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the susceptib ility of the causative organism(s) to
MEFOXIN®. Therapy may be started while
awaiting the results ot these tests, however,
modification of the treatment may be required
once these results become available.
Organisms particularly appropriate for therapy
with MEFOXIN® are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing and
non-producing strains)

E. coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes

Bacteroides fragilis

MEFOXIN® may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas,
most strains of enterococci, many strains of
Enterobacter cloacae, and methicillin-resistant
staphylococci and Listeria monocytogenes.
Clinical experience has demonstrated that
MEFOXIN® can be administered to patients who
are also receiving carbenicillin, gentamicin,
tobramycin, or amikacin (see PRECAUTIONS
and ADMINISTRATION).
Intravenous Administration

The intravenous route is preferable for patients
with bacteremia, bacterial septicemia, or other
severe or life-threatening infections, or for
patients who may be poor risks because of
lowered resistance resulting from such debili
tating conditions as malnutrition, trauma,
surgery, diabetes, heart failure, or malignancy,
particularly if shock is present or impending.

A

PROPHYLACTIC USE

MEFOXIN® may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal or
abdominal hysterectomy and abdominal
surgery when there is a significant risk of
postoperative infection or where the occurrence
of postoperative infection is considered to be
especially serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN® may
reduce the incidence of surgery related post
operative infections.
Effective prophylactic use depends on the time
of administration. MEFOXIN® usually should be
given one-half to one hour before the operation.
Prophylactic administration should usually be
stopped within 12 hours. It has been generally
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reported that continuing administration of any
antibiotic beyond 24 hours following surgery
increases the possibility of adverse reactions
but, in the majority of surgical procedures, does
not reduce the in cid e n ce o f subsequent
infection.
If signs of postsurgical infection should appear,
specimens for culture should be obtained for
identification of the causative organism(s) so
that appropriate therapy may be instituted.
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CONTRAINDICATIONS

►

MEFOXIN® is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.
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WARNINGS
Before therapy with MEFOXIN® is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN®, cephalo
sporins, penicillins or other drugs. MEFOXIN®
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
o f p a rtia l c ro s s - a lle r g e n ic ity between
cephamycins and the other beta-lactam anti
biotics, penicillins and cephalosporins. Severe
reactions (including anaphylaxis) have been
reported with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed with
caution in individuals with a history of gastro
intestinal disease, particularly colitis. It is
important to consider a diagnosis of pseudo
membranous colitis in patients who develop
diarrhea in association with antibiotic use. While
studies indicate that a toxin produced by
Clostridium difficile is one primary cause of
antibiotic-associated colitis, o ther causes
should also be considered.
Any patient who has demonstrated some form of
allergy, particularly to drugs, should receive
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs,
administration of the drug should be discon
tinued. Serious hypersensitivity reactions may
require treatment with epinephrine and other
emergency measures.

PRECAUTIONS
The total daily dosage should be reduced when
MEFOXIN® is administered to patients with
transient or persistent reduction of urinary
output due to renal insufficiency (see DOSAGE
AND ADMINISTRATION) because high and
prolonged serum antibiotic concentrations can
occur from usual doses.
In patients treated with MEFOXIN® a false
positive reaction to glucose in the urine may
occur with Benedict's or Fehling’s solutions but
not with the use of specific glucose oxidase
methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100pg/mL. Serum
samples from patients treated with MEFOXIN®
should not be analyzed for creatinine if with
drawn within two hours of drug administration,
increased nephrotoxicity has been reported
fo llo w in g c o n co m ita n t adm in istra tio n of
cephalosporins and aminoglycoside antibiotics.
The safety of MEFOXIN® in the treatment of
infections during pregnancy has not been
established. If the administration of MEFOXIN®
to pregnant patients is considered necessary, its
use requires that the anticipated benefits be
weighed against possible hazards to the fetus.
Reproductive and teratogenic studies have been
performed in mice and rats and have revealed no
evidence of impaired fertility or harm to the fetus
due to MEFOXIN®.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN® may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient’s condition is
essential and if superinfection occurs during
therapy, appropriate measures should betaken.
Should an organism become resistant during
antibiotic therapy, another antibiotic should be
substituted.
In children 3 months of age or older, higher
doses of MEFOXIN® (100m g/kg/day and

above) have been associated with an increased
incidence of eosinophilia and elevated SGOT.

ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse
reactions rarely required cessation of treatment
and usually have been mild and transient.
Local Reactions
Throm bophlebitis has occurred with intra
venous administration. Some degree of pain and
tenderness is usually experienced after intra
muscular injections using water. Induration has
occasionally been reported.
Allergic
Maculopapular rash, urticaria, pruritus, eosino
philia, fever and other allergic reactions have
been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported rarely.
Blood
Transient eosinophilia, leukopenia, neutropenia,
hemolytic anemia, and thrombocytopenia have
been reported. Some individuals, particularly
those with azotemia, may develop positive direct
Coombs tests during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase have
been reported.
Kidney
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure has
been reported rarely. The role of MEFOXIN® in
changes in renal function tests is difficult to
assess, since factors predisposing to prerenal
azotemia or to impaired renal function have
often been present.

should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given. After
a loading dose, the following recommendations
for maintenance dosage may be used as a guide:
RENAL
F U N C T IO N

C R E A T IN IN E
CLEARANCE
m L /m ln

Mild
impairment
Moderate
impairment

DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously
o r in tra m u s c u la rly when required. (See
complete monograph on ADMINISTRATION
and RECONSTITUTION.)
TREATMENT DOSAGE
Adults
The usual adult dosage is 1 g or 2 g of
MEFOXIN® every 6 to 8 hours. Dosage and route
of administration should be determined by
severity of infection, susceptibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
Typ e of
In fe c tio n

D a ily
Dosage

F re q u en c y
a n d R o u te

Uncomplicated
forms* of in
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
I.V. or I.M.

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing anti
biotics in higher
dosage (e.g. gas
gangrene)

12 9

2 g every 4 h
or
3 g every 6 h I.V.

•Including patients in whom bacteremia is
absent or unlikely
Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10days to guard against the risk of
rheum atic fever or glom erulonephritis. In
staphylococcal and other infections involving a
collection of pus, surgical drainage should be
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with
reduced renal function but a reduced dosage

FREQUENCY

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

impairment
Essentially
no function

In the patient undergoing hemodialysis, the
loading dose of 1 - 2 g should be given after each
hemodialysis, and the maintenance dose should
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants
and Children (See WARNINGS for Neonates
under ADMINISTRATION in the com plete
monograph.)
P r e m a tu r e In fa n ts
w ith B o d y W e ig h ts
Above 1500 g

20-40 mg/kg every 12 h I.V.

N e o n a te s

01 week of age 20-40 mg/kg every 12 h I.V.
1-4 weeks of age
20-40 mg/kg every 8 h I.V.
In fa n ts

1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

C h ild r e n

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN® can be
eliminated by dialysis in patients with renal
insufficiency.

DOSE

In severe infections, the total daily dosage in
infants and children may be increased to
200mg/kg, but not to exceed 12 g per day.
MEFOXIN® is not recommended for the therapy
of meningitis. If meningitis is suspected, an
appropriate antibiotic should be used.
A t present there is in s u ffic ie n t data to
recommend a specific dosage for children with
im paired renal fu n ctio n . However, if the
administration of MEFOXIN® is deemed to be
essential the dosage should be m odified
consistent with the recommendations for adults
(see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN® is recommended as follows:
Vaginal or abdominal hysterectomy and
abdominal surgery
2 g administered intram uscularly o r intra
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2 g doses should be
administered at 2-6 hour intervals after the initial
dose.
Cesarean Section
The first dose of 2g should be administered
intravenously as soon as the umbilical cord has
been clamped. The second and third 2g doses
should be given in tra ve n o u sly o r in tra 
muscularly four hours and eight hours after the
first dose.

AVAILABILITY
MEFOXIN® is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN® in the dry state should be stored
below 30° C.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST
(425-a,6,87x)
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Studies of DNA Content in Cervical
Intraepithelial Neoplasia by Cytologic and
Histologic Flow Cytometry
B. Lambert, MD, FRCSC;* B. Barrette, MD;* Y. LePage, PhDt
Flow cytometry was done on 82 specimens of cervical cytologic scrapings and
biopsies from patients with cervical intraepithelial neoplasia or condyloma. This
study yielded significant results when compared with standard cytologic (p < 0.01)
and histopathologic studies (p < 0.05). Histologic evaluation by flow cytometry
required more examinations and did not give significant results. The authors
conclude that cytologic flow cytometry, though not a replacement for standard
cytologic examination, may be of help in establishing therapeutic strategies and
follow-up protocols for patients with cervical precancerous conditions.

Un examen fluorocytometrique a ete pratique sur 82 prelevements cytologiques ou
biopsies cervicales provenant de patientes porteuses de neoplasies intra-epitheliales
cervicales ou de condylomes. Cette etude a revele des differences significatives par
rapport aux examens cytologiques (p < 0.01) et histologiques (p < 0.05) courants.
L’evaluation histologique par fluorocytometrie a necessity des examens plus nombreux et
n’a pas apporte de resultats significatifs. Les auteurs conduent que meme si la
cytofluorocytometrie ne remplace pas l’examen cytologique standard, elle peut contribuer a l’etablissement des strategies therapeutiques et du suivi clinique des patientes
souffrant de pre-cancer cervical.

bnormal DNA content is
known to influence tumour ag
gressiveness and the malignant po
tential of cervical intraepithelial
neoplasia (CIN).1-2 We studied DNA
indices by flow cytometry in rela
tion to cytologic and histopatholog
ic findings in patients with CIN.
We wanted to verify the clinical
applicability of cytologic flow cy
tometry as a screening test for
cellular malignancy, to evaluate the
association between DNA content

A

and histologic interpretation and to
evaluate the malignant potential of
the different degrees of CIN.

Patients and Methods
Patients with abnormal cervical
smears were seen at colposcopy
clinics for evaluation of CIN. Crit
eria for eligibility were: proposed
conservative treatment for CIN and
a lesion with a minimum surface

From the *Department o f Obstetrics and Gynecology, Hdtel-Dieu de Montreal, and the
fDepartment o f Mathematics, Universite de Montreal, Montreal, PQ
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area of 50 mm2. Cervical scrapings
were taken for the Papanicolaou
test and for cytologic flow cytome
try.
Originally, 97 patients underwent
two cytologic examinations for eval
uation of cytoploidy and one stan
dard cytologic examination.
In 82 patients, two biopsies were
taken using Kervorkian forceps —
one for histologic diagnosis, the
other for histologic flow cytometry.
Controls chosen had negative Papa
nicolaou test results, no colposcopic aceto-white epithelium, and no
punctate or mosaiform changes. Cy
tologic identification of a condylo
ma was the presence of cytoplasmic
koilocytosis, with enlarged hyperchromatic nuclei and, histologically,
the partial replacement of the cervi
cal epithelium with koilocytes. Cy
tologic features of CIN were the
presence, in variable quantities, of
cervical cells with hyperchromatic
nuclei and an increase in the nu
clear-cytoplasmic ratio. The histo
logic features of CIN corresponded
to those of progressive replacement
of the cervical epithelium by malig
nant cells with an increased nu
clear-cytoplasmic ratio varying in
thickness from one-third of the epi
thelium in CIN grade I to twothirds in CIN grade II and at least
seven-eighths in CIN grade III.
In the laboratory, the specimens
were processed to obtain a unicellu
lar suspension. The spatula of the
cervical scraping was washed with

DNA IN CERVICAL NEOPLASIA

normal (0.9%) saline and fixed in
95% ethanol. The microbiopsy spec
imen was minced mechanically with
a scalpel, passed through a 21
gauge needle, washed in normal
(0.9%) saline, then fixed. Before
staining with fluorochrome, fixed
cells were treated with 0.5% pepsin
for 8 minutes and then neutralized
with TRIS-buffer. They were
stained with propidium iodide for
20 minutes at 4°C. The cells were
then passed through a 70-gauge
nylon mesh filter and treated with
ribonuclease. Normal human lym
phocytes were used as normal dip
loid standard for the DNA content.
Statistical analysis was by the x 2
test.

Results
Cytoploidy and Cytologic Findings
Study of the association between
cytologic and cytoploidy findings
revealed that condyloma (HPV) and
CIN grade III yielded the highest

percentage of abnormal DNA con
tent (70% and 64.7% respectively)
as opposed to CIN I and normals (<
24%) (Table I).
Inversely, the normal content in
condylomas and CIN III fell to 30%
and 35.3% respectively. Despite the
small number of patients in each
group, comparison of CIN and con
dylomas with controls gave a sig
nificant result (p < 0.01). When
CIN I and CIN II were compared
with CIN III the difference was
mildly significant (p < 0.06).
Cytoploidy and Histologic Findings
The same tests were applied
when the cytoploidy findings were
compared with the histopathologic
findings (Table II). Condylomas and
CIN III behaved differently (p <
0.05) from the milder degrees of
CIN and controls. There was a
significant difference (p = 0.02)
between CIN I and CIN II versus
CIN III, although the difference
between CIN I versus CIN II and
CIN III was not significant.

T a b le 1. Association Between Cytoploidy and Cytologic Findings (N = 97)
C ytologic fin d in g s, no. ( % )
C ytoploidy

C ontrols

H PV

Normal
Abnormal

34 (77.3)
10 (22.7)

3 (30)
7 (7 0 )

Totals

44

10

C IN 1

CIN II

C IN III

10 (76.9)
3 (23.1)

8 (61.5)
5 (38.5)

6 (35.3)
11 (64.7)

13

13

17

T a b le II. Association Between Cytoploidy and Histologic Findings (N = 82)
H isto lo g ic fin d in g s, no. (% )
C ytoploidy

C ontrols

HPV

C IN 1

C IN II

C IN III

Normal
Abnormal

20 (76.9)
6 (23.1)

3 (42.8)
4 (57.2)

13 (76.5)
4 (23.5)

9 (7 5 )
3 (2 5 )

8 (40)
12 (60)

Totals

26

7

17

12

20

T a b le III. Association Between Histoploidy and Histologic Findings (N = 82)
H is to lo g ic fin d in g s, no. (% )
H istoploidy

C ontrols

HPV

C IN I

C IN II

C IN III

Normal
Abnormal

14 (73.7)
5 (26.3)

6 (54.5)
5 (45.5)

7 (63.6)
4 (36.4)

8 (61.5)
5 (38.5)

12 (42.9)
16 (57.1)

Totals

19

11

11

13

28

Histoploidy and Histologic Findings
Finally, when we compared biop
sies by fluorocytometry to histopa
thologic findings (Table III), no sig
nificant difference was found. Con
tamination by normal stromal tissue
underlying the cervical epithelium
could be a factor in this unexpected
finding.

Discussion
Our study showed that, com
pared with standard cytologic and
histologic studies, flow cytometry,
which assesses DNA content, gave
significant results when condylomas
and CIN III were compared with
control specimens.
Similarly, Jakobsen and col
leagues3 found a majority (78%) of
aneuploid cells in severe dysplasias
and carcinomas in situ, in spite of
diploidy in mild and moderate dys
plasias. They then associated the
aneuploidy index with both progres
sive and regressive characteristics.
Tsou and colleagues4 observed clus
ter cells in early S-phase region and
a higher DNA content in 74.5% of
patients who had condyloma.
We also found higher aneuploidy
in condylomatous lesions, as if the
viral infection was severely disturb
ing the DNA cellular content. Barres and associates5 delineated tetraploidy indices as a demarcation be
tween CIN grade I and CIN grades
II and III. We found discrimination
between CIN grades I and II and
CIN grade III, but we conclude that
cytologic flow cytometry is not real
ly suitable for cytologic mass
screening because we found abnor
mal patterns in 22% of control
specimens but normal cells in 35%
of CIN III specimens. It seems that
the numerous abnormal cells in the
latter indicate a greater malignant
potential than in CIN I and CIN II.
The fact that histologic flow cyCJS, VOL. 32. NO. 3. M A Y 1989
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tometry does not give significant
results may be explained by the
probable contamination of stromal
tissue in the biopsies; this will have
to be verified by control biopsies of
normal areas in the vicinity of CIN.
Further research is needed to refine
flow cytometry; this technique
should not be considered a replace
ment for cytology, but an aid in the
clinical evaluation of CIN.
We thank Dr. J. Latreille for technical

help and Dr. Harry Bard for reviewing
the manuscript.

3. J akobsen A, Kristensen PB, P oulsen

HK: Flow cytometric classification of bi
opsy specimens from cervical intraepi
thelial neoplasia. Cytometry 1983; 4:
166-169
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BOOK REVIEWS
continued from page 200

range from plasma exchange and immunoadsorption to cryofiltration and
in-vivo adsorption using incompatible
red blood cell transfusions. The last
article reports the effects of a new
immunosuppressive agent, Spergualin,
on the humoral immune system.
Overall, the book is an excellent
reference manual for physicians inter
ested in ABO-incompatible transplanta
tion and is essential for anyone with
research interest in xenotransplanta
tion. It lacks the general overview and
cohesiveness of a textbook but makes
up for this by being up to date. The
editors have included papers that pres
ent opposite viewpoints so that readers
can formulate their own opinions on the
controversial topics that surround ABOincompatible transplantation.
Francis Sutherland, MD, FRCSC
Clinical Fellow,
Transplantation,
University Hospital,
London, Ont.

APPLICATIONS OF NONINVASIVE
VASCULAR TECHNIQUES. Amil J.
Gerlock, Jr., Vishan L. Giyanani and
Carol Krebs. 541 pp. Illust. W.B.
Saunders Company, Philadelphia;
W.B. Saunders Company Canada Lim
ited, Toronto, Ont., 1988. $93.60.
ISBN 0-7216-2335-2.

This text provides an enormous amount
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of anatomic and physiologic data and
describes in detail numerous noninvasive vascular techniques. There is excel
lent anatomic, angiographic and patho
logic correlation. The role of duplex
ultrasonography in extracranial carotid
artery disease is adequately discussed,
but its role in evaluating peripheral
arterial and venous disease is understat
ed. Other obvious omissions include
colour-encoded Doppler and abdominal,
pelvic and obstetric applications of noninvasive vascular techniques. The text
is verbose and somewhat repetitive, par
ticularly in the discussion of plethys
mography evaluating cutaneous and
digital perfusion. In many chapters, the
number of figures and examples is
excessive.
The description of instrumentation
and Doppler principles is simple but too
concise, and the use of nonstandardized
terminology causes some confusion.
The concept of aliasing is not explained
or discussed and no references have
been included at the end of this section.
The section on extracranial carotid
arteries is organized, comprehensive
and well referenced. High-quality, real
time ultrasound images and various
spectral analysis patterns are included.
The text refers to “frequency shift”
based on a kilohertz scale, but the
spectral images depict a velocity format,
which is more meaningful clinically and
should have been used throughout the
text. Plaque morphology is well de
scribed and illustrated, but the limita

tion of duplex ultrasonography in the
presence of heavily calcified plaque is
not emphasized. Correlative duplex ul
trasonography and angiography are
nicely illustrated. The authors describe
five categories of internal carotid artery
stenosis but do not elaborate on how
the grading system was derived. Exter
nal carotid, common carotid and perior
bital flow patterns are clearly explained.
The section on peripheral venous
anatomy, flow hemodynamics, deep-vein
thrombosis and venous insufficiency is
well organized and beautifully illustrat
ed. Nonimaging modalities, particularly
photoplethysmography and straingauge plethysmography are empha
sized.
An extensive, well-organized section
describes systolic pressure measure
ments and indices and peripheral arteri
al waveforms as they pertain to aortoiliac and lower-extremity arterial dis
ease. Again, nonimaging noninvasive
techniques are emphasized but duplex
ultrasonography is only mentioned
briefly.
The section on upper-extremity anat
omy and pathology is excellent. In this
section the chapter on duplex ul
trasonography of superficial masses,
however, seems rushed and incomplete,
and greater emphasis should be placed
on its role in the assessment of patients
after reconstructive vascular surgery.
This text is comprehensive, accurate,
continued on page 209

ORIGINAL ARTICLES

Prophylaxis of Deep-Vein Thrombosis in
Total Hip Surgery
Richard Hu, MD
Thromboembolism is a common and serious complication of total hip replacement.
Methods of prophylaxis include combinations of physical compression of the legs
and anticoagulation. Results of treatment are difficult to document and quantitate.
The authors reviewed 122 patients who underwent hip arthroplasty with
intermittent pneumatic calf compression, intravenous administration of dextran and
platelet inhibitors. In 20% of them, clinically suspected pulmonary embolism was
confirmed by ventilation perfusion lung scanning. The true incidence of pulmonary
embolism is probably greater than this and it appears that the prophylactic regimen
used in this study does not confer any benefit.

La thromboembolie est une complication frequente et grave de l’arthroplastie totale
de la hanche. Les moyens prophylactiques comprennent diverses associations de
compression physique de la jambe et d’anticoagulation. Les resultats de ces
traitements sont difficiles a verifier et a quantifier. Les auteurs ont etudie 122
patients qui ont subi une arthroplastie de la hanche avec compression pneumatique
intermittente du mollet, administration intraveineuse de dextran et d’inhibiteurs de
l’agregation plaquettaire. Dans 20% des cas, une embolie pulmonaire diniquement
soupconnee fut confirmee par scintigraphie pulmonaire de perfusion. L’incidence
reelle des embolies pulmonaires est probablement superieure a cela et il semble que
le traitement prophylactique utilise dans cette etude n’ait eu aucun effet favorable.

eep-vein thrombosis and pul
monary embolism are major
complications of total hip replace
ment. It is estimated that 40% to
60% of patients who do not receive
prophylaxis will suffer deep-vein
thrombosis.1 Pulmonary embolism
occurs in 10% to 15% of patients
after hip replacement, and 1% to 2%
of all those who undergo elective
hip replacement will die if no pro
phylactic measure is used.2

D

The magnitude of thromboembol
ic disease has spurred clinicians to
attempt to lower its incidence. Dex
tran has been used by many34 and
in combination with intermittent
pneumatic compression of the legs
has proven useful in preventing
deep-vein thrombosis and, by infer
ence, pulmonary embolism.
At one institution in Edmonton,
dextran combined with intermittent
calf compression was begun on an

From the Division o f Orthopedic Surgery, Department o f Surgery, University o f Alberta,
Edmonton, Alta.

empirical basis for all patients ad
mitted for total hip surgery. It is
the aim of this paper to review the
results of this regimen in terms of
its effect upon the occurrence of
pulmonary embolism.

Patients and Methods
A retrospective survey was done
of all 122 patients admitted for
total hip replacement surgery be
tween January 1984 and December
1987. Charts were reviewed for
pertinent aspects of patient history,
physical examination, laboratory in
vestigations, preoperative, intraop
erative and postoperative care as
well as diagnosis of thromboembol
ic disease and other complications.
All patients met the following
criteria: they were operated on by
one group of surgeons; they had
pre- and postoperative prophylaxis
for deep-vein thrombosis; the in
traoperative management and surgi
cal technique were similar; a ce
mented Charnley total hip replace
ment prosthesis was used.
The end-point of the study was
clinically detectable pulmonary em
bolism proven by lung scanning.
Differences were analysed by Stu
dent’s f-test.

Prophylactic Regimen

Accepted fo r publication Aug. 30, 1988
Reprint requests to: Dr. R. Hu, Division o f Orthopedic Surgery, Department o f Surgery,
University o f Alberta, Walter C. MacKenzie Health Sciences Centre, 8440 - 112th Street,
Edmonton, Alta. T6G 2B7

All patients were admitted to hos
pital at least 2 days before the
operation and started on Persantine
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(Boehringer Ingelheim [Canada]
Ltd., Burlington, Ont.) 50 mg three
times daily. They were instructed
on the postoperative use of the
circoelectric bed and the intermit
tent pneumatic compression (IPC)
boots.
The IPC apparatus (ALP 501;
Twee Corp., Lake Oswego, Ore.)
with a sterile boot was placed on
the operative leg and a non-sterile
boot on the opposite leg at the time
of operation. Immediately postoperatively, 500 ml of dextran 70 solu
tion was given intravenously. Over
the next 3 days the patient was
given a total of 1 litre of low
molecular weight dextran (dextran
40).
Patients continued to have IPC of
the calf for 1 week postoperatively.
Weight bearing and active assisted
physiotherapy were begun on post
operative day 2 or 3.

Results
Of the 122 patients, 60 met the
inclusion criteria for further analy
sis. The remainder were excluded
for various reasons (Table I).
Age, weight, sex, operating time,
blood loss and volume of blood
replacement were analysed (Table
II). There was an equal distribution
of male and female patients. Associ
ated major medical problems oc
curred in 50% of patients.
In these 60 patients, 12 had
clinically detected pulmonary embo
li proven by lung scanning. There
did not appear to be any statistically
significant difference in these pa
T a b le 1. R e a so n s fo r E x c lu s io n o f P a tie n ts
R e a so n

No.

H e m ia rth ro p la s ty
H y b rid p ro c e d u re
R e v is io n
N o n c e m e n te d p ro s th e s is
In s u ffic ie n t data

18
12
8
16
8

T o ta l

62
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tients in any of the factors analysed
compared with the nonembolism
group.
Complications included three
wound hematomas and three hip
dislocations, two in the group of
patients who had pulmonary embo
lism. There were no episodes of
congestive heart failure and no al
lergic reactions to dextran. There
were no postoperative deaths.

Discussion
Many methods of prophylaxis
have been used in an attempt to
manipulate Virchow’s triad of vas
cular stasis, blood hypercoagulabili
ty and vessel wall damage. Dextran
is thought to alter blood coagulabil
ity through a number of mecha
nisms. Lowering of blood viscosity
is important as is a slight heparin
like effect. Intermittent compres
sion of the leg makes intuitive
sense in that it directly affects the
vascular stasis limb of the triad.
In our patients, those treated
with dextran and IPC of the calf
had a frequency of pulmonary em
bolism equal to that in previous
reports of those who did not receive
prophylactic measures.2 The rea
sons for this high rate of pulmo
nary embolism can only be speculat
ed upon. However, some factors in
our patient population were of
prime importance in thrombus pro
duction.

Surgical approach may have a
bearing on the occurrence of embo
lism. The anterolateral approach
with trochanteric osteotomy has
been shown to produce more deepvein thrombosis than the posterior
approach.1 This is possibly a result
of the more extensive soft-tissue
dissection required to reach the hip
joint.
Type of prosthesis inserted may
have a bearing upon thrombus pro
duction. Francis and associates5
have reported a far higher incidence
of deep-vein thrombosis in patients
with cemented total hip prostheses
than with noncemented ones. They
believe that the type of prosthesis
inserted may have more impact on
thromboembolism than the prophy
lactic regimen.
Intermittent compression of the
calf alone has little effect on those
thrombi that originate in the thigh
(approximately 20%). Full length
compression of the limb is effective
on its own and is a useful adjunct
to thromboembolism prophylaxis.24

Conclusions
Intermittent pneumatic compres
sion of the calf in association with
dextran confers no benefit in pa
tients who undergo cemented total
hip replacement.
The empiric use of a therapeutic
regimen should be monitored regu
larly to ensure that it is efficacious.

T a b le II. F a c to rs A n a ly s e d in P a tie n ts W ith and W ith o u t P u lm o n a ry E m b o lis m
P u lm o n a ry e m b o lis m
W ith o u t
(n = 4 8 )
A ge, yr
W e ig h t, kg
O p e ra tin g tim e , m in
B lo o d lo s s, m l
D ro p in h e m o g lo b in , g /L
B lo o d re p la c e m e n t, u n its
N o. w ith a s s o cia te d m e d ic a l p ro b le m s
C o m p lic a tio n s
H e m a to m a
D is lo c a tio n

W ith
(n = 12)

6 0 .5
77
85
540
32
2 .4
23

6 2 .5
72
84
518
28
2 .5
6

2
1

1
2

THROMBOEMBOLISM IN HIP REPLACEMENT

I thank Drs. Joseph and Paul Moreau
and Dr. Paul Leung for allowing me to
review their patients.
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practical and easy to read. Although it
has a few limitations, it is an appropri
ate reference for anyone interested in
learning noninvasive vascular tech
niques.
Anne R. Buckley, MB, FRCR, FRCPC
Section o f Ultrasound,
Department o f Radiology,
Vancouver General Hospital,
University o f British Columbia,
Vancouver, BC
V5Z 1H9

THE BASIC SCIENCE OF VASCU
LAR SURGERY. Edited by Joseph M.
Giordano, Hugh H. Trout, III and
Ralph G. DePalma. 773 pp. Illust.
Futura Publishing Co., Inc., Mount
Kisco, New York, 1988. $89.00 (US).
ISBN 0-87993-321-6.
Despite the recent publication of a
number of textbooks of vascular sur
gery, this book fulfils a vital need
because it presents under one cover
information that has been spread
through a number of publications,
many of which are not readily available
to the vascular surgeon. The editors are
three senior vascular surgeons from the
George Washington University Medical
Center. Each of the 22 chapters is
written by an expert in the field, includ
ing vascular surgeons, internists and
anesthetists. The textbook covers the
basic science and related clinical fea
tures of vascular embryology, the lym
phatic system, endothelial cells, cere
brovascular disease and arteriovenous

fistulas; the physiologic and biochemi
cal events associated with mesenteric
vascular insufficiency and infarction;
the anatomy and physiology of male
sexual function; the role of the carotid
sinus and other baroreceptors; and ar
terial and vascular graft infections. Of
value is the presentation, in an objective
and mature fashion, of the controversial
aspects of each topic, reflecting the
authors’ wide experience and knowl
edge of the subject.
In their introduction the editors state
“Within three decades vascular surgery
evolved into a unique specialty dedicat
ed to treatment of patients with vascu
lar diseases. Vigorous local and national
certification in vascular surgery all at
test to the maturation of a distinct
discipline.” Professor John Bergan
summarizes the need for this book in
his preface: “This volume identifies the
components of basic sciences peculiar
to vascular surgery, clarifies each and
relates them to practice. Thus, vascular
surgery which once was just technique
and mechanics has become an intellec
tual endeavor as well.”
Despite the number of authors, this
book reads well. It should be in the
library of all practising vascular sur
geons and candidates for certification in
vascular surgery, since it covers the
basic science portion of this specialty,
filling in the gaps in standard text
books.
T. Keith Scobie, MD, MSc, FRCS,
FACS
120 Clearview Ave.,
Ottawa, Ont.
K1Y2L2

ESSENTIAL SURGICAL PRACTICE.
2nd edition. Edited by A. Cuschieri,
G.R. Giles and A.R. Moosa. 1438 pp.
Illust. Butterworth International Edi
tion, Stoneham, Mass., 1988. $125.00
(US). ISBN 0-7236-1127-0.
This textbook has been extensively
modified and revised, and a new section
on trauma has been added since its first
edition.
The first section is devoted to gener
al aspects of surgical disease and covers
common surgical problems. I particular
ly liked the chapters on surgical infec
tion, in which bacterial, viral, fungal
and parasitic infections are discussed,
the one on oncology, which covers
chemotherapy and radiation and that on
cutaneous disorders and malignancy,
which will be of use to general sur
geons who have to deal with these
problems without the help of a derma
tologist.
The eight chapters on the various
aspects of trauma were written by
North American authors, because it is
acknowledged that this area of surgery
is more fully developed on this conti
nent. This section is particularly appro
priate in light of the current interest in
trauma training for surgical residents.
The nine chapters on head and neck
surgery provide a wider scope than
most general textbooks on this subject
and include chapters on nose and para
nasal sinuses, the ear and ocular trau
ma. The general surgeon will find the
chapters on intracranial emergencies,
spinal injury and the surgery of pain of
interest.
continued on page 217
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BCefizoxw
sterile ceftizoxime sodium

THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from in
hibition of cell-wall synthesis in aerobic and anaerobic gram-positive and gram
negative organisms. In vitro, ceftizoxime shows a strong affinity for penicillin
binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the
infections listed below when caused by susceptible strains of the designated
microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (includ
ing S. pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis;
Escherichia coli; Haemophilus influenzae (including ampicillin-resistant strains);
Staphylococcus aureus (including penicillinase-producing but excluding
methicillin-resistant strains); Serratia sp.; and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis; Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia
marcescens; and Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to
Pseudomonas infections of the urinary tract, a good clinical response accompanied
by bacterial eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus
epidermidis; Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides
sp. (including B. fragilis); Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S.
pneumoniae); Staphylococcus aureus (excluding methicillin-resistant strains);
Escherichia coli; Bacteroides sp. (including B. fragilis); Klebsiella sp.; and Serratia
marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding
m ethicillin-resistant strains); Staphylococcus epidermidis; Escherichia coli;
Klebsiella sp., (including K. pneumoniae); Streptococcus sp. (excluding enterococci
but including Group A B-hemolytic Streptococcus pyogenes); Proteus mirabilis;
Serratia sp.; Enterobacter sp.; Bacteroides sp. (including B. fragilis); Peptococcus
sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding
methicillin-resistant strains); Proteus mirabilis; Peptococcus sp.; and Pepto
streptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to
identify the causative organisms and to determine their susceptibilities to cefti
zoxime. Therapy with CefizoxTM may be initiated before results of the susceptibility
studies are known. However, modification of the treatment may be required once
these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have
shown hypersensitivity to ceftizoxime or other members of the cephalosporin group
of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful
inquiry should be made to determine whether the patient has had previous hyper
sensitivity reactions to cephalosporins, penicillins, or other drugs. CefizoxTM
should be given cautiously to penicillin-sensitive patients. Antibiotics, including
CefizoxTM, should be administered with caution to any patient who has demon
strated some form of allergy, particularly to drugs. If an allergic reaction to Cefi
zoxTM occurs, its administration should be discontinued. Serious acute hyper
sensitivity reactions may require epinephrine and other emergency measures.
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other
antibiotics). Therefore, it is important to consider this diagnosis in patients adminis
tered CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may
permit overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe
cases should be managed with fluid, electrolyte and protein supplementation as
indicated. When the colitis is not relieved by drug discontinuance or when it is
severe, consideration may be given to the administration of oral vancomycin or
other suitable therapy. Other possible causes of colitis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in
clinical studies. However, there is no other evidence that CefizoxTM (sterile cefti
zoxime sodium) has produced alterations in renal function. Renal status should be
periodically evaluated, especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible
organisms including species originally sensitive to the drug. Careful observation of
the patient is essential. If superinfection occurs during therapy, appropriate
measures should be taken.
CefizoxTM should be administered with caution to individuals with a history of
gastrointestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine,
patients with impaired renal function (i.e., creatinine clearance <1.32 mUs or
^ 7 9 mL/min) should be placed on a special dosage schedule recommended under
DOSAGE AND ADMINISTRATION. Normal dosages in these individuals are likely to
produce excessive serum concentrations of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and
aminoglycosides has caused nephrotoxicity. The effect of administering CefizoxTM
concom itantly with aminoglycosides is not known.
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Pregnancy: The safety of CefizoxTM jn pregnancy has not been established. The
use of CefizoxTM jn pregnant women requires that the likely benefit from the drug
be weighed against the possible risk to the mother and fetus. The pharmacokinetics
of CefizoxTM jn pregnant patients has not been investigated. Reproduction studies
performed in rats and rabbits have revealed no evidence of impaired fertility or harm
to the fetus caused by ceftizoxime. Animal reproduction studies, however, are not
always predictive of human response.
Labour and Delivery: The safety and efficacy of CefizoxTM use during labour and
delivery has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations
(less than 4% of serum concentrations at 1 hour after dosing). The clinical signifi
cance of this is unknown; therefore caution should be exercised if CefizoxTM jS to
be administered to a nursing woman.
Infants and Children: The safety of CefizoxTM jn infants less than 6 months of age
has not been established. In children six months of age and older, treatment with
CefizoxTM has been associated with transient elevated levels of eosinophils,
SGOT, SGPT and CPK (creatine phosphokinase). The CPK elevation may be related
to intramuscular administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an agedependent reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Incidence
Incidence
Reaction
< 1%
>1% but < 5 %
Hypersensitivity:

Rash
Pruritus
Fever

Liver:

Transient elevation of SGOT,
SGPT and alkaline phosphatase
Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test

Blood:

Neutropenia
Leukopenia
Thrombocytopenia

Renal:

Transient elevation
of BUN and creatinine
Injection site: burning, cellulitis,
phlebitis (with IV administration),
pain, induration, tenderness,
parasthesia

Local:

Genitourinary:

Vaginitis

Gastro
intestinal:

Diarrhea, Nausea, Vomiting, Pseudomembranous colitis

No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no
specific information available on symptoms or treatment. In cases of suspected
overdosage, supportive therapy should be instituted according to symptoms. Serum
ceftizoxime levels can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly
or intravenously after reconstitution.
Dosage and route of administration should be determined by the condition of the
patient, severity of the infection and susceptibility of the causative organism(s). The
intravenous route may be preferable for patients with bacterial septicemia, or other
severe or life threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at
least 48 hours after evidence of bacterial eradication has been obtained. For
B-hemolytic streptococcal infections, a minimum of 10 days of treatment is
recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM js 1 to 12 grams admin
istered in equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
Type of Infection

Daily Dose
(Grams)

Frequency and Route

Uncomplicated
Urinary Tract

1

500mgq12h, IVorIM

Other Sites

2-3

1 g q8h orq12h, IV or IM

Severe or
Refractory

3-6

1 g q8h, IV or IM, to
2g q8horq12h, IVorIM *

Life-Threatening

9-12

3 or 4 gq8hIV

*When administering 2 g intramuscularly, the dose should be divided and injected
into different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas
aeruginosa and because many strains are only moderately susceptible to CefizoxTM,
higher dosage may be appropriate when urinary tract infections are caused by
these organisms. Other therapy should be instituted if the response is not prompt.

Adults with Impaired Renal Function: In patients in w hom the creatinine clearance
is 1.32 mL/s (79 mL/min) or less, the d o sa g e of CefizoxTM m ust be reduced. Fo llo w 
ing an initial loading d o se of 500 mg to 1.0 g IM or IV, the m aintenance dosing
schedule presented in Table 2 sho uld be followed in pa tie n ts with reduced renal
function.

RECONSTITUTION
ST A N D A R D V IA L S (1 G R A M and 2 G R A M S )
For Intramuscular Injection: R e co n stitu te with Ste rile W a te r for Injection or B a c 
te rio sta tic W ater for Injection.
Reconstitution Table for Standard Vials - I.M. Injection

TABLE2
Creatinine
Clearance
mUs
mL/min

Renal
Function
Mild
Impairment

0.83-1.32

Less Severe
Infections

Life-Threatening
Infections

50-79

500 mg
q8h

750 mg to 1.5 g
q8h

5-49

250 or 500 mg
q12h

500 mg to 1.0 g
q12h

500 mg q48h or
250 mg q24h

500 mg to 1.0g
q48h or 500 mg
q24h

0.08-0.82
Moderate to
severe im pairment
Hem odialysis
patients*

0-0.07

0-4

*ln patients undergoing h e m o d ia ly sis no a d ditional supplem ental dosing is
required. DOSING, H O W E V ER , S H O U L D B E S C H E D U L E D SO TH AT T H E PATIENT
RE CE IVE S TH E D O S E AT T H E EN D O F T H E DIALYSIS. W hen started 24 hours after
adm inistration of 1 g of CefizoxTM, h e m o d ia ly sis has been show n to reduce serum
levels by 50%.
When only the serum creatinine level is available, creatinin e cle a ra nce m ay be
calculated from the follow ing form ulae (for patients 18 years and over only). The
serum creatinine level should represent renal function at the steady state.
Males:
Creatinine Cle a ra n ce

Vial
Size

D iluent to be
Added to Vial

A pproxim ate
A vailab le
Volum e

A pproxim ate
Average
C o nce ntratio n

ig
2g

3.0 m L
6.0 m L

3.7 m L
7.4 m L

270 mg/m L
270m g/m L

S h ak e well until dissolved.
For Intravenous Injection: R e co nstitute o nly w ith S te rile W a te r for Injection.
Reconstitution Table for Standard Vials - I.V. Injection
Vial
Size

D iluent to be
Added to V ia l

A p p ro xim ate
A vailab le
Volum e

A p p ro xim ate
Average
C o nce ntratio n

ig
29

10 m L
20 m L

10.7 m L
21.4 m L

95 mg/m L
95 mg/m L

S h ak e well until dissolved.
For Intravenous Infusion: R e co n stitu te as for intra ve n ou s injection. Further
d ilute the re co nstitu te d so lutio n to 50 to 100 m L w ith one o f the “ S o lu tio n s for
Intravenous Infu sio n" (see below).
TABLE 4: Solutions for Intravenous Infusion

W eight (kg) x (140-age)

(mL/min)

72 x serum creatinine (mg/100 mL)
W eight (kg) x 140-age)

Creatinine C learan ce

49 x serum creatinine ( /zmol/L)

(mL/s)

Females: 0.85 of the above values
Infants and Children: The follow ing d o sa g e schedule is recomm ended:
TABLE 3
Age Group
Infants (6 mo-2 yrs.),
and
Children (2-12 yrs.)

Sod ium C h lo rid e Injection
5% or 10% D extrose Injection
5% D extrose and 0.9%, 0.45% o r 0.2% Sod ium C h lo rid e Injection
R in g er’s Injection
Lactated R in g er’s Injection
10% Invert S u g a r in Sterile W ater for Injection
5% Sodium B icarb o na te in Ste rile W ater for Injection
5% D extrose in Lactated R in g er’s Injection O N L Y w hen reco nstitu te d
4% Sodium B icarb o na te Injection.

w ith

STABILITY OF SOLUTIONS

Unit Dosage

Frequency and Route

50 mg/kg IV orIM

q 6 h o rq 8 h , IV o rIM

Storage: A ll reconstitu ted so lu tio n s and tho se further d ilute d sho uld be used
w ithin 24 h o urs if stored at room tem perature o r w ith in 48 hours if refrigerated.
Th ese sto rag e lim its are from the tim e of the initial reco nstitu tio n .
Incompatibility: CefizoxTM sh o u ld not be ad ded to b lood products, protein
hyd rolysates or am ino acids. CefizoxTM sh o u ld not be m ixed together w ith an
a m in og lyco sid e.

The pediatric d o sag e should not e xce e d the m axim um adult d o sag e for se riou s
infections.

DOSAGE FORMS

ADMINISTRATION

Availability: CefizoxTM js a v ailab le as a ste rile pow der in Standard V ia ls of
1 gram or 2 gram s, con tain ing ce ftizo x im e as so d ium salt.

Intramuscular. The reconstituted so lutio n of CefizoxTM should be injected well
within the body of a relatively large m uscle, su ch as the gluteus. W hen a d m inister
ing 2 g IM doses, the do se should be divided e q ually and then injected into different
large m uscle m asses.

Storage: CefizoxTM powder for injection sh o u ld be stored at room tem perature
(15°-30°C).

Intravenous: Injection (bolus): The reconstituted so lutio n of CefizoxTM sho uld be
injected slow ly over 3 to 5 m inutes, d irectly or through the tubing system by w hich
the patient is receiving another com p atib le intravenous solution. During a d m inistra 
tion of the so lu tio n containing CefizoxTM, it is de sirab le to tem porarily d isco n tin u e
adm inistration o f the other solution.
Intermittent or con tinuo us infusion: The further d iluted reconstituted so lutio n of

CefizoxTM sho uld be adm inistered over a 20 to 30 m inute period.
NOTE: CefizoxTM so lu tio n s sh o u ld not be p h y sica lly m ixed with any other drug.
There is a known inco m p atib ility w ith am in og lycosid e antib io tics. Therefore, they
should not be p h y sica lly m ixed w ith CefizoxTM so lu tio n s nor adm inistered at the
sam e site.
PHARMACEUTICAL INFORMATION
CHEMISTRY

FOOTNOTES
'A s indicated in the manufacturer's product monograph Cefizox, S m ith Kline & French Canada Ltd . 1988
2A s indicated in the m anufacturer's product monograph cefoxitin, M erck S harp & Dohm e Canada, 1985
3Lou M .A. et al.: 14th International Congr. Chemother.. Kyoto, Japan, Ju n e 1985, pp 2378-2379.
4Neu H.C.. Chin N X : The activity and beta-lactamase stability of cefotetan com pared to other beta-lactam antibiotics
Chemioterapia 1985;4:271-277

Trade Name: CEFIZOXTM

5Fu K.P., Neu H C : Antibacterial activity of ceftizoxim e, a B-lactam ase-stable cephalosporin Antim icrob. Agents
Chemother. 1980;12:583-590

Proper Name: C eftizo xim e Sod ium
Chemical Name: Sodium (e R -JS 0*, 7 B (Z )]]-7 -[[(2 ,3 -d ih y d ro -2 -im in o -4 -th ia z o ly l)
(m e th o x yim in o )a ce tyl]a m in o ]-8 -o xo -5 -th ia -1 -a za b ilcy clo [4 .2 .0 ] o c t - 2 - e n e - 2 carboxylate
Structural Formula:

6Thornsberry C : Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibio tics
against clin ically important bacteria Am . J. M ed 1985;79 (Suppl. 2A): 15-20.
7Drulak M .W ., Chow A W : Com paritive in vitro activity of ceftizoxim e cefo perazone and cefoxitin against anaerobic
bacteria. Antim icrob. Agents Chemother. 1981;20:683-685.
*Aldridge K.E et a l.: Com parision of the activities of penicillin G and new B-lactam antibio tics again st clin ical isolates of
Bacteroides species Antim icrob Agents Chemother 1984:26(3) 410-413.
9Adapted from Parker D .D : Abstr. Annu M eet Am . Soc. M icrobiol. .Atlanta, GA. M arch 1987, Abstract no. A-107, p. 18.
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Spontaneous Rupture of the Diaphragm
in Labour: a Case Report
D.B. Ross, MD; G.E. Stiles, MD, FRCSC, FACS
Spontaneous rupture of the diaphragm during normal labour is extremely rare. It
requires emergency surgical correction. The authors report what they believe is
only the second reported case. Eleven hours after delivery of a male infant, a
27-year-old woman experienced severe epigastric pain, vomiting and dyspnea,
followed by cardiopulmonary arrest. Although the ruptured diaphragm was
diagnosed and repaired, she suffered severe anoxic encephalopathy and died 3 weeks
after operation without regaining consciousness. Clinicians must be aware of the
existence of this rare condition because failure to diagnose and treat the ruptured
diaphragm will almost certainly lead to the patient’s death.

La rupture spontanee du diaphragme durant le travail est extremement rare. Elle
exige une correction chirurgicale immediate. Les auteurs decrivent ce qu’ils croient
etre le deuxieme cas rapporte seulement. Onze heures apres la naissance d’un
garcon, la mere de 27 ans souffrit de douleurs epigastriques intenses, de
vomissements et de dyspnee, suivis d’un arret cardiorespiratoire. Malgre le
diagnostic de rupture du diaphragme et sa reparation, la femme souffrit d’encephalopathie anoxique grave et elle mourut 3 semaines apres l’operation, sans avoir repris
conscience. Les medecins doivent etre sensibilises a l’existence de cette affection
rare car, faute d’avoir diagnostique et traite une rupture du diaphragme, le deces
suivra presque invariablement.

pontaneous rupture of the dia
phragm during labour is ex
tremely rare. To our knowledge
only one such case has been report
ed.1 We describe another case.

S

Case Report
A 27-year-old primigravid woman
was delivered of a healthy 3640-g
infant boy after a 20-hour labour at
another hospital. The second stage
was prolonged at 3 hours and vacu
um extraction was necessary. Elev
en hours after delivery, the woman

complained of severe epigastric pain
radiating to her left shoulder, asso
ciated with vomiting and shortness
of breath. Thirty-two hours after
delivery she had a full cardiopulmo
nary arrest on her way to the
radiology department for a chest
x-ray. She was successfully resusci
tated, but it was approximately 1
hour before her blood pressure was
restored. A chest x-ray film showed
an air-fluid level in the chest on the
left side. A tube thoracostomy was
performed and gastric contents
were drained. The patient was then
transferred to our hospital.

On arrival, she was intubated,
unresponsive and the pupils were in
the mid-position. Blood pressure
was 7 0/50 mm Hg, heart rate 95
beats/min and she was markedly
cyanosed. Breath sounds were de
creased on the left side. The initial
arterial blood gas values demon
strated a metabolic acidosis with
the pH 7.22, Po2 77 mm Hg, PC02
22 mm Hg, HC03 10 mmol/L
on F,o2 1.0. The chest x-ray film
showed loops of bowel and stomach
in the left hemithorax with devia
tion of the mediastinum to the right
(Fig. 1).
The diagnosis of rupture of the
left hemidiaphragm with herniation
of abdominal contents was made
and the patient was taken immedi
ately to the operating room. At
laparotomy the transverse colon,
stomach and spleen were found in
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FIG. 1. Portable chest x-ray film dem
onstrating mediastinal shift to right,
nasogastric tube in left chest and loop
of bowel in left hemithorax.

DIAPHRAGMATIC RUPTURE IN LABOUR

the left side of the chest. These
were easily reduced and the small
hole in the stomach caused by the
chest tube was oversewn. There
was a large fresh tear in the left
hemidiaphragm extending from the
hiatus to the posterolateral chest
wall. This was closed with inter
rupted 0 Ethibond (Ethicon Ltd.,
Peterborough, Ont.) sutures.
Postoperatively, she showed
signs of severe anoxic encephalopa
thy and did not regain conscious
ness. She died 3 weeks after admis
sion from anoxic brain damage sec
ondary to the initial cardiopulmo
nary arrest.
Discussion

Spontaneous rupture of the dia
phragm during labour is extremely
rare, only one other case having
been reported in the literature.1
Strangulation of abdominal viscera
in a pre-existing congenital or trau
matic diaphragmatic defect is more
common, 21 such cases having
been reported during pregnancy (16
congenital, 4 acquired, 1 spon
taneous).13
Our patient’s presentation was
similar to the other reported case,
that is, chest pain radiating to the
left shoulder and progressive dys
pnea. Unfortunately, the correct di
agnosis was not entertained until
the patient had sustained irrevers
ible brain damage secondary to car
diopulmonary arrest, probably
caused by the mediastinal compres
sion.
The site of the rupture of the
diaphragm in this case was the left
posterolateral region which is the
most common site for a ruptured
diaphragm in blunt abdominal trau
ma, and is probably due to a con
genital weakness in the area.4 The
fact that a fresh tear was present in
the diaphragm with no apparent
congenital defect suggests that the

rupture was precipitated by the dif
ficult labour and not by strangula
tion of viscera in a congenital de
fect. Both conditions are lethal if
untreated.
Once suspected, the diagnosis is
easily confirmed by chest x-ray.
Pleural aspiration or decompression
is unnecessary and dangerous. Salo
mon and associates4 reported an
iatrogenic injury to the spleen
caused by this maneuver and our
patient sustained a perforation of
the stomach. Treatment consists of
reduction of the herniated contents
and suturing of the diaphragmatic
edges through either a laparotomy
or thoracotomy. In our opinion,
laparotomy is the procedure of
choice because it facilitates resec
tion of any nonviable abdominal
tissue.
Although uncommon, spontane
ous rupture of the diaphragm or

strangulation of abdominal viscera
in a pre-existing diaphragmatic her
nia during pregnancy are potential
ly lethal conditions and should be
suspected in any pregnant or post
partum woman with chest pain and
dyspnea.
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Undiversion in Patients With
Meningomyelocele
David Stewart, MD, FRCSC;* Hjalmar W. Johnson, MD, FRCSC;* Patrick J. Moloney, MD, FRCSC;*
William J.D. Arnold, MD, FRCPC;f Bonita J. Sawatzky, BPE*
Since 1981, 12 patients with neurogenic bladder due to meningomyelocele who had
had previous ileal conduit urinary diversions underwent assessment for undiversion.
Two important criteria for undiversion were motivation and a reconstructable
bladder. Four patients either did not fulfil these criteria or refused surgery. Eight
patients (six females and two males) underwent undiversions. Ureteroureteral anastomosis was achieved in 13 ureters and ureteroneocystostomy in 2;
transureteroureterostomy was necessary in 1 ureter. Augmentation cystoplasty and
vesicourethropexy were important in establishing continence postoperatively; these
procedures were not performed in two patients whose undiversion failed early in the
series. The evolution of an investigation protocol, surgical technique and final
approach to this complex problem are discussed.

possible candidates for an undiver
sion. Four were deemed unsuitable
because of low intelligence or un
willingness to undergo the proce
dure. The evolution of investiga
tions considered necessary in prepa
ration for undiversion and the sur
gical techniques employed have
been an instructive process for us
and are described.

Depuis 1981,12 patients souffrant de vessie neurogene due a un meningomyelocele
et qui avaient subi une derivation ileale du conduit urinaire ont ete reevalues en vue
de retablir la continuite des voies urinaires. Deux criteres importants etaient retenus
pour justifier l’operation, soit la motivation du patient et la possibility de
reconstruire la vessie. Quatre patients n’ont pu rencontrer ces criteres ou ont refuse
la chirurgie. Huit patients (six filles et deux garfons) ont ete operes. Une
anastomose uretero-ureterale a pu etre pratiquee sur 13 ureteres et une uretero-cystoneostomie sur 2; une transuretero-ureterostomie fut necessaire pour 1 uretere. En
vue d’obtenir la continence, il etait important de pratiquer, en postoperatoire, une
cystoplastie de dilatation et une vesico-uretropexie; ces interventions n’ont pas ete
effectuees chez deux patients pour qui l’operation s’etait soldee par un echec, tot au
debut de la serie. On commente revolution du protocole experimental, de la
technique chirurgicale et de l’approche finalement retenue pour corriger ce
probleme complexe.

Patients and Methods

he goals of urinary undiversion
are to preserve renal function,
to establish good bladder capacity
and to preserve or establish conti
nence.1 With these goals in mind, in
1981 we embarked on a program to
select p atients w ith m enin
gomyelocele for undiversion. At the

T

British Columbia Children’s Hospi
tal, a multidisciplinary team of urol
ogists, neurosurgeons, orthope
dists, pediatricians, nurses, thera
pists and social workers have con
tributed to the assessment of pa
tients with meningomyelocele.
Twelve patients were selected as
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Undiversion was performed on
six females and two males. All me
ningomyeloceles were lumbosacral
or sacral. All patients were ambula
tory, well-motivated and of normal
intelligence, and all had undergone
ileal conduit diversion in the late
1960s or early 1970s at ages rang
ing from 13 months to 6 years. A
review of the indications for the
initial diversion included frequent
lower and upper urinary tract infec
tions, progressive hydronephrosis
or unmanageable incontinence (in
older children). The long-term com
plications of ileal conduits are well
known.23 Four of our eight patients
required stomal revision for steno
sis, three had partial ureteroileal
anastomotic obstruction (Fig. 1)
and five suffered from recurrent
pyelonephritis. One teenager found
her ileal conduit with external appli
ance socially unacceptable.
Urologic evaluation included as
sessment of upper tracts, bladder
and bladder outlet. Intravenous uro
grams and loopograms (retrograde

URINARY UNDIVERSION

filling of ileal segment and ureters
with Hypaque) were used to assess
renal function and identify the
length of the proximal ureter. Renal
function was grossly normal (serum
creatinine less than 100 jumol/L) in
all patients; isotope renography was
not routinely performed. Ureteral
dilatation ranging from mild to se
vere was noted in 7 of 16 ureters.
All patients underwent cystos
copy and retrograde ureterography
to identify the distal ureteral stump
for measurement (Fig. 2). Ureteral
stumps varied in length from 2 to 9
cm, with 13 having stump lengths
of 4 to 6 cm. Cystoscopy revealed

an incompetent bladder neck in all
female patients. Voiding cystoureterography was performed if
reflux was known to be a problem
prior to diversion, although reflux
in an undiverted bladder may not be
important.4
Urodynamic tests were performed
on all patients, with virtually all
showing a poorly compliant bladder
with a low urethral pressure profile.
All had perineal electromyographic
activity. Bladder cycling was initial
ly attempted with a suprapubic cystocath and later in conjunction with
the teaching of clean intermittent
catheterization. Continent cycled
volumes were less than 150 mi in
four patients, 150 to 200 ml in two
and 250 ml in two patients. Initial
ly, we used these data to estimate
which patients would need augmen
tation cystoplasty, but this ap
proach failed and we now routinely
perform this procedure.
Surgical Procedures

FIG. 1. Preoperative ureteroileal anas
tomotic obstruction with left-sided hy
dronephrosis.

t
i
\

Results
Early complications of undiver
sion were minimal. They included
one wound infection, two persistent

Table I. Cycled Bladder Capacities

t
t

Undiversion involves re-establish
ing continuity of upper and lower
urinary tracts, with or without aug
mentation cystoplasty or proce
dures to prevent incontinence. The
initial procedure consisted of a
ureteroureterostomy in 13 of the 16
renal units. Intraoperative place
ment of a ureteral stent to identify
the stump greatly facilitated this,
since the proximal end of the distal
stump was otherwise difficult to
identify because of the dense scar
tissue. Transureteroureterostomy

was performed in one case because
of a short (2 cm) distal stump and
because the proximal ureter was
not long enough to be reimplanted
into the bladder. In another patient,
two grossly dilated ureters second
ary to ureteroileal anastomotic ob
struction required trimming and
reimplantation into an augmented
bladder.
Neither of the two male patients
underwent a procedure to prevent
incontinence. Both were undiverted
after puberty (at 17 and 21 years) in
the anticipation that normal bladder
neck growth would aid in conti
nence. A standard Burch vesicourethropexy was performed on four of
the six female patients to prevent
incontinence. The first two females,
who did not undergo a vesicourethropexy, were both incontinent
postoperatively. We now perform
Burch repairs on all females.
Our initial surgical approach with
augmentation cystoplasty is sum
marized in Table I. Bladders were
augmented with the ileal conduit, in
most cases as a cupped patch
opened on the antimesenteric bor
der and sutured to the superior
surface of the open bladder. These
patients were selected for augmen
tation because of a small capacity
bladder on cycling.

FIG. 2. Preoperative retrograde cystogram showing ureteral stump lengths
of approximately 3 cm and 5 cm.

Patient
no.

Sex

Augmentation
cystoplasty

Cycled
capacity, ml

1
2
3
4
5
6
7
8

F
M
F
F
F
F
M
F

Yes, own loop
Yes, ileum
Yes, own loop
Yes, own loop
No
No
No
No

100
1 0 0 -1 5 0
1 0 0 -1 5 0
150 - 200
200 - 250
200 - 250
150 - 200
1 0 0 -1 5 0

►
►
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leaks (one ureteral, one ileal cystoplasty) managed by conservative
means and one urinary tract infec
tion due to Pseudomonas sp that
was difficult to eradicate because of
multiple antibiotic resistance. There
were two early failures (patients 6
and 8, Table II). Both were inconti
nent and had vesicoureteral reflux.
Neither had undergone augmenta
tion cystoplasty or vesicourethropexy. Initially, patient 5 did
well, but increasing incontinence
developed associated with uterine
prolapse. Cycled bladder capacities
in patients 5 and 6 were good
before undiversion and they were
selected to forgo augmentation cys
toplasty (Table I). All three of these
patients were managed early in our
series and none underwent anti
incontinence or augmentation pro
cedures. Patients 5 and 6 had aug
mentation ileocystoplasties and
Burch vesicourethropexies, which
in the case of patient 5 was a repeat
procedure with bladder neck recon
struction.
Our final results are listed in
Table II. Both male patients were
continent using anticholinergic
drugs. Four of the six females were
continent (three without anti
cholinergics). Two patients contin
ued to have problems: patient 8 had
to catheterize herself every 2 hours
to avoid incontinence and patient 4
had stress incontinence, not consid
ered serious enough to warrant fur
ther surgery.

Follow-up ranged from 48 to 72
months. Follow-up intravenous pye
lography or ultrasonography
showed improvement or resolution
of hydronephrosis in all the ureters
that were markedly dilated preoperatively (Fig. 3).
All patients were taking low-dose
antibiotics prophylactically. One pa
tient had two episodes of cystitis,
but there was no episode of pyelo
nephritis and no deterioration in
renal function. Two patients suf
fered mucus retention necessitating
an emergency room visit early after
hospital discharge. Both were catheterized and more than 700 ml of
urine drained, indicating the suc
cess of augmentation cystoplasty.

Discussion
Undiversion has clearly emerged
as a viable option for patients with
meningomyelocele who have previ
ously undergone supravesical diver
sion, provided they are carefully
selected. The extent of our assess
ment of these patients has been
modified by our management expe
rience.
Bladder cycling was initially per
formed by way of a suprapubic
cystocatheter, but it became evident
that this could be more readily
accomplished in conjunction with
the teaching of clean intermittent
catheterization. Moreover, the cy
cled capacity eventually reached

was not predictive of good operative
results in terms of continence. We
now augment all bladders in this
type of patient regardless of cycled
capacity. Perlmutter5 rejected pa
tients for undiversion who had se
vere incontinence and small bladder
capacity after cycling, apparently
because of the complexity of aug
mentation cystoplasty and urethrovesical suspension. However,
we found that the ileal conduit can
usually be readily mobilized into the
pelvis and used to augment the
bladder.6’7 Similarly, a simple Burch
vesicourethropexy does not add
complexity or time to the operation
and has been successful in our
hands. We also prefer to perform
this suspension on all our patients
at the time of original undiversion.
Our patients are prepared to main
tain clean intermittent catheteriza
tion for life as a consequence of
their original affliction and so blad
der emptying problems are not a
concern.8
In summary, our clinical experi
ence has modified our approach to
undiversion in patients with menin-

i
4

T a b le II. R e s u lts o f P o s to p e ra tiv e U n d iv e rs io n
P a tie n t
no.

C le a n in te rm itte n t
c a th e te riza tio n , h

M ean
v o lu m e , m i*

1

2
3
4

3
4
3
3

300
250
350
250

5
6
7
8

4
3
3
2

250
250
250
150

'C o n tin e n t v o lu m e s n o t m a x im u m v o lu m e s .

C ontinence
Yes
Y es
Y es
S tre s s
in c o n tin e n c e
Y es
Y es
Y es
No

A nticholinergic
ag en t
No
Yes, D itro p a n
Y es, T o fra n il
Y es, T o fra n il
No
No
Y es, D itro p a n
Y es, D itro p a n

FIG. 3. Postoperative ureteroureteros
tomy and resolution of left-sided hy
dronephrosis approximately 6 months
after undiversion.
4
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gomyelocele. We prefer to augment
all bladders and perform a Burch
vesicourethropexy on all our female
patients. Ipsilateral ureteroureteros
tomy is almost always possible; one
available intraoperative option in
cludes transureteroureterostomy.
Although this is primarily a cosmet
ic operation resulting in improved
quality of life and a better body
image, the resolution of hydroureteronephrosis and absence of
upper tract infections in our pa
tients suggest that it provides some
protection from future deterioration
in renal function.

We thank Drs. G. Coleman and J.
Masterson for allowing us to include
their patients in this study.
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Thoracic and cardiac surgery are well
covered and contain the core of knowl
edge needed by surgical trainees. Mes
enteric vascular disease, which, in the
past, has been poorly understood and
treated, is a welcome addition to the
section on vascular diseases. Fortunate
ly, this condition is increasingly being
diagnosed before laparotomy and appro
priate preoperative investigations are
being performed. The topics covered in
most general surgery textbooks are
considered in the section on general
surgery. There are also chapters on
organ transplantation, surgery for vas
cular access and peritoneal dialysis, and
gynecology. The last section, on genito
urinary surgery, covers topics clearly.
To the editors' credit, one is not
aware of changes in style between au
thors. Photographs and x-rays clearly
illustrate the points made, and the
many line diagrams are of excellent
quality. Of interest is that many chap
ters end with a prediction as to the
direction in which the field is heading.
The bibliography is adequate and pre
dominantly from the 1980s.
The authors state that their intention
is to provide an organized, up-to-date
account of modern surgical practice,
covering the core material for those
preparing for postgraduate examina
tions. I believe that they have done this
in a very readable form. The book is not

intended to be a reference book for the
surgeon, but I found much useful infor
mation, particularly in those areas in
which I do not regularly deal. I recom
mend the book for general surgeons in
the core years of their training.
S. Meban, MB, FRCS(Edin), FRCSC
Suite 269,
737 Parkdale Ave.,
Ottawa, Ont.
K1V1J8

PRINCIPLES OF ORGAN TRANS
PLANTATION. Edited by M. Wayne
Flye. 687 pp. Illust. W.B. Saunders
Company, Philadelphia; W.B. Saun
ders Company Canada Limited, Toron
to, 1989. $180.00. ISBN 0-72161323-3.
Transplantation is a surgical specialty
in continuous evolution as principles
are modified by new concepts, better
understanding and research. This book,
written by 57 contributors who are well
known in their fields, reflects the opin
ions and experience of many transplan
tation centres in the United States and
France.
The first section of the book is a
review of basic science aspects of im
munology. The authors describe the
immune system in its two parts, the
cellular and the humoral. They cover

new concepts of cellular interaction
with antigen, immunoglobulin structure
and lymphokine function. The major
histocompatibility complex is well de
scribed with its class I and II antigens.
Two other chapters are dedicated to
immunobiology — one on immunohematology, the second on effects
of blood transfusion in transplantation.
These are excellent reviews of the im
portance of blood-group antigens in
transplantation. The immunologic as
pect of blood transfusion and its clinical
application in renal allografts is also
mentioned.
The second section describes the
basic principles of transplantation, in
cluding immunogenetics, immune regu
lation and methods of histocompatibility
testing. The author mentions all possi
ble immunologic tests identifying the
most important and applicable in clini
cal use. Pre- and post-transplant sero
logic tests to improve recipient selection
and predict graft survival are also de
scribed. The rejection phenomenon, its
immunobiologic features, mechanism
and specific pathologic characteristics
regarding the kidney, liver, heart and
lungs, is also explained in this section.
Finally, the main author presents a
good review of immunosuppressive
therapy, the drugs and methods used in
continued on page 223
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^PRIMAXIN®
(imipenem and cilastatin sodium
for injection)
Antibiotic

•
•
•
•
•
•

Morganella morganii
Neisseria
Proteus (indole positive and indole negative
strains)
Providencia
Pseudomonas aeruginosa
Serratia marcescens

Gram-positive Anaerobes

CNS adverse experiences such as myoclonic
activity, confusional states, or seizures have
been reported with PRIMAXIN® especially when
recommended dosages based on renal function
and body weight were exceeded. These expe
riences have occurred most commonly in patients
with CNS disorders (e.g., brain lesions or
history of seizures) and/or who have compro
mised renal function. However, there were rare
reports in which there was no recognized or
documented underlying CNS disorder. Close
adherence to recommended dosage schedules
is urged, especially in patients with known
factors that predispose to seizures.

•
•
•

Clostridium (excluding C. difficile)
Peptococcus
Peptostreptoccus

Gram-negative Anaerobes

•
•

Bacteroides fragilis
Bacteroides (non-fragilis)

CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium for
injection) is contraindicated in patients who have
shown hypersensitivity to either component of this
product.

ACTION

WARNINGS

Imipenem exerts a bactericidal action by inhibiting
cell wall synthesis in aerobic and anaerobic gram
positive and gram-negative bacteria.

PRIMAXIN® (imipenem and cilastatin sodium for
in je c tio n ) SHOULD BE ADMINISTERED WITH
CAUTION TO ANY PATIENT WHO HAS DEMONS
TRATED SOME FORM OF ALLERGY, PARTICULARLY
TO STRUCTURALLY-RELATED DRUGS. IF AN
ALLERGIC REACTION TO PRIMAXIN® OCCURS,
DISCONTINUE THE DRUG. SERIOUS HYPER
S E N S IT IV IT Y R EAC TIO N S MAY REQUIRE
EPINEPH R IN E AND OTHER EMERGENCY
MEASURES.

P R IM A XIN ® c o n s is ts of tw o c o m p o n e n ts :
(1) im ipenem , a derivative of thienam ycin, a
carbapenem antibiotic; and (2) cilastatin sodium, a
specific inhibitor of dehydropeptidase-l a renal
enzym e w h ic h m etabolizes and in a c tiv a te s
imipenem. Cilastatin blocks the metabolism of
imipenem in the kidney, so that concom itant
administration of imipenem and cilastatin allows
antibacterial levels of imipenem to be attained in the
urine.
Inhibition of cell-wall synthesis is achieved in gram
negative bacteria by the binding of imipenem to
penicillin binding proteins (PBPs). In the case of
E s c h e r ic h ia c o li and s e le c te d s tra in s of
Pseudomonas aeruginosa, imipenem has been
shown to have highest affinity for PBP-2, PBP-1a
and PBP-1 b, with lower activity against PBP-3. The
preferential binding of imipenem on PBP-2 and
PBP-1 b leads to direct conversion of the individual
cell to a spheroplast resulting in rapid lysis and cell
death without filament formation. When imipenem
is removed p rio r to complete k illing of gram
negative species, the remaining viable cells show a
measurable lag, termed a "post-antibiotic effect"
(PAE), prior to resumption of new growth.

INDICATIONS AND CLINICAL USE
PRIMAXIN® (imipenem and cilastatin sodium for
injection) may be indicated in the treatment of
serious infections when caused by sensitive strains
of bacteria Where considered necessary, therapy
may be initiated on the basis of clinical judgment
before results of sensitivity testings are available.
Continuation of therapy should be reevaluated on
the basis of bacteriological findings and of the
patient's clinical condition.
Imipenem is active in vitro against a wide range of
gram -positive and gram-negative aerobic and
anaerobic bacteria, including most strains which
are beta-lactam ase producing. Patients have
responded while under treatment with PRIMAXIN®
for single or mixed infections of the following body
systems, when they were associated with a number
of pathogenic species and strains of the genera
listed:
1.
2.
3.
4.
5.
6.
7.
8.

Lower Respiratory Tract Infections
Urinary Tract Infections
Intra-Abdominal Infections
Gynecological Infections
Septicemia
E ndo carditis caused by S taphylococcus
aureus
Bone and Joint Infections
Skin Structure Infections

Gram-positive Aerobes

•
•
•
•

Listeria monocytogenes
Nocardia asteroides
Staphylococcus (excluding many strains
which are methicillin resistant)
Streptococcus (excluding S. laecium)

Gram-negative Aerobes

•
•
•
•
•
•
•

Acinetobacter
Citrobacter
Enterobacter
Escherichia coli
Haemophilus influenzae
Haemophilus parainfluenzae
Klebsiella

emesis, inappetence, body weight loss, diarrhea
and death) at doses equivalent to the average
human dose in pregnant rabbits and cynomolgus
monkeys that is not seen in non-pregnant animals in
these or other species. In other studies, PRIMAXIN®
was well tolerated in equivalent or higher doses (up
to 11 times the average human dose) in pregnant
rats and mice (see REPRODUCTION STUDIES
under TOXICOLOGY in the complete monograph).
Nursing Mothers

It is not known whether PRIMAXIN® is excreted in
milk. If the use of PRIMAXIN® is deemed essential,
the patient should stop nursing.
Pediatric Use

Efficacy and tolerability in infants under the age of
3 months have not yet been established; therefore,
PRIMAXIN® is not recommended in the pediatric
age group below the age of 3 months.
Drug Interactions

Concomitant administration of PRIMAXIN® and
probenecid results in only minimal increases in
plasma levels of imipenem and plasma half-life. It is
not recommended that probenecid be given with
PRIMAXIN®.
PRIMAXIN® should not be mixed with or physically
added to other antibiotics. PRIMAXIN® has been
administered concomitantly with some antibiotics,
such as aminoglycosides.
There is no evidence to suggest that association of
PRIMAXIN® with any other beta-lactam antibiotics
has any therapeutic advantage.

Pseudomembranous colitis

ADVERSE REACTIONS

Pseudomembranous colitis has been reported with
the use of PRIMAXIN®. Therefore it is important to
consider this diagnosis in patients who develop
diarrhea during or after therapy. This colitis may
range from mild to life threatening in severity.

PRIMAXIN® (imipenem and cilastatin sodium for
injection) is generally well tolerated. The following
adverse reactions were reported on 1,723 patients
treated in clinical trials. Many of these patients were
severely ill and had multiple background diseases
and physiological impairments, making it difficult to
determine causal relationship of adverse ex
periences to therapy with PRIMAXIN®.

Mild cases of pseudomembranous colitis may
respond to drug discontinuance alone. In more
s e v e re cases, m a n a g e m e n t m ay in c lu d e
sigm o idosco py, a p p ro p ria te b a c te rio lo g ic a l
studies, fluid, electrolyte and protein supple
mentation, and the use of a drug such as oral
vancomycin, as indicated. Other causes of colitis
should also be considered.

Local Adverse Reactions

Adverse local clinical reactions that were reported
as possibly, probably or definitely related to therapy
with PRIMAXIN® were:

PRECAUTIONS
General

Prolonged use of PRIMAXIN® (imipenem and
cilastatin sodium for inje ctio n ) may result in
overgrowth of resistant organism s. Repeated
evaluation of the patient's condition is essential. If
superinfection occurs during therapy, appropriate
measures should be taken.
CNS adverse experiences such as m yoclonic
activity, confusional states, or seizures have been
reported with PRIMAXIN® especially when recom
mended dosages based on renal function and body
weight were exceeded. These experiences have
occurred most commonly in patients with CNS
disorders (e.g., brain lesions or history of seizures)
and/or who have compromised renal function.
However, there were rare reports in which there was
no recognized or documented underlying CNS
disorder. Close adherence to recommended dosage
schedules is urged especially in patients with
known factors that predispose to seizures (see
D O S AG E AND A D M IN IS T R A T IO N ). A n ti
convulsant therapy should be continued in patients
with a known seizure disorder. If focal tremors,
myoclonus, or seizures occur, patients should be
evaluated neurologically and placed on an ti
convulsant therapy if not already instituted. If CNS
symptoms continue, the dosage of PRIMAXIN®
should be decreased or discontinued.
Use in Patients with Impaired Renal Function

Dosage in patients with impaired renal function is
based on the severity of infection but the maximum
daily dose varies with the degree of renal functional
im p a irm e n t (see DOSAGE AND A D M IN IS 
TR A TIO N - Dosage in P atien ts w ith Renal
Insufficiency).
Use In Pregnancy

The use of PRIMAXIN® in pregnant women has not
been studied, therefore, PRIMAXIN® should be
used during pregnancy only if clearly needed. Use
of this drug in women of childbearing potential
requires that the anticipated benefits be weighed
against possible hazards.
Reproduction studies with bolus I. V. doses suggest
an apparent intolerance to PRIMAXIN® (including

Incidence (%)

Phlebitis/thrombophlebitis
Infused vein pain
Vein induration
Infused vein infection

1.7
0.6
0.2
0.1

Systemic Adverse Reactions

Adverse clinical reactions that were reported as
possibly, pro b a b ly, or d e fin ite ly related to
PRIMAXIN® were:
Incidence (%)
Gastrointestinal

nausea
diarrhea
vomiting
tongue papillar hypertrophy
pseudomembranous colitis
(see WARNINGS)
hemorrhagic colitis
gastroenteritis
abdominal pain
glossitis
heartburn
pharyngeal pain
increased salivation

2.0
1.7
1.6
0.2
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

CNS

fever
dizziness
seizures
(see PRECAUTIONS)
somnolence
confusion
myoclonus
vertigo
headache
encephalopathy
paresthesia

0.4
0.3
0.2
0.2
0.2
0.1
0.1
0.1
<0.1
<0.1

Special Senses

transient hearing loss in
patients with impaired hearing
tinnitus

<0.1
<0.1

Respiratory

dyspnea
hyperventilation
thoracic spine pain

0.1
<0.1
<0.1

The maximum daily dose should not exceed 4 g or
50 mg/kg, which ever is less.

Cardiovascular
hypotension
palpitations
tachycardia

0.4
0.1
<0.1

Dosage in Elderly Patients
The recommended dosage of PRIMAXIN® in elderly
patients with normal renal function is the same as
given for adults above. Renal status of elderly
patients may not be accurately po rtra yed by
measurement of BUN or creatinine alone. Deter
mination of creatinine clearance is suggested to
provide guidance for dosing in such patients.

Renal
oliguria/anuria
polyuria

<0.1
<0.1

Skin
rash
pruritus
urticaria
skin texture changes
candidiasis
erythema multiforme
facial edema
flushing
cyanosis
hyperhidrosis
pruritus vulvae

0.9
0.3
0.2
0.1
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Dosage in Patients with Renal Insufficiency

Body as a whole
polyarthralgia
asthenia/weakness

<0.1
<0.1

Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug
relationship, that were reported during clinical trials
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs
test, decreased WBC and neutrophils, increased
WBC, increased platelets, decreased platelets,
decreased hemoglobin and hematocrit, increased
monocytes, abnormal prothrombin time, increased
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, indreased
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red
blood cells, urine white blood cells, urine casts,
urine bilirubin, and urine urobilinogen.

TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium for
injection) is cleared by hemodialysis.

DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN®
(imipenem and cilastatin sodium for injection)
represent the quantity of imipenem to be ad
ministered by I V. infusion only. An equivalent
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN® should be determined
by the severity of the infection, renal function, body
weight, the antibiotic susceptibility of the causative
organism(s) and the condition of the patient. Doses
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN®
in clinical trials for infections of the various body
systems ranged from 6 to 10 days except for
endocarditis and bone and joint infections for which
the median duration of treatment was 4 weeks.
Dosage in Adults

TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN®
IN RELATION TO RENAL FUNCTION

RENAL
F U N C T IO N

M ild
im p a irm e n t

M oderate
im p airm e nt

C R EA TIN IN E
CLEARANCE
m L /m ln/1.73 mJ
(m L/s/1.73 m*)

M A X IM U M
TOTAL
D A IL Y
DOSAGE

DOSE
(9)

DOSAGE
INTERVAL
(h)

3 1 -7 0
(0 .5 2 -1 .1 7 )

0.5

6 -8

1 .5 -2

2 1 -3 0
(0.35 - 0.50)

0.5

8 -1 2

1 - 1 .5

(9 )

TABLE 1

Severe*
im p airm e nt

0 -2 0
(0 - 0.33)

0.25 - 0.5

12

0 .5 -1 .0 **

P a t ie n t s w it h c r e a t i n in e c le a r a n c e o f 6 t o
2 0 m L /m in /1 .7 3 m 2 (0.1 - 0.3 m L /s /1 .7 3 m 2) s h o u ld
b e tre a te d w ith 250 m g (o r 3 .5 m g /k g w h ic h e v e r is
lo w e r) e v e ry 12 h o u rs f o r m o s t p a th o g e n s . W h e n
th e 5d0 m g d o s e is u sed in th e s e p a tie n ts, th e re m a y
be an in cre a se d ris k o f s e iz u re s .
x x T h e h ig h e s t d o s e is o n ly r e c o m m e n d e d f o r
in f e c t io n s d u e t o le s s s u s c e p t ib le o r g a n is m s
p rim a rily so m e s tra in s o f Ps. aeruginosa.

When only the serum creatinine level is available,
the following formula (based on sex, weight, and
age of the patient) may be used to convert this value
into creatinine clearance (mL/min). The serum
creatinine should represent a steady state of renal
function.
Males:

Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)

Females:

0.85 x above value.

When using the International System of units (SI),
the estimated creatinine clearance (mL/s) in males
can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736

I.V . A d m inistration
Dosage
Interval

D aily
Dose

250 mg

6h

1.0 g

Moderate

500 mg

8h

1.5 g

Severe (fu lly
susceptible)

500 mg

6h

2.0 g

1000 mg
1000 mg

8h
6h

3.0 g
4.0 g

Dose
(m g of im ip e n em )

and in females the estimated creatinine clearance
(mL/s) is:

PRIMAXIN® is cleared by hemodialysis. After each
dialysis session the dosage schedule should be
restarted.
Dosage in Infants and Children

Mild

Severe* infections
due to less
susceptible
organisms
or life threatening
conditions

x P rim a rily s o m e s tra in s o f Ps. aeruginosa.

A suggested procedure is to transfer approximately
10 mL from the 100 mL of the appropriate infusion
solution to the vial (see list of diluents under
COMPATIBILITY AND STABILITY). Shake well.
Return the resulting 10 mL of suspension to the
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to
ensure complete transfer of the contents of the vial
to the infusion solution.
CAUTION: CONTENTS OF V IA LS NOT FOR
DIRECT INFUSION.

COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection
5% or 10% Dextrose Injection
5% Dextrose Injection w ith 0.02% sodium
bicarbonate solution
5% D extrose and 0.9% S odium C hloride
Injection
5% Dextrose Injection with 0.225% or 0.45%
saline solution
NORMOSOL-M in D5-W
5% Dextrose Injection with 0.15% potassium
chloride solution
Mannitol 2.5%, 5% and 10%
Solutions of PRIMAXIN® range from colourless to
yellow. Variations of colour within this range do not
affect the potency of the product.
PRIMAXIN®, as supplied in vials and reconstituted
as above maintains satisfactory potency for four
hours at room temperature and for 24 hours under
refrigeration (4°C). PRIMAXIN® has been found to
be stable in 0.9% Sodium Chloride Injection for
10 hours at room temperature and 48 hours under
refrigeration.

DOSAGE FORMS
AVAILABILITY
PRIMAXIN® is supplied as a sterile powder mixture
in vials con ta in in g im ipenem anhydro us and
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature
below 30° C.

FULL PRODUCT MONOGRAPH
AVAILABLE ON REQUEST
(318-b,1,89)
®Trademark Merck S Co., Inc./
Merck Frosst Canada Inc., R.U.

MSP

2164

MERCK
S H A R ft
DOHME

T h e re com m e nde d to ta l d a ily dosage o f
PRIMAXIN® in children and infants 3 months of age
and older is 60 to 100 mg/kg of body weight divided
into 4 equal doses given at six hour intervals. The
higher dosages should be used for infants and
young children. The total daily dosage should not
exceed 2 grams. Clinical data are insufficient to
recommend an optimum dose for infants and
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.

C A N AD A

MEMBER

(lean body weight, kg) x (140 - age, years) x 1.2526
(72) x (serum creatinine concentration, pmol/L)

ADULT DOSAGE OF PRIMAXIN®

RECONSTITUTION
Contents of the vials must be suspended and
transferred to 100 mL of an appropriate infusion
solution.

Reconstituted solutions

(72) x (serum creatinine concentration, pmol/L)

The recommended daily dose is 1 to 2 g adminis
tered in equally divided doses every 6 to 8 hours
(see Table 1).

S everity
o f In fe c tio n

P a tie n ts w ith c r e a tin in e c le a r a n c e s o f
< 5 mL/min/1.73m2 (<0.08 mL/s/1.73m2) should
not receive PRIMAXIN® unless hemodialysis is
instituted within 48 hours. Both imipenem and
cilastatin are cleared from the circulation during
h e m o d ia ly s is . The p a tie n t sh o u ld re c e iv e
PRIMAXIN® after hemodialysis and at 12 hour
intervals timed from the end of that hemodialysis
session. Dialysis patients, especially those with
background CNS disease, should be ca re fu lly
m o n ito re d ; fo r p a tie n ts on h e m o d ia ly s is ,
PRIMAXIN® is recommended only when the benefit
outw eighs the potential risk of seizures (see
PRECAUTIONS). Currently, there are inadequate
data to recommend the use of PRIMAXIN® in
patients undergoing peritoneal dialysis.

Each reconstituted 250 mg or 500 mg dose should
be given by intravenous infusion over twenty to
th irty minutes. Each 1000 mg dose should be
infused over 40 to 60 minutes. In patients who
develop nausea during the infusion, the rate of
infusion may be slowed.
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|

P.O. BOX 1005, POINTE-CLAIRE
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D ifficult Implant Retrieval: a Case Report
Hugh U. Cameron, MB, ChB, FRCSC
Artificial joint prostheses can be expected to fail eventually. The author describes
the case of a woman whose cemented knee-joint hinge prosthesis failed and required
revision. This prosthesis was designed so that the stem became thinner as it
approached the bearing surfaces. As a result the implant could not be removed from
the cement and the cement could not be removed without severe destruction of
surrounding bone. Although this prosthesis is no longer being used, there may be
patients having this implant who will require revision in the future. This paper
warns surgeons that its removal will be extremely difficult and appropriate plans
should be made preoperatively. The author concludes that no stemmed implant
should be cemented in place if it cannot readily be removed from the cement.

On peut toujours s’attendre a la defaillance eventuelle des protheses d’arthroplastie.
L’auteur decrit le cas d’une femme dont la prothese a charniere du genou, cimentee
a 1’os, fit defaut et necessita une revision. Cette prothese etait con$ue de fa?on a ce
que la tige soit plus mince a proximite des surfaces d’appui. II en suivit que
l’implant ne pouvait etre degage du ciment et que le ciment ne pouvait etre enleve
sans causer une importante destruction de l’os adjacent. Bien que cette prothese ne
soit plus en utilisation, certains patients peuvent encore en etre porteurs et devoir
faire Tobjet d’une revision future. Cet article vise a informer les chirurgiens que
l’enlevement de ces protheses se revelera extremement difficile et qu’une bonne
planification preoperatoire s’impose. L’auteur conclut qu’un implant a tige ne
devrait jamais etre cimente en place s’il ne peut etre degage du ciment.

lthough the short-term success
rate of artificial joint replace
ment is high, the predictions from
Sweden1 suggest that all joints will
eventually fail. Revision, therefore,
should be anticipated and implants
designed to allow a quick, simple,
change of prosthesis because softtissue scarring and loss of bone
stock will make the surgery difficult
enough.
I recently encountered a case in
which the implant violated these
precepts; revision was extremely

A

difficult and a multistage revision
was required.

Case Report
A 65-year-old woman had injured
her knee in 1937. She had under
gone a number of subsequent oper
ations and at one of these a hinge
prosthesis had been inserted and a
patellectomy performed. The tibial
stem on the hinge prosthesis frac
tured. This was revised to an un-
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FIG. 1. Broken stem of original hinge
prosthesis can clearly be seen. Some
radiolucency surrounds tibial compo
nent which was relatively loose. There
is no femoral radiolucency and femoral
component was firmly fixed to bone.

IMPLANT RETRIEVAL

FIG. 2. What was not realized before removal of prosthesis was that femoral
component was thicker proximally than distally, thus making extraction by
longitudinal driving impossible. Distal femur was severely damaged in extraction of
stem.

linked type of hinge prosthesis (Fig.
1 ).

When seen, she had severe patel
lar tendon symptoms probably be
cause the implant had no anterior
femoral condylar bearing flange.
She also had tibial pain from mild
loosening of the tibial stem.
During revision surgery, the tibi
al component and broken tibial
stem and cement were fairly easy to
remove, but the femoral side simply
could not be extracted by conven
tional methods. The cement was
broken up as far as possible with
curved osteotomes, but the bone,
which was thin and osteoporotic,
began to disintegrate long before
the stem tip was reached. When the
femoral stem was eventually ex
tracted it was found to be widened
proximally in both planes (Fig. 2)
(i.e., it was wedge shaped in the

FIG. 3. After two sessions of allograft
ing, length was restored. Guepar long
stem was cemented in place. It was
necessary to cement these stems in
order to gain stability to allow healing
of grafts.

wrong direction). Attempts to re
move the implant simply tightened
it in place.
A long-stem Guepar II hinge was
inserted to act as an internal splint
and the patient was placed in trac
tion. Four weeks later, extensive
allografting was carried out around
the Guepar II stems. The allografts
were allowed to heal for 9 months
then the knee was again opened.
Much of the allograft had united,
but further extensive grafting was
needed to restore length; the Gue
par II stems were then cemented in
place (Fig. 3).

cement, the cement cannot be re
moved without splitting the bone.
Had the reverse wedge nature of
the prosthesis in this patient been
recognized before surgery, a formal
split of the femur should have been
performed removing a huge window
for later replacement.
This prosthesis is obsolete. How
ever, there may still be patients who
have this implant and will need
revision surgery in the future. The
moral of this case report is quite
clear: a prosthesis should never
be inserted if it cannot easily be re
moved.

Comment

Reference

This case illustrates one of the
truths of orthopedic surgery; if a
prosthesis cannot be extracted from

1. Ryd L: Micromotion in knee arthroplasty.
A roentgen stereophotogrammetric analy
sis of tibial component fixation. Acta

Orthop Scand Suppl 1986; 220: 1-80
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continued from page 217

clinical practice and their indications,
mode of action and side-effects.
The third section is on the major
organs transplanted in clinical practice.
The largest part, on renal transplanta
tion, covers the causes of chronic renal
failure and methods of dialysis and
describes the technique and indications
for creating an arteriovenous fistula.
The authors then describe the mode of
assessment of donors and recipients in
renal transplantation. Immunosuppres
sive therapy, mainly with cyclosporine,
corticosteroids and anti-lymphocyte
globulin, and their side-effects, is dis
cussed. Infectious complications in
renal transplant patients are well de
scribed in one chapter that covers
cause, diagnosis and treatment. Finally,
the follow-up of patients is studied and
an overview provided of the differential
diagnosis in the rejecting kidney allo
graft.
Transplantation of other organs is
also described by different authors, well
known in their fields. Each author
presents a historical review, followed by
clinical and research information and
own experience. Chapters on liver, pan
creas, bone marrow, heart and lungs
are interesting because they offer the
reader general concepts in an under
standable manner. However, each is
based solely on the techniques and
practice of the author’s centre.
In the final section, information on
the criteria of brain death, selection of
donors, organ preservation and anesthe
siology are discussed. The risk of malig
nant disease in the transplant patient is
also covered.
Overall, the book is a good reference
for physicians and fellows interested in
organ transplantation.
Maroun Abou-Jaoude, MD
Clinical Fellow,
Transplantation,
University Hospital,
PO Box 5339, Station A,
London. Ont.
N6A 5A5
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H.W. Schreiber. 374 pp. Illust. Springer-Verlag New York, Inc., Secaucus,
NJ, 1988. $240.00 (US). ISBN
0-387-17116-9.
Textbook of Microsurgery. Edited by
G. Brunelli. 1038 pp. Illust. Masson,
Milano, 1988. Price not stated.
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Dalacin® C Phosphate stemesolution
(clindamycin phosphate)

Antibiotic
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and
also by causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infec
tions where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium
species and micro-aerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci)
when the patient is intolerant of, or the organism resistant to other appropriate antibiotics.
Warnings: Some cases of severe and persistent diarrhea have been reported during or after
therapy with Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally
associated with blood and mucus in the stools and has at times resulted in acute colitis. When
endoscopy has been performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary,
continued only with close observation. Significant diarrhea occuring up to several weeks post
therapy should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes
may respond to simple drug discontinuance. Moderate to severe cases, including those showing
ulceration or pseudomembrane formation, should be managed with fluid, electrolyte, and protein
supplementation as indicated. Corticoid retention enemas and systemic corticoids may be of help
in persistent cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other
causes of colitis should be considered.
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in
patients previously found to be hypersensitive to this compound, the parent compound, clinda
mycin, or clindamycin palmitate. Although cross-sensitization with Lincocin® (lincomycin hydro
chloride) has not been demonstrated, it is recommended that Dalacin C Phosphate not be used in
patients who have demonstrated lincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn
(infants below 30 days of age), or in pregnant women. Studies indicate a toxin(s) produced by
Clostridia (especially Clostridium difficile) may be a principal cause of clindamycin and other
antibiotic-associated colitis. These studies also indicate that this toxigenic Clostridium is usually
sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vancomycin were administered orally
four times a day for 5 -1 0 or more days, there was a rapid observed disappearance of the toxin
from faecal samples and a coincidental recovery from the diarrhea.
It should be noted that serious relapses have occurred up to one month after apparently successful
treatment. A relatively prolonged period of continuing observation is therefore recommended.
Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed
with caution in atopic individuals. Dalacin C Phosphate must be diluted for intravenous admin
istration. (See Dosage and Administration) The use of antibiotics occasionally results in overgrowth
of nonsusceptible organisms - particularly yeasts. Should superinfections occur, appropriate
measures should be taken as dictated by the clinical situation.
As with all antibiotics, culture and sensitivity studies in conjunction with drug therapy should
be performed.
Since abnormalities of liver function tests have been noted occasionally in animals and man,
periodic liver function tests should be performed during prolonged therapy. Blood counts should
also be monitored, during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in
patients with impaired hepatic function is greater than that found in normal patients, the dose of
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are
not effective means of removing the compound from the blood. Periodic serum levels should be
determined in patients with severe hepatic and renal insufficiency.
Adverse Reactions: Local
(a) Intramuscular Injections: Of 404 patients treated with Dalacin C Phosphate (clindamycin
phosphate) intramuscularly (with a solution containing 150 mg/mL), six (1.5%) demonstrated
local reactions as follows: Two complained of pain at the injection site, two demonstrated indura
tion at the injection site and two developed sterile absesses.
(b) Intravenous Infusions: Of 192 patients with Dalacin C Phosphate by intravenous infusion,
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis
and one patient developed both superficial and deep thrombophlebitis. The majority of these
cases developed in conjuction with the use of indwelling I V. catheters and it is difficult to know
how much the drug contributed to the irritation. Two patients developed localized erythema,
swelling and pain at the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clinda
mycin phosphate) by either the intramuscular or intravenous routes developed systemic side
effects as follows:
Number of Patients
Rash........................................................................................................................................................ 7
U rticaria.................................................................................................................................................. 1
P ru ritu s .................................................................................................................................................. 1
Fever, Leucocytosis .............................................................................................................................. 1
Nausea, with or withoutvomiting ........................................................................................................ 1
Diarrhea (See also under"W arnings")................................................................................................. 4
Hypotension........................................................................................................................................... 1
Hypertension......................................................................................................................................... 1
Shortness of Breath.............................................................................................................................. 1

Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate
(clindamycin phosphate) were followed with clinical laboratory tests, including complete hema
tology, urinalysis and liver and kidney function tests. Some of these tests were abnormal initially
and returned to normal during therapy with Dalacin C Phosphate, while others were normal initially
and became abnormal during therapy. Overall evaluation of clinical laboratory values in these
patients does not indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic,
hepatic or renal systems. Transient elevations of serum transaminases have occured in some
patients, but other liver function tests (alkaline phosphatase, serum bilirubin) have not shown any
tendency to increase and there have not been clinical signs of drug-induced hepatic toxicity.
Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. No
specific antidote is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion
for five days have been given without adverse effects.
DOSAGE AND ADMINISTRATION
Adults:
Intramuscular Injection: 600 mg/day in 2 equal doses.
Moderately severe infections: 600 to 1200 mg/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2 ,3 or 4 equal doses. Intramuscular injections of more
than 600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior
to I.V. administration to a concentration of 600 mg in 50 mL of diluent (12 m g/m L or less) and
infused in not less than 10 minutes. Administration of more than 1200 mg in a single 1 hour
infusion is not recommended. Dalacin C Phosphate should not be injected intravenously undiluted
as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses,
each infused over 20 minutes or longer.
Severe infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused
over 20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by con
tinuous drip or in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution and infusion rates:
Dose
Diluent
Time
300 mg
50 mL
10 min.
600 mg
50 mL
20 min.
900 mg
100 mL
30 min.
1200 mg
100 mL
45 min.
Alternatively, the drug may be administered in the form of a single rapid infusion of the
followed by continuous I.V. infusion as follows:
To maintain serum
Rapid
Maintenance
clindamycin levels
infusion rate
infusion rate
Above 4 mcg/mL
10 mg/min. for 30 min.
0.75 mg/min.
Above 5 mcg/mL
15 mg/min. for 30 min.
1.00 m g/min.
Above 6 mcg/mL
20 mg/min. for 30 min.
1.25 m g/min.
Children (Over one month of age):
Intramuscular injection: 10 to 15 mg/kg/day in 2, 3 or 4 equal doses.
Moderately severe infections: 15 to 20 mg/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 mg/kg/day in 3 or 4 equal doses.
Intravenous Administration: Moderately severe infections: 15 to 25 mg/kg/day by continuous
drip or in 3 or 4 equal doses, each infused over 20 minutes or longer.
Severe infections: It is recommended that children be given no less than 300 mg/day regardless
of body weight.
Preparation for Intravenous use: 4 mL (600 mg) Dalacin C Phosphate when diluted with 1000 mL
of the following commonly used infusion solutions was found to be physically compatible and
demonstrated no significant change in pH or antimicrobial potency over a period of 24 hours:
Sodium chloride injection
Dextrose 5% in water
Dextrose 5% in saline
Dextrose 5% in Ringer's Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride
Dextrose 21/2% in Lactated Ringer's Solution (Hartman’s Solution)
Compatibility with other products: Dalacin C Phosphate was not stable when added to Dextrose
5% in water plus vitamins. Therefore it is not recommended that Dalacin C Phosphate be mixed
with any infusion solution containing B vitamins. Dalacin C Phosphate has been shown to be
compatible with Gentamicin sulfate, Tobramycin sulfate and Amikacin sulfate.
Composition: Each mL of Dalacin C Phosphate Sterile Solution contains Clindamycin phosphate
equivalent to clindamycin base 150 mg, Benzyl alcohol 5 mg, Disodium edetate 0.5 mg, Water for
injection q.s. When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid
to maintain a pH range of 5.5 to 7.0.
Dosage forms:
Availability: Dalacin C Phosphate Sterile Solution is available in 2 mL and 4 mL ampoules as well
as a 6 mL vial.
Pharmacy Bulk Vial: Dalacin C Phosphate Sterile Solution is also available in a 60 mL Pharmacy
Bulk Vial. The availability of the Pharmacy Bulk Vial is limited to hospitals with a pharmacy
based IV admixture program. The Pharmacy Bulk Vial is intended for single puncture, multiple
dispensing for intravenous use only.
NOTE: Do not store below 15°C.
Product Monograph available upon request. CE 1377.D

Superinfection* .............................................................................................................................................. 4

Cardiac a r r e s t" ..................................................................................................................................... 1
Bad or bitter taste in m outh.................................................................................................................. 5
* Superinfection is a complication of antibiotic therapy in general and is not necessarily a true
side effect of clindamycin phosphate.
** Due to underlying myocarditis in this patient.
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1
month before issue date. Regular classified rates (for each insertion): $45.00 for the first 40 words or less, additional words 604 each (additional
$17.00 for frame). Special Display under 100 words, 2'A in. X 2 in., $110.00. $6.00 charge (first insertion only) for CJS box numbers. Display
rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.

GENERAL SURGEON: BC - Well-estab
lished general surgical practice for sale in
choice lower mainland location. Canadian fel
lowship required. Reply in confidence with
curriculum vitae to: Box 800, Canadian
Journal of Surgery, PO Box 8650, Ottawa.
O NK1G O G 8.
-S89-13
GENERAL SURGEON AND ORTHOPEDIC
SURGEON: BC - For thriving BC sunshine
coast community of 20 0 00 on the doorstep
o f Desolation Sound. Fully accredited
140-bed hospital under construction. Medical
staff includes 17 GPs, 4 GP anesthetists,
internist, pediatrician and 2 surgeons. Excel
lent year round recreation and cultural attrac
tions include boating, fishing, golfing, modern
indoor recreation theatre complex and com
munity college. Frequent daily air and ferry
connections to Vancouver. Contact: Dr. B.K.
Cutler, Department of Surgery, Powell
River General Hospital, 5871 Arbutus
Ave., Powell River, BC V8A 4S3. Tel:
(6 0 4 )4 8 3 -3 2 1 1 .
-S89-10
GENERAL SURGEON: MB - Required to
join a progressive group of twelve general
practitioners, one obstetrician/gynecologist,
and one orthopedic and plastic surgeon.
Guaranteed income provided for first 12
months, and thereafter, if mutually agreeable,
partnership would be offered. Early partner
ship by agreement is available. The clinic
occupies three floors of a modern, downtown
medical facility in a university city of 40 000,
and services a large trading area. A 220-bed
hospital with a 12-bed, intensive care unit, a
201-bed geriatric and rehabilitation hospital, a
large regional laboratory, and an ultrasound
department, is located in the city. Interested
persons are asked to contact: Mrs. D.J.
Mistal, Western Medical Clinic. 144 6th
St., Brandon, MB, R7A 3N2, Tel: (204)
7 2 7 -6 4 5 1 .
-S89-14
SPINAL SURGERY FELLOWSHIP: ON Available July 1, 1989 and July 1, 1990,
Department of Surgery, Division Orthopedic
Surgery, University of Western Ontario, Lon-

ADVERTISERS’ INDEX
Davis & Geek
Surgilene

Outside Back Cover

Merck Sharp & Dohme Canada
Mefoxin
Primaxin

152,153, 202, 203
178,1 7 9 ,2 1 8 ,2 1 9

Miles Canada Inc.
Cipro

162, 163, 194, 195

Rhone-Poulenc Pharma Inc.
Stemetil

191

Smith Kline & French Canada Ltd.
Cefizox

210, 211, Inside Back
Cover

Upjohn Company o f Canada, The
Dalacin C

224

223, Inside Front Cover

CJS, VOL. 32, NO. 3, M A Y 1989

don. For information contact: Stewart I. Bai
ley, MD, FRCSC, 345 Westminster Ave.,
London, ON N6C 4 V 3 . Tel: (519)
4 3 9 -0 7 0 1 .
-S89-11
CHIEF, DEPARTMENT OF SURGERY:
ON - The Ottawa Civic Hospital, a
922-bed tertiary care, teaching and re
search institution, closely associated with
the University of Ottawa, invites applica
tions for the position of Chief of the
Department of Surgery. The Department
and its appointments are closely linked to
the University of Ottawa Department of
Surgery. Applicants must have a Royal
College of Physicians and Surgeons Fel
lowship in a surgical subspecialty and
have achieved, or be a candidate for,
appointment at the associate or full pro
fessor level at the University of Ottawa.
Previous administration and clinical or
basic research experience is essential.
The hospital is rapidly expanding its re
search efforts in two campus research
institutes. The recruitment of new clinician
scientists in hospital division is a priority
and University, Hospital and Department
of Research resources are dedicated to
this. Several division head positions are
now open and the new Chief is to be
involved in recruitment. In accordance
with Canadian immigration policies, initial
preference for this position will be given
to Canadian citizens and permanent resi
dents of Canada. Please reply with curric
ulum vitae, and names of three referees,
to: Dr. J.D. Grimes, senior vice presi
dent, Research and Clinical Adminis
tration, Ottawa Civic Hospital. 1053
Carling Ave., Ottawa, ON Canada K1Y
4E9. Tel: (613) 7 6 1 -4 6 1 4 .
-S89-15

CHAIR OF UROLOGY: ON - Applications
are invited for the position of Chairman of the
University Division of Urology, University of
Ottawa, School of Medicine. The Children's
Hospital of Eastern Ontario, the Ottawa Civic
Hospital and the Ottawa General Hospital are
participating institutions which offer excellent
resources to a Urology Training Program
which is fully approved by the Royal College
of Physicians and Surgeons of Canada. There
is a complement of 14 urologists with univer
sity appointments, of which 6 are GFTs;
currently the Division of Urology has an estab
lishment of 9 residents in training. The suc
cessful candidate shall be a certified specialist
of the Royal College of Physicians and Sur
geons of Canada and be eligible for licensure
by the College of Physicians and Surgeons of
Ontario. Candidates will have a proven record
in clinical and academic urology. While the
position requires a major leadership role in the
university/hospital/community settings, pref
erence will be given to a qualified individual
devoted to the pursuit of academic excellence
in teaching and research. Part of the mandate
will focus on the development of research in
urology and continuing quality teaching pro
grams at both the undergraduate and post
graduate levels. The successful candidate will
hold a joint appointment as Chairman of the
University Division of Urology and Head of

Urology at one of the teaching hospitals.
Salary and fringe benefits are commensurate
with qualifications and experience and are in
accordance with existing academic scales at
the University of Ottawa. In accordance with
Canadian immigration requirements, priority
will be given to Canadian citizens and perma
nent residents of Canada. Employment equity
is University policy. Applicants are requested
to forward their curriculum vitae and the
names of three referees, prior to June 1,
1989, to: Gilles D. Hurteau, MD, dean School of Medicine. University of Ottawa,
451 Smyth Rd., Ottawa, ON K1H 8M 5.
CHAIRE D'UROLOGIE: ON - L'Universite
d'Ottawa ouvre un concours pour le poste de
directeur de la division d ’urologie, Universite
d'Ottawa, Ecole de Medecine. Les candi
d a te s q u a lifie rs devront avoir un certificat
du College royal des medecins et chirurgiens
du Canada et §tre 6legibles au permis d'exercer du College des medecins et chirurgiens de
I'Ontario. Le(la) candidat(e) choisi(e) sera le(la)
responsable de la coordination des pro
grammes d’enseignement integres dans les
hopitaux affilies, soit I'Hopital General d'Ot
tawa, I'Hopital Civic d'Ottawa, et I'Hopital
pour enfants de I'est de I'Ontario. Le(la) candi
date) choisi(e) aura aussi la responsabilite des
programmes de formation au nivea pr4diplome et postdoctoral et du developpement
des programmes de recherche. Le(la) candi
date) choisi(e) agira conjointement comme
directeur(trice) de la division d'urologie dans
I'un des hopitaux affilies. L'Universite et les
hopitaux affilie offrent d'excellentes resources
qui assurent une medecine de qualite et des
programmes de formation bien structures.
L'Universite d'Ottawa offre un salaire de base
concurrentiel, ainsi que des conditions de
travail et des avantages sociaux allechants.
L'Universite a une politique d'egalite en matiere d'emploi. Selons les exigences d'lmmigration Canada, cette annonce s'adresse d'abord aux citoyens canadiens et aux residents
permanents du Canada. Priere de faire parvenir votre curriculum vitae et la liste des
references avant le 1 juin 1989 a I'attention
de: Gilles D. Hurteau, MD, Doyen, Ecole de
medecine, Universite d'Ottawa, 451, chemin Smyth, Ottawa, ON K1 H 8M 5.
-S89-16

VASCULAR SURGEON: ON - Applications
are invited for a clinical position at the Ottawa
Civic Hospital. Candidates must hold a certifi
cate of special competence in vascular sur
gery (or equivalent) and have added qualifica
tions in epidemiology/public health. Training
in critical care is an asset. The closing date for
applications is 30 days after publication of
this advertisement. Applications, including
curriculum vitae and names of three referees,
should be submitted to: C. Wm. Cole, MD,
Division of Vascular Surgery, Ottawa Civic
Hospital, 1053 Carling Ave., Ottawa, ON
K1Y4E 9.
-S89-17
GENERAL SURGEON: SK — An opportunity
exists for a general surgeon to join in busy
practice of general surgery, university centre,
western Canada. Please send CV to: Box
726, Canadian Journal of Surgery, PO Box
8650, Ottawa. ON K1G 0G8.
-S89-01

For prescribing information see page 210

Whose side is
your favourite

M n d in g an effective treatm ent for intraabdom inal infections has b e co m e m uch
easier since the ad ve n t of cephalosporins.
Their broad spectrum o f activity has greatly
im proved the prognosis for m any patients
with serious infections.
The trouble is, the cost o f cephalosporins has
been m aking m any hospital pharmacists
(and cost control staff) see red. It is also now
increasingly more difficult for m any hospital
formulary com m ittees to be ab le to strike an
agree able balance betw een effectiveness
and cost control.

New Cefizox™ m a y be th e answer everyone's
been looking for. N ot only does it give m u ch
wider p a th o g e n cove rag e* (including B.
fragilis) th a n cefoxitin,1,2 b u t its superior
dosage schedule (exam ple: q!2h vs q6h)
m ay m ake Cefizox™ m u ch less expensive?'4
It even has p a c k a g in g designed for easy
identification.
So if the cost o f e ffe ctive cephalosporin
therapy is just to o m uch for your hospital to
handle, consider new Cefizox™ Its
com bina tion o f e ffic a c y a n d low cost m a y
just be w h a t e ve ryb o d y ordered.

Cefizox*
ceFtizoxime sodium

A cephalosporin that plays favourites with everybody.
PAAB
CCPP

SKGrF SMITH

KLINE SfRENCH CANADA LTD. 1989

CX:M:189CA
‘ Refers to in vitro coverage; does not necessarily imply clinical coverage,

Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan

y1

CARDIOVASCULAR SUTURES
Improved Cardiovascular Needles
• Special highly adherent silicone
lubricant further reduces
resistance...first pass, last pass
• Securely attached to the suture

Needles Resist Bending
t
<
• New, stronger needle configuration
• Superior sharpness
>
• Lower penetration force reduces
strain on needle - minimizes
bending and breaking

